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General introduction
Until recen tly  it was custom ary fo r  gene tic  tes tin g  to  be done  m any years a fte r 
cancer d iagnosis and the  main reason fo r gene tic  tes tin g  was a cancer related 
fa m ily  h is to ry. In th e  near fu tu re , a change in t im in g  o f gene tic  counse lling  and 
testing from  patients given tim e after cancer diagnosis towards recently diagnosed 
pa tien ts  is to  be expected . Physicians w ill o ffe r these pa tien ts  referra l fo r  gene tic  
counse lling  and tes tin g  at a p o in t in tim e  w hen pa tien ts  are s till ad jus ting  to  the  
diagnosis o f cancer and the re fo re  e m o tio n a lly  vu lne rab le . There is a gap in 
kno w le dg e  on the  psycho log ica l im p ac t o f a c o n fro n ta tio n  w ith  a h igh gene tic  
risk o f Lynch synd rom e sho rtly  a fte r a personal co lo recta l cancer diagnosis.
Clinical aspects Lynch syndrome
Colorectal cancer is one o f the  m ost frequen t m alignant tum ours in industrialised 
countries. W orld w id e  m ore than one m illio n  pa tien ts  w ill be d iagnosed w ith  CRC 
in 2010 \  In the  Netherlands, m ore than 11.500 peop le  are d iagnosed w ith  
co lo recta l cancer each y e a r2. This means th a t around 1 in 20 D utch peop le  w ill 
deve lop  co lo recta l cancer d u rin g  his or her life. The m a jo rity  o f co lo recta l cancer 
pa tien ts  have sporad ic disease and on ly  a m in o r ity  o f co lo recta l cancers have a 
gene tic  cause. One w e ll-described  co lo recta l cancer gene tic  syndrom e is Lynch 
syndrom e (fo rm erly  know n as HNPCC) w h ich  p ro b a b ly  accounts fo r  3-5% o f all 
co lo recta l cancers 3'8. Lynch syndrom e is an autosom al d o m in a n t inhe rited  
d iso rder characterized by an increased risk to  deve lop  co lo recta l cancer (60-90% 
life tim e  risk) and an increased risk o f ex tra -co lo n ic  tu m ours, especia lly endom etria l 
cancer (25-70% life tim e  risk); the  mean age to  deve lop  co lo recta l cancer is 41-54 
years, to  deve lop  en dom etria l cancer 45-50 years 916. Lynch syndrom e is caused 
by he terozygous germ  line m u ta tio ns  in m ism atch repair (MMR) genes such as 
MLH1, MSH2, MSH6, PMS27il o r by EPCAM de le tions  1819. Due to  fa ilu re  o f the  MMR 
m echanism  errors in m ic rosa te llite  repeat sequences are n o t corrected causing 
m ic rosa te llite  in s ta b ility  (MSI) 20 21. MSI is easily de tec tab le  in tum our-D N A , 
p ro v id in g  a useful pre -screen ing to o l fo r  Lynch syndrom e 22.
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F i g u r e i  Mismatch Repair Mechanism.
Lynch syndrome is caused by germline mutations in the 'mismatch repair' (MMR) genes: MLH1, 
MSH2, MSH6, PMS2. The MMR proteins form units which recognize and repair errors which are 
created during DNA replication. In case of failure, microsatellite instability (MSI) occurs.
Relevance of Lynch syndrome detection
C olorecta l cancer has a p re m a lign an t stage o f adenom as (polyps). The m ain aim 
o f the  co lonoscop ies is to  p reven t the  de ve lopm e n t o f cancer by means o f 
d e te c tin g  and rem oving  po lyps. Lynch syndrom e m u ta tio n  carriers are advised to  
have regu lar co lo recta l screening. In the  N etherlands, co lo recta l cancer screening 
recom m enda tion  includes co lonoscop ies, usually s ta rtin g  at the  age o f 25, w ith  a 
m axim um  in te rva l o f 24 m onths be tw een each exam ina tion . It has been proven 
th a t in tensive surve illance o f co lo recta l cancer in Lynch syndrom e fam ilies  is very 
e ffec tive  w ith  a fast red uc tio n  o f m o rta lity  and m o rb id ity  23‘25. For fem a le  Lynch 
synd rom e m u ta tio n  carriers surve illance also includes annual gynaeco log ic  
exam ina tion , s ta rtin g  be tw een  30-35 years 26‘29. Endom etria l cancer surve illance 
in fem ale  Lynch m u ta tio n  carriers seems m ore e ffec tive  w ith  en dom etria l b iopsies 
than  w ith  transvag ina l u ltrasound alone 28. Surve illance fo r o th e r types o f Lynch 
associated cancers is on ly indicated in case o f fam ilia l occurrence o f these cancers 
(e.g. b ladder or stom ach carcinoma). A no ther m ajor advantage o f the  de tec tion  o f 
Lynch syndrom e, is the  resu lting  p o ss ib ility  o f gene tic  tes tin g  o f relatives. This so
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called presymptomatic genetic testing can detect with certainty who and who is 
not a carrier of the Lynch syndrome predisposing mutation in the family. Genetic 
testing of healthy family members allows those who do not carry the mutated 
gene to avoid costly and burdensome surveillance. Such family members can 
experience reduced anxiety to develop cancer because they are not at increased 
risk. In summary. Lynch syndrome detection leads to more effective surveillance 
and subsequently prevents premature death from colorectal cancer.
The traditional Lynch syndrome detection procedure
Clinical aspects
When a patient is diagnosed with colorectal cancer and other established criteria 
are fulfilled, the general practitioner or treating physician can discuss referral for 
genetic testing. In the Netherlands, genetic counselling and testing is provided at 
hereditary cancer clinics30. There, a family pedigree will be drawn which is used to 
establish fulfilment of the Amsterdam criteria 31 and Bethesda guidelines 32 33. The 
clinical (Amsterdam) criteria can be used to recognize families and patients at 
high risk for Lynch syndrome; the Bethesda guidelines describe patients who 
merit MSI testing.
The Revised Bethesda Guidelines for testing colorectal tumors for 
microsatellite instability (MSI)
Tumors from individuals should be tested for MSI in the following situations;
1) Colorectal cancer diagnosed in a patient who is less than 50 years of age.
2) Presence of synchonous, metachronous colorectal, or other HNPCC- 
associated tumors* regardless of age.
3) Colorectal cancer with the MSI-H # histology (D diagnosed in a patient who 
is less than 60 years of age >K.
4) Colorectal cancer diagnosed in one or more first-degree relatives with an 
HNPCC-related tumor, with one of the cancers being diagnosed under age 
50 years.
5) Colorectal cancer diagnosed in two or more first- or second degree rela­
tives with HNPCC-related tumors, regardless of age.
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* Hereditary nonpolyposis colorectal cancer (HNPCC)- related tumors include colorectal, endometrial, 
stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as 
seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas in Muir-Torre 
syndrome and carcinoma of the small bowel.
#, MSI-H= microsatellite instability-high in tumours refers to changes in two or more of the five National 
Cancer Institute-recommended panels of microsatellite markers.
®, Presence of tumour infiltrating lymphocytes, Crohn's like lymphocytic reaction, mucinous/signet-ring 
differentiation, or medullary growth pattern.
*, There was no consensus among the workshop participants on whether to include the age criteria in 
guideline 3 above; participants voted to keep less than 60 years of age in the guidelines.
AMSTERDAM CRITERIA II
There should be at least three relatives with colorectal cancer (CRC) or with a 
Lynch syndrome-associated cancer: cancer of the endometrium, small bowel, 
ureter or renal pelvis.
• One relative should be a first-degree relative of the other two,
• At least two successive generations should be affected,
• At least one tumor should be diagnosed before the age of 50 years,
• FAP should be excluded in the CRC case if any,
• Tumors should be verified by histopathological examination.
Testing the patient's tumour for the presence of MSI is the first technical step 
towards detection of Lynch syndrome. Only after the patient has been enabled to 
make a well-informed decision regarding genetic risk assessment and after 
informed consent, the genetic counsellor will initiate the genetic testing 
procedure. In case of a MSI-positive test result, the patient will be considered to 
be at high risk for Lynch syndrome. In order to pinpoint the deficient MMR-gene 
and to establish the exact cause of the micro satellite instability immuno- 
histochemistry analysis (IHC) 34-36 and DNA germ line mutation analysis are 
subsequent steps. After detection of a pathogenic germ line mutation, genetic 
testing becomes available for relatives at risk. In summary, the current model for 
detection of Lynch syndrome starts with a physician who signals a patient with a 
family history indicating a hereditary form of colorectal cancer. MSI testing of 
tumour tissue will then be initiated by the genetic counsellor, but only after 
extensive genetic counselling and informed consent.
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The genetic counselling procedure
Because of specific characteristics of hereditary diseases and genetic tests, 
extensive genetic counselling as an integrated part of the genetic testing 
procedure is widely recommended 37. The genetic counsellor has to ensure that 
individuals have all relevant information to enable them to make their own 
decisions. This includes knowledge of the genetic risks, as well as a clear 
appreciation of the short-term as well as the long-term consequences, that may 
result from a particular course of action 37. Issues that are explored in the context 
of genetic testing for hereditary cancer include strategies for coping with an 
abnormal resultand likelysupportfromfamily andfriends.familyand reproductive 
issues including the genetic implications for relatives and implications for future 
employment and insurance 37. Moreover, the counsellor helps the patient to gain 
insight into his personal motives, perceptions and capability of coping with the 
result 38. The information provided can have great impact on the psychosocial 
well-being of the counselled individual and their family members 39'41. Time taken 
in genetic counselling is an important factor 37 and additional professional 
psychosocial support may be needed as part of the genetic counselling process42.
Psychological impact of genetic testing under the traditional method
Predictive testing for Lynch syndrome is welcomed by a majority of individuals at 
risk43 and does not induce major psychological problems44. Some patients as well 
as healthy relatives may experience increased distress immediately after disclosure 
of genetic test result45'47, especially patients with higher pre-test levels of distress, 
lower quality of life, lower social support46 and those with many colorectal cancer 
deaths in the family 48. A patient's former experience of cancer may play an 
important role in genetic testing responses 49. Studies, which address the 
psychological impact of genetic counselling and testing for hereditary colorectal 
cancer in healthy individuals or given time after cancer diagnosis generally 
indicate that genetic information does not result in adverse psychological 
outcomes in the long term.
Family communication in the context of genetic testing for cancer
Effectiveness of genetic testing strongly depends on family communication 50_53. 
The index patient, i.e. the first person in a family in whom a genetic condition is 
established, is often one who has been diagnosed with cancer 53-55. Communication 
by this index patient allows other family members to have access to information.
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to adequate surveillance programs and if possible to DNA-testing 5156.The women 
in the family often take responsibility for informing other family members 55 57. 
Generally, families prefer the information to be provided by relatives rather than 
by clinicians 58 59. The family context and history is relevant to participation in 
genetic testing and screening and it may help to address communication strategies 
and disclosure of information about risk 56. Next to the influence of family 
communication on genetic testing uptake 55, family support was found to be 
associated with perceptions of the benefits of and barriers to colonoscopy 60. The 
ways in which families communicate with each other may have a major impact on 
uptake of genetic testing and attendance at screening 56. The quality of 
communication with the family regarding hereditary cancer is important as those 
individuals who hesitate discussing such issues report more psychological distress 
in the first 6 months after genetic test disclosure 61. A review shows that directive 
counseling to encourage disclosure to relatives is usually well-supported 62. 
Knowledge of patients' medical and psychosocial barriers to inform relatives is a 
prerequisite to improve effectiveness of genetic testing for Lynch syndrome. 
Family communication may be inhibited by a desire not to cause worry, by 
estranged relationships, infrequent contact and concerns about the impact on 
insurance and employment 54 55 63 64. Motives for avoiding family communication 
might lie in expected psychological distress 6S, questions about death 66 or 
protective buffering, i.e. the desire for mutual protection 67. In studies on the 
impact of genetic testing only a minority report changes on family relationships 
and those are mainly positive 44 68. Family relationships are perceived more 
frequently as positive than negative 69 and individuals report feeling closer to 
family members as a result of genetic testing 70. Adverse effects mainly comprise 
the relationship with siblings and parents 71. Similarly, parental guilt, the creation 
of a conspiracy of silence about hereditary cancer and more emotional distance 
are reported occasionally 72. When long-term distress occurred it was associated 
with less open communication about the test result with the family and changes 
in relationships with relatives71. The ability of relatives to provide social support is 
of importance for the relationship since relatives are perceived as key social 
support providers to facilitate adjustment to genetic testing 72. Support of the 
family is an important buffer against hereditary cancer distress 59.
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The additional Lynch syndrome detection procedure: MIPA
Clinical aspects
The detection of patients at risk for Lynch syndrome based on signaling familial 
occurrence of colorectal cancer appeared is not optimal 73'76. To improve the 
recognition of patients at risk for Lynch syndrome additional methods were 
developed. Because almost all tumours of patients with Lynch syndrome have a 
deficient mismatch repair system, these additional methods are based on tumour 
testing. Microsatellite instability (MSI)-testing of the tumour can be used as an 
efficient pre-screening tool for Lynch syndrome 11. In the so-called MIPA-method, 
the pathologist starts recognition of patients at risk for Lynch syndrome by 
selecting a tumour for MSI-testing and after that sending the MSI-test result to 
the clinician. MIPA-testing is performed in a selection of patients who are recently 
diagnosed with colorectal cancer and who fulfil one of the individual Bethesda 
criteria 32 33. The next step of the MIPA-method is discussion of the MSI-test result 
and of referral to genetic counselling with a patient with an MSI-positive tumour 
(high risk Lynch Syndrome) by the clinician. When a tumour is MSI-positive, a visit 
to a hereditary cancer clinic is scheduled for both medical, technical and 
psychosocial reasons78. As in the traditional method, genetic counselling precedes 
additional tumour testing and germline analysis of mismatch repair genes. 
Model-based analysis has shown that by the MIPA-method, 2.2 more Lynch 
syndrome mutation carriers can be identified compared to the traditional method 
alone 11. The MIPA-method is incorporated in the most recent Dutch Guideline 
Hereditary Colorectal Cancer79.
MIPA CRITERIA
1) Colorectal cancer < 50 years.
2) Second colorectal cancer < 70 years (synchrone or metachrone).
3) Colorectal cancer and a cancer associated with Lynch syndrome < 70 years.
4) Colorectal adenoma with high grade dysplasia < 40 years.
In 2007, more than 11,500 of new cases of colorectal cancer were registered in the 
Netherlands2. On average 1 in 8 of all patients with colorectal cancer will fulfil the 
selection criteria for MIPA 11. This amounts to 1440 patients per year in the
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Netherlands. Of this population approximately 20% will be MSI positive 80 and 
thus offered genetic testing. Most of these patients will have at least 10 relatives 
(children, sibs, uncles and aunts) who might be at risk for Lynch syndrome also. 
Hence, each year approximately 3000 individuals need to be informed of their risk 
for Lynch syndrome related cancers by patients shortly after their own colorectal 
cancer diagnosis in the Netherlands.
Psychological impact of MIPA on the patient: MIPAPS
Figure 2 Detection of high risk for Lynch Syndrome by MIPA-testing.
MIPA-testing is performed at the initiative of a pathologist, either because the CRC is diagnosed 
below 50 years or because it is the second CRC below 70 years. An MSI-positive tumour means the 
patient is at high risk for Lynch syndrome. In the MIPAPS-study psychological assessementtook 
place immediately after MSI-test disclosure and 6 months later.
The most striking psychological difference between MIPA and the traditional 
method is the timing of the message of a potential risk for hereditary colorectal 
cancer. A positive MSI test is discussed with the patient very shortly after the 
colorectal cancer diagnosis. Therefore, patients are confronted with three major
I
MIPAPS = 
Psychological 
impact of MIPA
Clinical Geneticist
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tasks in quick succession: 1) to cope with their diagnosis of colorectal cancer, 2) to 
cope with a possibly hereditary predisposition for colorectal cancer and 3) to 
discuss this hereditary predisposition for colorectal cancer with children and 
relatives 81. A positive MSI test does not prove that a predisposition for Lynch 
syndrome is present. Nonetheless, the MIPA-strategy involves an unexpected 
message of being at high risk for hereditary cancer. For decades, ethical issues in 
genetic counselling and testing have emphasized an individual's right to chose 
not to know their genetic status or even that they have an increased risk for 
carrying a mutation. Informed consent procedures were put in place to protect 
the individual's right to self determination: more specifically, their right to make 
autonomous decisions about their health care 51. Moreover, the MIPA-strategy 
involves an offer of referral for genetic counselling and genetic testing shortly 
after surgery and probably even during adjuvant treatment for colorectal cancer. 
At that moment a patient might be expected to be especially emotionally 
vulnerable. One could hypothesize that individuals who visit a hereditary cancer 
clinic after careful reflection and on their own initiative may be better prepared 
for a negative test result than patients who are referred at the time of treatment. 
Although genetic testing for Lynch syndrome does not lead to clinically relevant 
levels of distress in general46, little is known about the impact of genetic testing 
shortly after a colorectal cancer diagnosis. Further, little is known whether specific 
subgroups are more vulnerable for genetic testing related distress shortly after a 
colorectal cancer diagnosis.
A number of models coming from health psychology can be used to gain insight 
in psychological aspects regarding genetic testing for hereditary cancer 82'87. 
Gooding et a l83 demonstrated that theories like the Common Sense Model of Self­
regulation and the Transactional Model of Stress and Coping of which the Stress 
and Coping Model of Baum is an elaboration, provide a solid framework for 
studying genetic testing related issues. According to Baum et al 88, the extent to 
which genetic testing for disease causes significant distress varies as a function of 
the test result, characteristics of the disease, uncertainty remaining after testing, 
the degree of uncertainty reduction, the availability of active coping options and 
personal factors such as social support, perceived risk, beliefs about disease and 
social skills. Stressors have the capacity to threaten or harm. The extent to which 
an individual appraises events as dangerous or harmful depends on mediating 
situational or exposure variables. If the result is experienced as threat or as an 
excessive demand, stress and associated physiological, behavioural and cognitive 
changes will occur.
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The selection of patient related determinants in the MIPAPS study (chapter 5) is 
based on the Stress and Coping Model from Baum et al 88. In the MIPAPS study 
psychological distress in patients is defined by general psychological distress, 
measured by the Symptom-Checklist-90 (SCL-90) and cancer specific distress 
measured by the Impact of Event Scale (IES-CRC). Our hypothesis is that MSI-testing 
in recently diagnosed patients with CRC (MIPA-testing) is followed by high 
psychological distress. Social support and cancer risk perception are studied as 
possible predictors of patients' distress.
Preceding research on genetic testing following cancer 
diagnosis
A majority of newly diagnosed colorectal cancer patients find an offer of genetic 
testing for hereditary colorectal cancer to be highly acceptable 89. Other studies 
addressed the impact of genetic counselling and testing among women with a recent 
diagnosis of breast cancer. Despite emotional vulnerability due to recent breast cancer 
diagnosis and treatment, recently diagnosed patients seem as interested in genetic 
testing as patients diagnosed longer ago90. The main reason for women affected with 
breast cancer to have a genetic test is to make relatives more alert to their own risk 
even though informing family members is perceived as a difficult task91. Patients with 
breast cancer who were approached at the time of adjuvant radiotherapy and who 
immediate decline from genetic risk assessment tend not to consider genetic testing 
as relevant for them. Early decliners are found to be more hesitant and anxious about 
the influence of the test result on their future, and often opt to postpone further 
testing. Late-decliners are themselves afraid of the test result or withdraw after a 
relative's objection 92. Breast cancer patients who are approached for genetic 
counselling during adjuvant radiotherapy do not report additional psychological 
distress either in the shortterm 93 94 or the long term 95 and neither do their partners87. 
Patients who are young, single with little social support, less optimistic, those who 
use an avoiding coping style, experience a lower quality of life or who are previously 
depressed need extra attention 93. Highly distressed patients with highly distressed 
partners are most likely to experience high distress in the long term 87. While there is 
comprehensive knowledge on cancer susceptibility testing itself, less is known about 
the psychological impact of genetic testing shortly after cancer diagnosis and even 
less on the impact of genetic testing among newly diagnosed patients with colorectal 
cancer. Above mentioned studies indicate that psychological consequences of genetic
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risk assessment shortly after cancer diagnosis can be expected to be mild. Nevertheless, 
genetic counselling and testing of patients who are diagnosed with cancer may cause 
prolonged uncertainty in a minority of patients. Awareness of the increased risk of 
second cancer and of the genetic contribution to an increased risk of cancer for their 
children may lead to an increased level of cancer specific distress 96. The message of 
being at high genetic riskfor cancer may reactivate distress related to cancer diagnosis 
and treatment 97. Therefore, psychological consequences of these two potentially 
distressing events in tandem need to be examined and vulnerable patients need to 
be identified.
Summary
Signalling and detecting Lynch syndrome families is important to prevent 
premature death of patients and relatives. Unfortunately, the traditional detection 
method of hereditary colorectal cancer appears inefficient73'76. A new strategy for 
the identification of hereditary colorectal cancer was developed, which should 
improve the recognition of Lynch syndrome from 25 to 75% 779899. In this strategy 
tumours of newly diagnosed colorectal cancer patients are selected by the 
pathologist within a few days after cancer operation for a pre-screening test of 
hereditary cancer, known as the micro satellite instability (MSI)-test. Patients are 
selected if they are diagnosed with colorectal cancer before age 50 or if they have 
multiple Lynch syndrome associated cancers before age 70. Patients with a 
positive MSI-test result are at considerable risk for Lynch Syndrome. There is not 
much known about the psychological impact of a confrontation with a genetic 
cancer risk shortly after a personal colorectal cancer diagnosis.
Hereditary Breast Cancer with or without Ovarian cancer
Clinical aspects
Hereditary Breast and Ovarian Cancer caused by a germline mutation in BRCA1 or 
BRCA2 is a common hereditary cancer syndrome. The BRCA1 and BRCA2 genes 
were identified in 1994 and 1995 respectively 100101. Germline mutations in BRCA1 
and BRCA2 account for approximately 3-5% of all breast and ovarian cancers. 
Women with a BRCA1/2 mutation have a cumulative lifetime risk (up to the age of 
70 years) of breast cancer of 39-85% and of ovarian cancer of 11-63% 102-105. After a 
history of breast cancer, the life-time risk of cancer in the contralateral breast 
ranges from 35 to 64% 106 1 07.
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CRITERIA FOR REFERRAL FOR HB(0)C
Breast cancer
• Breast cancer before age 35 years.
• Bilateral breast cancer with primary tumor before age 50 years.
• Breast cancer before age 50 and ovarian cancer in the same branch of the 
family.
• Man with breast cancer and woman with breast cancer in same branch of 
the fam ily.
• Two or more first degree relatives with breast cancer, of which at least one 
tumor before age 50 years.
• Multiple first and second degree relatives with breast cancer.
Ovarian cancer
• Ovarian cancer before age 50 years.
• Ovarian cancer and breast cancer in same branch of the family orinone patient.
Relevance of BRCA detection
Genetic testing for BRCA1/2 mutations offers the opportunity to choose cancer 
risk reduction strategies 109. Current surveillance protocols entail clinical breast 
examination, annual mammography and annual contrast-enhanced breast 
magnetic imaging (MRI) starting from the age of 25 years 110 nl. Regular breast 
cancer surveillance aims at early detection of breast cancer, but does not guarantee 
the detection of a tumour before metastasis has occurred. Ablation of the breasts 
is effective with respect to cancer risk reduction. It was shown that the remaining 
risk of developing a primary breast cancer after prophylactic bilateral mastectomy 
(PBM) is very low m. Regular surveillance of the ovaries starts at 35 years of age 
and includes annual gynecological examination, transvaginal ultrasound 
examination and serum CA-125 assay 113. Screening by means of the current 
modalities fails to detect ovarian cancer at an early stage and provokes a high 
number of false positive findings and so the option of prophylactic bilateral 
salpingo-oophorectomy (PBSO) may be discussed with BRCA1/2 mutation carriers 
from age 40 years 114. After PBSO a small residual risk of developing extra ovarian, 
peritoneal cancer remains 115. It is estimated that removing the ovaries and 
fallopian tubes reduces the risk of developing breast cancer by 50% 116117.
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Psychological impact of genetic testing for HBOC
Many studies are available on the psychological impact of the process of genetic 
testing for a BRCA1/2 mutation 118-125. Meta-analysis has shown that ß/?G4-mutation 
testing generally does not lead to a decline in patient well-being124126127. Individuals 
who seek referral for genetic testing may be less distressed compared to those 
who refrain from genetic testing 128. Of all individuals undergoing BRCA testing, 
10-27% is clinically distressed 118 120 122 129-132. Predictors for long-term hereditary 
cancer distress are the level of hereditary cancer distress shortly after blood 
sampling for genetic testing, the experience with affected relatives, having young 
children, perception of high cancer risk and hesitation to discuss the test result 
with family members 71. In general, distress levels are not higher than those in the 
general population or in a primary care population n8 129133-135, but some women at 
high riskfor ß/?G4-related distress need more attentive care71. Passive coping and 
an emotionally oriented illness representation are significant and consistent 
predictors of hereditary cancer distress and cancer w o rry136. Predictive factors for 
hereditary cancer distress 6 months after genetic testing are pre-test levels of 
distress, complicated grief, number of affected first-degree relatives, strong 
emotionally oriented illness representation, illness coherence, passive coping, 
distraction seeking, young age (<13 years) at the time a parent was affected by 
cancer and problematic family communication 137. Identifying unhelpful illness 
representations, cognitive restructuring and stimulating active coping styles may 
be appropriate interventions to help distressed individuals undergoing genetic 
testing 140.
Psychological impact of ßRC^-related cancer risk management
Expressed motivations for obtaining prophylactic surgery are a fear of developing 
breast and ovarian cancer, risk reduction, obligation felt by women towards family 
members, physician's advice, worries about effectiveness of regular surveillance 
and genetic testing 138-144. Higher age is found to be related with PBSO 109 139. Most 
women can undergo PBM and/or PBSO without developing major emotional 
distress145 and the vast majority of women do not regret prophylactic mastectomy 
and breast reconstruction 123138146-149. After PBM, anxiety and cancer-related distress 
are significantly reduced 145. Compared to female BRCA1/2 mutation carriers who 
favour surveillance, women opting for PBM report higher distress and cancer 
worry and distress levels significantly decrease after surgery 123138140. Predictors of 
distress at 6 months after PBM are a high level of cancer-related distress one week 
before surgery and being a mutation-carrier. In contrast, having comforting
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thoughts is negatively associated with cancer-related distress 15°. Cancer-related 
distress before PBM was predictive of cancer-related distress one year after 
surgery 15°.
It is shown that only 60% of the women are satisfied with the results of breast 
reconstruction 145. Nearly half of all women experienced adverse affects regarding 
their sexual relationship and this was unrelated to satisfaction with the procedure. 
A decline in sexual functioning was related to perceived lack of information, 
expectations that were not met, ongoing physical complaints and limitations in 
daily life, altered feelings of feminity and body image and perception of the 
partner's negative view  of the sexual attractiveness of his wife MJ. Thus, the 
impact of prophylactic surgery on body image and sexuality should not be 
underestimated 71.
Psychosocial care for female ß/?C^-mutation carriers
Few supportive services exist for women who test positive for BRCA1 and BRCA2 
mutations 15\ even though they face a complex choice between intensive 
surveillance and prophylactic surgery. A challenging issue for many health care 
professionals is how to optimally guide and support these women in making the 
psychologically most appropriate choice as both intensive breast cancer 
surveillance and prophylactic mastectomy are medically possible in most 
developed countries. The decision regarding breast cancer risk management 
involves the processing of complex and evolving information and choices 152. 
Generally, the decision is not a medically urgent one and women can take time to 
process all the information and to talk about it with others 153. All family cancer 
clinics in the Netherlands offer individual professional support for women from 
HBOC and HBC families 42. A supportive-expressive group intervention appeared 
to be relevant for and highly acceptable to women who carry mutations in BRCA1/ 
BRCA2 and appeared to be an optimal forum for exploring key-issues such as the 
notification of test results to family, guilt regarding transmission of a mutation 
and decision-making regarding risk-reducing options 154. For more than ten years 
social workers of the family cancer clinic of the Radboud University Nijmegen 
Medical Centre in the Netherlands have organized educational-support groups 
for recently proven female ß/?G4-mutation carriers. The main goal of an educational- 
support group is assisting women in making an informed choice regarding cancer 
risk management, while respecting and taking into account their private lives and 
circumstances. Evaluation of patient care in clinical practice is necessary to be 
able to monitor and if necessary improve psychosocial interventions. For these
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reasons, the second part of this thesis addresses breast cancer risk management 
behaviour, emotional distress and family communication in the context of 
educational-support groups for recently proven female ß/?G4-mutation carriers.
Aims and outline of the thesis
Referral for genetic testing shortly after the diagnosis of cancer is becoming more 
common. This implies a shift in timing regarding a patient's confrontation with 
genetic risk assessment. The psychosocial impact of genetic testing on patients 
with a recent diagnosis of colorectal cancer is not yet known.
The first part of this thesis addresses the psychological impact of offering genetic 
testing to patients with colorectal cancer. First, a literature review was conducted 
to determine the psychological impact of colorectal cancer during the first year 
after diagnosis and the impact of genetic testing for Lynch syndrome in patients 
affected with colorectal cancer (chapter 2). Next, the psychological impact of MSI 
testing under the traditional Lynch detection method was examined and 
described. The study focus was the relation of time between CRC diagnosis and 
MSI-analysis with colorectal cancer specific distress (chapter 3). In the MIPAPS-pilot 
study, the reactions of patients to an offer of genetic testing directly after the 
diagnosis of colorectal cancer (MIPA-method) were explored (chapter 4). In the 
MIPAPS study psychological distress of patients with colorectal cancer and of 
caregiver distress of their partners were determined immediately after 
MIPA-testing and 6 months later (chapter 5).
The second part of this thesis addresses the evaluation of educational-support 
groups for recently proven female ß/?C/\-mutation carriers. Breast cancer risk 
management preferences of women with a recent diagnosis of a BRCA1/2 mutation 
were assessed. Their mastectomy status after two years and foil owing participating 
in an educational-support group were explored (chapter 6). In chapter 7, overall 
ß/?G4-related issues following participating in an educational-support group for 
women with a recently detected mutation were addressed.
A general discussion is provided in chapter 8. Implications for clinical practice are 
discussed and suggestions for further research are made.
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Genetic testing for Lynch syndrome 
in the first year of colorectal cancer: 
a review of the psychological impact
Abstract
In tro d u ctio n  An increasing number of patients with colorectal cancer (CRC) 
receive genetic counselling within 1 year after diagnosis. Little is known whether 
specific subgroups are more vulnerable to genetic testing related distress. 
M ate ria l and  m ethods A literature review was conducted to identify the 
psychological impact of CRC in the first year, and the additional impact of genetic 
testing. The electronic databases of PubMed, Psych Info, Embase and the Cochrane 
Library were searched to identify all reports published between January 1997 and 
October 2007 on the psychological impact of (1) CRC-diagnosis up to 1 year after 
treatment and of (2) genetic testing for Lynch syndrome in patients with CRC. 
Results Studies on the psychological impact of genetic testing in newly diagnosed 
patient with CRC were not available. Either CRC patients diagnosed several years 
ago were studied and the focus was also often on the psychological impact of 
genetic testing prior to DNA-test disclosure. They show that limitations in 
emotional and social functioning can persist up to 1 year after CRC treatment, 
especially in those with a stoma or diagnosed before age 60. Female patients and 
male patients diagnosed before age 50 appear to be more vulnerable to genetic 
test-related distress.
Conclusion It is well known that being treated for CRC has great impact on 
psychological functioning. Little is known about the psychological impact during 
the first year after diagnosis and very little is known about the additional 
psychological effect of genetic testing for hereditary cancer in this period. We 
found presumptive evidence that specific subgroups of patients with CRC are 
more vulnerable to genetic-testing-related distress.
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Introduction
Up to 5%  of patients with colorectal cancer have Lynch syndrome (hereditary 
non-polyposis colorectal cancer (HNPCC) [1-3]. Unfortunately, only a small 
proportion of the expected number of patients undergo genetic testing. 
Identification of a hereditary predisposition can be life-saving. When more 
patients are traced with hereditary colorectal cancer, an increasing number of 
relatives can receive appropriate surveillance, which will prevent premature death 
from colorectal cancer [4]. To enhance the detection of Lynch syndrome, a special 
strategy has been developed for risk patients who cannot be recognized by family 
history. This new strategy called MIPA involves MSI-testing by pathologist in new 
patients with CRC below the age of 50 [5]. It is being introduced at an increasing 
number of hospitals. In this strategy, the pathologists select patients and tumour 
specimens for microsatellite instability (MSI) testing. In case of a positive MSI test, 
the patient is at risk for Lynch syndrome and thus referred for genetic counseling 
to a clinical genetic center.
For the patients, the difference between the new strategy and the existing procedure 
is that genetic counselling and testing is discussed very shortly after the diagnosis 
of colorectal cancer, instead of a long period after diagnosis and treatment. In this 
early stage after diagnosis, patients with colorectal cancer may be more emotionally 
vulnerable. Concurrently, these patients are confronted with three major tasks: (1) 
to cope with their cancer, (2) to cope with the consequences of a possible genetic 
risk and (3) to consider informing and discussing genetic counseling and DNA-testing 
with their blood relatives. Extended work already has been accomplished on familial 
cancer in general, including colorectal patients tested for Lynch syndrome. In a 
number of reviews on familial cancer, colorectal cancer was included as one of the 
familial cancers [6, 7]. Many studies describe the psychological impact of pre 
symptomatic testing for Lynch syndrome [8-22]. From these studies it can be 
concluded that in general genetic counselling and pre symptomatic testing for 
Lynch syndrome can lead to increased distress immediately after DNA-test disclosure 
but does not lead to long-term adverse effects. Other related studies assessed 
experiences of patients and family members with genetic counselling for hereditary 
cancer and [23], the impact of attendance of a familial colorectal clinic on 
cancer-related concerns [24], subjective perception regarding colorectal cancer [25, 
26], compliance with screening after testing [25]], genetic testing for Lynch 
syndrome in colorectal cancer survivors who were more than 1 year after diagnosis 
[27] and quality of life after various surgical procedures [28].
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Obviously, this new Lynch detection strategy gave rise to systematically survey 
relevant data related to the issue of the impact of symptomatic genetic testing in 
patients with colorectal cancer in their first year after colorectal cancer diagnosis. 
A literature review was conducted to identify the psychological impact of 
colorectal cancer, focusing on the impact of the malignancy during the first year 
after primary treatment and of the additional impact of genetic testing for Lynch 
syndrome in affected patients.
Material and methods
The electronic databases PubMed and Psychlnfo were searched to identify all the 
reports published between January 1997 and October 2007 on the psychological 
impact of colorectal cancer and genetic testing for hereditary colorectal cancer 
(Lynch syndrome) in patients during their first year of colorectal cancer. Two 
searches were performed in each database.
Search 1 retrieved literature on the psychological impact of the diagnosis and 
treatment of colorectal cancer. A sensitive search strategy was adopted using the 
following keywords: colorectal cancer, colorectal tumour(s), colorectal carcinoma, 
colorectal neoplasms, psychological distress, psychological adaptation, coping, 
emotional adjustment, anxiety, depression and quality o f life. Using these keywords, 
470 abstracts were retrieved: 415 from PubMed and 55 from Psychlnfo. After 
removing doubles, one of the reviewers (KL) checked all the titles and abstracts. 
Full text copies were obtained when the studies had possible relevance. Inclusion 
criteria were (1) studies on patients in their first year with colorectal cancer (2) 
psychological outcome measurements, (3) peer-reviewed articles in English, 
French or Dutch. From studies with a prospective design with long-termfollow-up, 
only the results up to 1 year were retrieved. Exclusion criteria were (1) Patients 
with colorectal cancer aged >70 years. These patients are not generally referred 
for genetic testing due to their advanced age. (2) Colorectal cancer disease 
management studies and subjective experiences. (3) Qualitative design. (4) 
Research into non-standard medical treatment. (5) Publications of which no 
relevant data (mean scores) could be retrieved. Based on these criteria, 17 studies 
remained (see Fig.1).
Search 2 retrieved literature on the psychological impact of genetic testing in 
patients with colorectal cancer. The keywords in search 1 were used in combination
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Figure 1 Selection of studies on the psychological impact of colorectal 
cancer until 1 year after treatment (*1) and diagnostic genetic 
testing for hereditary colorectal cancer (*2)
Abstracts identified by keywords Abstracts identified by keywords
(*1) n=470 (*2) n=101
After reading 
abstracts and 
removing doubles 
n= 415
> 1 year after CRC 
diagnosis 
n= 18
Review
n=8
Too specific medical 
treatment or patient 
group 
n=3
No psychological 
outcome 
measurements 
n= 2
Other non-relevant 
design n=7
After reading 
abstracts and 
removing doubles 
n= 74
Qualitative design 
n=3
Review
n=2
Presymptomatic 
-► testing n=7
Other non-relevant 
design n=5
Included n=17 Included n=10
with the terms genetic testing, genetic predisposition to disease, genetic screening, 
genetic counseling and genetics. Using these keywords, 101 abstracts were retrieved. 
After removing doubles, one of the reviewers (KL) checked all the titles and abstracts. 
Full text copies were obtained of all the possibly relevant studies. Inclusion criteria 
were (1) patients diagnosed with colorectal cancer (2) psychological outcome 
measurement, (3) peer-reviewed articles in English, French or Dutch. Exclusion 
criteria were (1) Pre-symptomatic/predictive testing, because our focus was on the 
impact of genetic testing in patients diagnosed with colorectal cancer. (2) Qualitative 
design. (3) Genetic testing for Familial Adenomatous Polyposis (FAP). (4) Publications 
of which no relevant data (mean scores) could be retrieved. Based on these criteria, 
ten studies remained (see Fig.1).
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Additional free text searches were performed in PubMed, Psychlnfo as well as in 
the Cochrane Library database and in Embase using all the above-mentioned 
keywords to select reviews on the psychological impact of colorectal cancer and 
genetic testing for hereditary colorectal cancer. However, none of these searches 
led to any relevant publications.
Methodological quality
The studies were assessed according to the guidelines for levels of evidence and 
grades of recommendation, supplied by the Oxford-Centre for Evidence-based 
Medicine. A level of evidence LEI refers to RCT studies, LE2 to cohort studies, LE3 
to case-control studies, LE4 to case-series and LE5 to expert opinions (http://www. 
cebm.net/levels of_evidence.asp).
Results
I Psychological impact of colorectal cancer
Table 1 gives a summary of each of the 17 papers [29-45] included in our review. 
The vast majority of the patients with colorectal cancer were older than 50 years. 
As a result of the heterogeneity of psychological variables and used measurement 
instruments of the retrieved studies, a limit was set in describing those studies 
that used the European Organization for Research and Treatment in Cancer 
(EORTC) QLQ-C30 scale. In ten out of the 17 studies, the European Organization 
for Research and Treatment in Cancer (EORTC) QLQ-C30 scale had been used to 
measure the quality of life of the patients [29-32, 35, 41, 43-46]. This scale has 
frequently been used to assess health-related quality of life in various groups of 
cancer patients [47].
The mean scores on functional status were retrieved from the studies, because an 
important aim of this review was to evaluate functioning after treatment for 
colorectal cancer. The scores are presented in Table 2. Our comparison may not do 
justice to the special qualities of each individual study, as their designs were 
intended to provide answers to specific research questions, not to facilitate 
comparability. Nevertheless the comparison adds new dimensions to our 
knowledge in this area. To evaluate the significance of these function scores, they 
were compared to reference data from a random sample (n = 2081) of the general
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(non-cancer) adult population [47] and from breast cancer patients [48] (Table 2). 
According to the MIPA (MSI test by pathologist) procedure, MSI-positive patients 
are usually informed about the results and offered genetic testing within 3 months 
after surgery. Therefore, clear distinction is made between psychological 
functioning in the first 3 months after treatment and in the subsequent period up 
to 1 year after treatment. In the publications of Schmidt [42] and Tsunoda [44] the 
EORTC-QLQ-C30 data were presented in graph and mean data could not be 
obtained and used reliably. The study of Wilson et al. [45], only presented mean 
data on EORTC-QLQ-C30 Global Health Status. Therefore, these three studies are 
not reflected in Table 2.
Regarding the psychosocial impact of CRC with other instruments than the 
EORTC-QLQ-C30, it appeared that often different questionnaires were used, 
concerning patients at different ages, with different types of colorectal cancer 
and often with different times of data collection. Still, an overall impression was 
obtained that demands of illness, especially psychosocial and existential concerns, 
were greater among the youngest age group below 45 years. Moreover, patients 
with a stoma showed higher levels of depression and poorer social function than 
non-stoma patients. Especially men with a stoma reported sexual problems as did 
patients after treatment for rectal cancer.
Impact of colorectal cancer on functional status 
Up to 3 months a fte r treatm ent
Table 2 shows that compared to the reference data, colorectal cancer led to 
reduced social functioning (especially in the patients with a stoma) as well as to 
decreased role and physical functioning [29-32, 37, 41, 43]. Patients of younger 
than 65 years and those with a stoma reported reduced health-related quality of 
life 6 weeks after surgery [45]. In the group with rectal cancer the men suffered 
from more problems with their sexual functioning after abdominoperineal 
resection than the women [43]. It can be concluded that immediately after 
treatment for colorectal cancer, physical, social and role functioning were 
diminished especially in patients with a stoma, compared to levels of physical, 
social and role functioning of a selected sample of adults [47] and of patients with 
lung cancer (another common malignancy worldwide) [49, 50].
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Table 1 Characteristics of the studies on the psychological impact of diagnosis
and treatment for colorectal cancer up to 1 year after primary treatment (n = 17)
Author LE N Mean age at 
inclusion years 
(SD) [range]
Time of 
data collection
Study m ethod/ 
questionnaires
Kopp et al. [37] 1 79 72.4 [53-90] At discharge and 
6 months after 
treatment
EORTC QLQ-C30/CR38
Marijnen et al. 
[38]
1 990 64 [NP] Pre-treatment, 3,6,12, 
18 and 24 months after 
treatment
RSCL; VAS
Allai et al. [29] 2 53 58(11) Pre- and 12-16 months 
post
EORTC QLQ-C30/CR38
Arndt et al. [30] 2 309 65.1 (9.4) 1 year after diagnosis EORTC QLQ-C30
Engel et al. [32] 2 299 <70 n = 212; >70 
n = 87
At treatment and
annuallyto4years
follow-up
EORTC QLQ-C30/CR38
Fatma et al. [31] 2 160 50 [18-83] During visit first line MD FACT-C; Spitzer QoL
Fernsler et al.
[33]
2 121 51.9 [26-82] Through computer 
networks
DON; SWBS
Gall et al. [34] 2 338 <60 n = 43; 60-69 
n = 77; >70 n = 218
6 weeks, 6 months after 
treatment until 2 years 
follow-up
HADS; S F12 ; PSVQ
Guren et al. [35] 2 42 67 [38-78] Start and end treatment 
and 4-6 weeks follow- 
up
EORTC QLQ-C30/CR38
Klemm et al. [36] 2 21 51.9 (NP) Via online CRC support 
group
DON
Nordin and 
Glimelius [39]
2 139 67 (NP) <12 weeks after 
diagnosis
RDCQ; IES; MAC; HADS
Norum [40] 2 94 62 [40-76] 16 months after 
treatment
IES
Ross et al. [41] 2 249 64.5 (NP) 3,6,12 and 24 months 
after initial treatment
EORTC QLQ-C30/CR38
44
Main outcome measures Main psychological findings
Quality of life Six months after surgery, global quality of life approximated normal 
values but deficits remained in role, physical and social functioning
Health-related quality of life 
and overall perceived health
Few QoL differences between PRT+ and PRT- group. PRT negative effect 
on sexual functioning, deteriorating overtime
Quality of life Compared to pre-RT scores, at 1 year, improvement in emotional state, 
perspective of the future, global QoL. Sexual dysfunction increased, 
particularly in men
Quality of life Severe limitations in emotional and social functioning predominantly in 
patients younger than 60 years
Quality of life Compared to a general population sample, patients had the largest 
differences with regard to role and social functioning
Quality of life >40% of the patients reported signs of psychological distress, 35% 
expressed fear of dying
Demands of illness; spiritual 
well-being
DOI greater among men, the youngest subjects (26-45 years), who 
received treatment in the previous 2 months. Women reported greater 
spiritual well-being than men
Anxiety, depression, health- 
related quality of life
At baseline, mental HRQoL scores consistent with average values in the 
population. Levels of anxiety and depression consistent with or lower 
than population norms
Quality of life At the end of RT, physical and social functioning and global quality of life 
poorer than population norms. HR QoL scores returned to pre-treatment 
levels 4-6 weeks after RT
Demands of illness The 10 most intense demands predominantly psychosocial and 
existential concerns. Respondents in the youngest age group (<45 years) 
greater demands
Diagnosis reactions; impact 
of event; adjustment to 
cancer, anxiety; depression
Patients with CRC more confrontational attitude than those with gastric 
cancer; avoidance in men lower than in women, mental adjustment 
better in women
Impact of event Less than one-third of the patients reported a moderate to high level of 
psychological distress
Quality of life Patients with stoma higher levels of depression and poorer social 
functioning than non-stoma patients. Male patients with stoma more 
sexual problems than males without
45
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Table 1 Continued
Author LE N Mean age at 
inclusion years 
(SD) [range]
Time of 
data collection
Study m ethod/ 
questionnaires
Schmidt et al. 
[42]
2 253 <70 n =  168; >70 
n = 85
Pre-surgery, 3,6,12 
and 24 months after 
treatment
EORTC QLQ-C30/CR38
Schmidt et al. 
[43]
2 368 64.9 (11.1) Pre-surgery, at 
discharge, 3,6,12 
and 24 months after 
treatment
EORTC QLQ-C30/CR 38
Tsunoda et al. 
[44]
2 100 64 [33-83] Pre-treatment and 
monthly follow up to 
1 year
EORTC QLQ-C30
Wilson et al. [45] 2 201 68.2 [36-91] 6 weeks after treatment EORTC QLQ-C30; FACT-C; SF12; 
EQ-5D
Questionnaires EORTC QOL-C30/CR38, DON, SW BS, FACT-C, Spitzer QoL, SF12, PVSQ, RSCL, VAS, IES, 
EQ-5D, RDCQ, MAC
NP( not present; MD, medical doctor; RT, radiotherapy; PRT, pre-operative radiotherapy; (HR)QoL, 
(health-related) quality o f life; LE, level o f evidence
Table 2 EORTC QLQ-C30 functioning scores concerning the psychological impact of
colorectal cancer (scores from 0 to 100, higher score means better functioning)
Time of data collection Physical
Refdata Servaesa et al. 
[48]
6-70 months after breast cancer treatment 72.6 (18.8)
Male Female
Schwarz and Hinzb [47] A-selected non-cancer population 92.0
(15.6)
88.7
(17.5)
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Main outcome measures Main psychological findings
Quality of life Role functioning better in patients <70 years. Younger patients more 
sexual problems
Quality of life QoL below baseline early postoperative period, after 3 months, global 
health, emotional and physical functioning improved. Men high levels of 
strain related to sexual problems
Quality of life Physical and role functioning below preoperative values 1 month after 
surgery, returned to preoperative values <3 months. Global health, 
emotional and social functioning improved within 3 months
Physical and mental health- 
related quality of life
Patients <65 years and those with a stoma poor health-related quality of 
life
Role Emotional Cognitive Social Global health 
status
71.4 (22.7) 71.2 (21.8) 73.7 (24.0) 82.5 (22.8) ND
Male Female Male Female Male Female Male Female Male Female
89.8
(21.7)
86.6
(23.7)
81.8
(18.8)
76.3
(22.2)
92.7
(15.0)
90.1
(18.4)
92.0
(18.3)
90.3
(20.1)
72.7
(22.2)
69.2
(21.9)
47
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Table 2 Continued
Time of data collection Physical
Schmidt et al. [43] Before surgery 86.1
(20.4)
78.5
(22.0)
At discharge 64.4
(27.1)
50.6
(25.7)
3 months after surgery 74.5
(22.8)
60.4
(24.8)
6 months after surgery 76.8
(20.9)
66.4
(23.5)
12 months after surgery 78.1
(21.8)
68.3
(25.5)
Koppc et al. [37] At discharge 54.5
6 months after surgery 69.9
Arndt et al. [30] 1 year after diagnosis 79.5 (24.0)
Engeld et al. [32] 1 year after surgery 81.8
Ross® et al. [41] Follow-up after surgery No stoma 75.2 (1.8)
FU stoma 67.3 (4.3)
Initial stoma 82.2 (4.4)
Initial stoma 
and FU stoma
78.5 (2.7)
Gurenf et al. [35] Before radiotherapy 78 (25.9)
Aliai9 et al. [29] Before radiotherapy No stoma 88
Stoma 77
12-16 months after No stoma 90
radiothera py Stoma 80
ND( no mean data available
aEORTC QLQmC30 reference data, mean and standard deviation (brackets) from severely fatigued 
disease-free breast cancer patients (n = 57)
bEORTC QLQ-C30 reference data, mean and standard deviation (brackets) from an a-selected general 
non-cancer adult population (n = 2028)
cData from the RCT group, standard deviation scores range between 22.8 and 32.4 score points at
discharge and between 16.1 and 29.5 score point 6 months after surgery
dlf n > 100 SD is 9.0-37.0 (SD scores derived from original SEM scores)
eFU stoma, stoma at follow-up, SD scores derived from original mean data and Cl scores
fSD scores derived from original SEM scores
gNo SD scores could be obtained
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Role Emotional Cognitive Social Global health 
status
82.7
(30.5)
76.7
(30.3)
66.5
(23.8)
58.5
(26.0)
85.1
(19.6)
80.8
(23.9)
78.4
(26.1)
75.1
(30.9)
62.4
(25.2)
57.7
(24.1)
41.3
(39.5)
37.2
(38.6)
63.4
(23.5)
52.6
(25.4)
75.5
(26.1)
72.8
(26.5)
58.2
(32.3)
57.5
(33.5)
47.5
(19.6)
43.3
(22.8)
66.0
(32.2)
58.6
(32.5)
70.8
(25.0)
66.0
(25.4)
80.4
(25.4)
78.0
(24.4)
63.5
(29.6)
57.1
(31.8)
61.4
(20.3)
54.4
(21.2)
68.6
(32.3)
64.5
(30.8)
71.4
(23.6)
66.9
(23.8)
81.6
(23.2)
80.8
(23.5)
64.4
(30.1)
64.9
(31.4)
63.3
(19.5)
58.1
(20.5)
72.0
(31.4)
70.5
(31.0)
71.3
(23.6)
68.2
(24.3)
81.8
(22.7)
82.2
(23.7)
68.5
(30.3)
64.9
(33.2)
65.3
(20.1)
61.0
(23.9)
46.5 66.3 70.9 72.1 52.6
61.6 73.3 73.7 74.9 63.6
74.4 (33.4) 67.0 (28.2) 78.5 (26.6) 74.7 (30.9) 62.8 (22.4)
65.2 68.9 82.6 73.7 65.3
79.3 (1.9) 83.9 (1.5) 84.7(1.5) 93.8(1.3) 72.9(1.5)
68.2 (6.0) 80.1 (4.1) 75.4(4.1) 84.1 (3.7) 65.1 (4.3)
84.4 (5.9) 86.7(4.1) 88.8 (4.1) 92.3 (3.6 73.5 (4.4)
78.4 (2.9) 82.7 (2.3) 86.9(2.2) 89.4(1.9) 72.9(2.3)
87(16.2) 84(15.6) ND 72 (29.8) 72 (24.6)
86 74 88 92 75
81 73 95 87 69
88 86 94 89 82
89 90 94 91 7
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Between 3 and  12 months a fte r treatm ent
Reduced role, emotional and social functioning continued up to 1 year after 
treatment. The women reported poor physical functioning [43] compared to the 
reference data [47] and the scores from a severely fatigued breast cancer group 
[48]. Global health status scores of the patients with colorectal cancer were also 
poorer than the reference data [47]. Severe limitations were found in emotional 
and socialfunctioning upto 1 yearaftertreatm ent.Theseproblem swereespecially 
likely to affect patients of younger than 60 years [30]. In the men, strain due to 
sexual impairment appeared to persist [29, 43, 46]; the men with a stoma had 
more sexual problems than those without [41]. Rectal cancer patients reported 
poor role and social functioning compared to the reference data [47] up to 1 year 
after treatment [32]. In the patients who had pre-operative radiotherapy, 
emotional functioning was impaired compared to the norm data [47]. At 
12-16 months after radiotherapy, these scores had returned to normal levels [29]. 
Thus, severe problems with emotional and social functioning persisted up to
1 year after treatment, especially in the patients of younger than 60 years and in 
those with a stoma.
Impact of colorectal cancer on demands of illness and spiritual 
well-being
In two studies, patients younger than 45 years reported greater demands of illness 
(hardships or stressors that require coping or adjustment to illness) than the older 
patients [33, 36]. Fernsler et al. [33] also showed that such demands of illness were 
greater in men and in men and women who had received treatment in the previous
2 months; in contrast, the women reported significantly higher spiritual well-being 
than the men. This leads to the conclusion that colorectal cancer caused more 
hardships and stressors in men and in patients diagnosed before the age of 
45 years.
II Psychological impact of genetic testing for Lynch syndrome
Summaries of the ten relevant studies are shown in Table 3. Nearly all the studies 
had gathered data on the patients before disclosure of the genetic test result. Two 
studies had made assessments pre-test and post-test [18, 33, 51], whereas one 
study had only made assessments post-test [52]. Very few studies gave specific 
details about the time interval since the diagnosis of colorectal cancer and
50
inclusion in the study [53,54]. Tab le 3 also shows the diversity in outcome measures 
and (self-administered) questionnaires to gather data [18, 51, 55-58]. The aim of 
this review was to determine how patients with colorectal cancer reacted to (the 
offer of) genetic testing.Therefore, the psychological reactions were documented 
according to stage of genetic testing the patients had reached at the time of the 
studies. The process of genetic counselling was divided into three distinct stages: 
(1) Period of genetic counselling and if desired, having a blood sample taken. (2) 
Period of waiting for the result of the DNA analysis. (3) Period after disclosure of 
the genetic test result.
Psychological reactions before genetic counseling
The three relevant studies showed that patients with colorectal cancer tended to 
have positive attitude towards genetic testing [56, 57, 59]. Their most common 
motivation to undergo genetic testing was concern about the risk of colorectal 
cancer in close relatives. Motivation was the highest in the younger patients, in 
those with early stage disease and in those who had more frequent thoughts 
about hereditary colorectal cancer [57]. In a group of patients with colorectal 
cancer who attended an information session about Lynch syndrome, 28% 
developed a clinically significant level of cancer-worry-related distress [56]. In 
conclusion, motivation to undergo genetic testing was primarily the need to know 
if close relatives were at increased risk for colorectal cancer and was strongly 
present in younger patients.
Psychological reactions before and after genetic counseling
Other studies obtained data on the patients after patients had consented to have 
a blood sample taken for DNA analysis. Keller [55] and Murakami [51] found 
clinically relevant depression scores before and after genetic counseling in 19 and 
5% of the patients, respectively. Another study reported clinically relevant anxiety 
levels in 32% of the patients before genetic counseling, whereas the scores 
dropped to 16% after genetic counseling [55]. In a group of patients who had 
given a blood sample for genetic testing, the prevalence of depressive symptoms 
was 24%, although all the scores remained within the clinically normal range [54]. 
Patients in the age group of younger than 50 years had higher levels of anxiety 
and depression but the scores were within the normal range; their data also 
showed significant associations between pre-test distress, a history of familial 
mortalityfrom colorectal cancerand anticipation of becoming depressed post-test 
[53]. Characteristics associated with depression were female sex, less formal
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Table 3 Characteristics of studies on the psychological impact of diagnostic genetic testing 
for Lynch syndrome on patients with colorectal cancer (n = 10)
Author N Inclusion age mean 
(SD)/median [range]
Time of data 
collection
Study m ethod/ 
questionnaires
Espíen et al. [53] 220 63 (9.6) At pre-test IES, STAI, CES-D
G ritz et al. [16] 155 >50 n = 56; <50 n = 99 At pre-test, 2 weeks,
6 and 12 months after 
result disclosure
CES-D, STAI, RIES, QU and Saq
Ho et al. [59] 62 42 (9.9) Pre and post result 
disclosure
DBS, C-HADS, C-MBSS, LOT
Kelleret al. [55] 65 Patients 50.3 (12.2); at 
risk persons 37.0 (9.1)
Pre and 4-6 weeks after 
genetic counselling
MOS-SF12,GBB, HADS, IES 
and Saq
Kelleret al. [56] 73 49 (17) After information 
session on HNPCC
Saq
Kinney et al. [57] 98 64 (13) Before genetic 
counselling or testing
Saq
Loader et al. [52] 36 59.9 (6.7) 3 and 12 months after 
result disclosure
SF36, IES, SSSQ, BSS
Murakami et al. 
[51]
42 50 [21-69] After first genetic 
counselling session for 
HNPCC and 1 month 
after result disclosure
SCID ASD/PTSD/PTSS and Saq
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Main outcome measures Main psychological findings
Impact of event, state and 
trait anxiety and depression
Women higher levels of intrusion and avoidance compared to males. 
Patients diagnosed before 50 years significantly higher levels of anxiety 
and depression than those diagnosed after 50 years. Diagnosed within 
one year significantly lower levels of intrusion and avoidance, than 
those over 2 years after diagnosis. Significant associations between 
pre-test distress, family history of CRC and mortality related to CRC and 
anticipation of becoming depressed at post-test
Depression, state and trait 
anxiety, impact of event test 
result, quality of life, cancer 
worries and perceived 
cancer risk
Mean scores of all outcome measures within normal limits for cancer- 
affected participants. Affected and unaffected carriers higher mean 
test-specific distress scores at 2 weeks post result disclosure compared 
to non-carriers; scores decreased in affected carriers and all unaffected 
participants from 2 weeks to 12 months post result disclosure. 
Unaffected mutation carriers may experience increased distress during 
the immediate post result disclosure period.
Decisional consideration, 
attitude genetic testing, 
anxiety, depression, coping 
style
Participants even more concerned about well-being and reactions of 
their significant others than their own well-being in their decisional 
consideration process. Those with higher depression levels tended to 
emphasise more on the negative consequences of learning test results
Health state and complaints, 
anxiety, depression, impact 
of event, evaluation of 
counselling
Distress and HNPCC related worries declined after counselling. Distress 
decrease partly attributable to increase in personal self-confidence. One- 
third reported enhanced family communication specific to hereditary 
cancer. Twenty-five per cent reported cancer-related worries before 
testing. This dropped to 13% post-genetic counselling.
Cancer worry, attitude 
genetic testing, family 
communication
Distress clinically significant in 28% of participants. Restricted family 
communication was reported frequently. Positive attitude towards 
obtaining a gene test result predominated
Knowledge and risk 
perception CRC genetics, 
health behaviour, 
knowledge/interest genetic 
test
61% worries about relative's CRC risk, 64% concerned about being a 
carrier. 81% had never heard of genetic test for hereditary CRC. 72% 
stated they would take the test. Predictors to take the test: younger age, 
less advanced stage of disease and more frequent thoughts about CRC 
being hereditary
Health state, impact of event, 
social support, preventive 
behaviour
At 12 months post result disclosure more knowledge in carriers, younger 
when DNA tested oryounger at CRC diagnosis. All but one told relatives 
about their gene mutation. Self-assessed mental health better in married 
patients
Acute stress disorder, post- 
traumatic stress disorder or 
symptoms and feelings of 
guilt
None of the participants met the criteria for major depression, ASD 
or PTSD 1 month after result disclosure. 7% met the criteria for minor 
depression and 5% had PTSS. The only predictor of psychological distress 
was the presence of a history of major or minor depression. 12% had 
feelings of guilt
53
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Table 3 Continued
Author N Inclusion age mean 
(SD)/median [range]
Time of data 
collection
Study m ethod/ 
questionnaires
Vernon et al. [54] 200 ORPS After provision of blood 
sample for DNA analysis
CES-D, STAI, SSSQ, MBSS
Vernon et al. [58] 269 <50 n = 105; >50 n = 164 After provision of blood 
sample for DNA analysis
CES-D, STAI, MBSS,SSSQ,QLI 
and Saq
Questionnaires (R)IES, CES-D, STAI, (C)HADS, SF12, (C)MBSS, Sarason SSQ, QLI, DBS, LOT, SCID 
Saq, self-administered questionnaires; ORS, only presented in relation to psychological scores; CRC, 
colorectal cancer; HNPCC, hereditary non-polyposis colorectal cancer (Lynch syndrome)
education, fewer sources of social contact; associations with anxiety were younger 
age, less formal education, Non-Caucasian race, more severe disease and fewer 
sources of social contact [54]. Intrusion scores reached clinically relevant levels in 
14% of the patients [55]. Higher intrusion and avoidance scores were found in 
women and in the patients who had been diagnosed with colorectal cancer less 
than 1 year previously, although all the scores remained within the normal clinical 
range [53]. Clinically relevant cancer-worry-related distress was detected in 25% 
of the patients before genetic counseling, but after genetic counseling, this 
dropped to 13% [55]. In conclusion, most psychological distress scores remained 
within the normal range before the result of the genetic test was disclosed, 
although a minority of the patients developed clinically relevant anxiety and 
depression levels. Vulnerable subgroups were female patients and male patients 
diagnosed before the age of 50 years.
Psychological reactions after disclosure of the genetic test result
Disclosure of the genetic test result led to significant depression scores in 7%  of 
the patients and post-traumatic stress symptoms in 5%  [51]. Lynch syndrome 
mutation carriers showed higher test-specific distress than non-carriers but these
54
Main outcome measures Main psychological findings
Depression, state and trait 
anxiety, social support, 
quality of life and coping 
style
Prevalence of depression symptoms was 24%. Female sex, less formal 
education, fewer sources of social contacts and less satisfaction 
with them were associated with high scores on the CES-D scale. 
Characteristics associated with high anxiety were younger age, less 
formal education, non-White race, advanced local-regional disease, 
fewer social contacts and less satisfaction with them
Depression, anxiety, coping 
style, social support, quality 
of life and intention genetic 
testing
90% intended to learn genetic test results. Intention positively associated 
with income, quality of life, a belief that being tested will help family 
members prevent cancer, being worried about carrying an altered 
gene and beliefthat one has ability to cope with test results. Negative 
association with beliefthat genetic counselling is too much trouble 
relative to benefits
scores returned to baseline between 2 and 12 weeks after receiving the test result 
[18]. The only predictor of psychological distress after disclosure of the test result 
was a history of depression [51]. It can be concluded that disclosure of the genetic 
test result did not lead to any relevant levels of psychological distress in most 
patients. Vulnerable subgroups seemed to be patients with pre-test distress, high 
familial mortality from colorectal cancer and a history of depression. Therefore, a 
subgroup of vulnerable patients whose genetic test discloses Lynch syndrome 
mutation carrier ship may benefitfrom  extra psychological counselling.
Discussion
This literature review shows that little is known about the additional psychological 
impact of obtaining a genetic test disclosure in newly diagnosed patients with 
colorectal cancer. Only ten studies were identified on diagnostic genetic testing 
in colorectal patients. Most of these studies measured distress prior to genetic 
test disclosure, but did not obtain data after disclosure of the test result. Prior to 
disclosure of the genetic test result, female patients and men who were diagnosed
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with colorectal cancer before the age of 50 years appeared to be more vulnerable 
to genetic-test-related distress. A history of depression and high levels of pre-test 
distress were strongly associated with genetic-test-related distress and cancer 
related worries. It is generally known that a young age at diagnosis and multiple 
family members with cancer are hallmarks of heredity. Therefore, significant levels 
of anticipated psychological distress prior to disclosure of the genetic test result 
in patients with a history offamilial mortality from cancer [53] can also be regarded 
as relevant to patients with colorectal cancer who are suspected of Lynch 
syndrome carriership.
The few studies available on distress after disclosure of the genetic test result 
revealed ambiguous results. For patients with different types of cancer, the impact 
of genetic testing many years after the initial cancer diagnosis and treatment was 
strongly influenced by their former experience of cancer [7]. Dorval hypothesized 
that after disclosure of the genetic test result, cancer patients may be more aware 
of their own risk developing a second primary tumour and be more conscious of 
the contribution of genetics to an increased risk of cancer in their offspring [60]. 
When genetic testing was offered to recently diagnosed colorectal cancer 
patients, the majority did not object to an active approach [61]. Individuals at 
high-risk for Lynch syndrome proved to know very little about microsatellite 
instability (MSI) testing, a hallmark for patients at risk for Lynch syndrome, but 
held positive attitudes towards MSI test utility [62].
This literature review also shows that most patients with colorectal cancer 
experience diminished physical, social and role functioning during the first
3 months after primary treatment. Decreased emotional and social functioning 
could persist for up to 1 year after treatment, especially in patients of younger 
than 60 years and in those with a stoma. Specific subgroups of patients with 
colorectal cancer appeared to be more vulnerable to genetic-testing-related 
distress, but their actual levels of distress did not generally reach clinical 
significance. Reduced emotional and social functioning may be related to the 
many taboos that still surround bowel dysfunction [63]. Especially the younger 
patients reported severe distress due to maladjustment to their colorectal cancer. 
Having a stoma can lead to feelings of stigmatization and lead to withdrawal from 
social activities [64, 65]. Recurring themes in patients with colorectal cancer are 
loneliness and isolation [63]. It might be expected that disabilities after colorectal 
cancer treatment prevent the younger patients from going to work and contribute
56
to their impaired social and role functioning, but it was found that most patients 
with colorectal cancer returned to work after treatment [64, 66]. An additional 
source of distress especially in younger male patients was the possible impact on 
sexual functioning [64, 67]. Studies have shown that after treatment for rectal 
cancer, sexual problems were common, inadequately discussed and/or treated by 
physicians [67]. Furthermore, the potential for impotence due to treatment for 
colorectal cancer was a serious concern especially in patients of younger than 
60 years [64].
Conclusion
This review identifies the psychological impact of colorectal cancer during the 
first year after treatment and indicates specific subgroups of patients with 
colorectal cancer who could be vulnerable to genetic-testing-related distress. 
Most of the retrieved studies on diagnostic genetic testing for Lynch syndrome 
exclusively measured distress prior to genetic test disclosure and focused on 
patients who were diagnosed with colorectal cancer several years ago. Therefore, 
we are still unable to identify the psychological impact of genetic testing for 
Lynch syndrome in recently diagnosed patients with colorectal cancer.
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Shortened time interval between 
colorectal cancer diagnosis and risk testing 
for hereditary colorectal cancer is not related 
to higher psychological distress
Abstract
In tro d u ctio n  Current diagnostic practices have shortened the interval between 
colorectal cancer (CRC) diagnosis and genetic analysis for Lynch syndrome by 
MSI-testing. We studied the relation of time between MSI-testing since CRC 
diagnosis (MSI-CRC interval) and psychological distress.
M ate ria l and m ethods We performed a cross-sectional study in 89 patients who 
had previously been treated for CRC. Data were collected during MSI-testing after 
genetic counseling. Psychological distress was measured with the IES, the SCL-90 
and the POMS; social issues with the ISS, ISB and the ODHCF.
Results The median time of MSI-CRC interval was 24 months (range 0-332), with 
23% of the patients diagnosed less than 12 months and 42% more than 36 months 
prior to MSI-testing. In 34% of the patients cancer specific distress was high (IES 
scores > 26). Mean psychopathology (SCL-90) scores were low, mean mood states 
(POMS) scores were moderate. Interval MSI-CRC was not related to psychological 
distress. High cancer specific distress was reported by 24% of patients diagnosed 
with CRC less than 12 months ago versus 39% and 35% by those diagnosed 
between 12-36 months and more than 36 months ago respectively. Distress was 
positively related to female gender (p=0.04), religiousness (p=0.01), low social 
support (p=0.02) and difficulties with family communication (p<0.001). 
Conclusion Shortened time interval between CRC diagnosis and MSI-testing is 
not associated with higher psychological distress. Females, religious persons, 
those having low social support and those reporting difficulties communicating 
hereditary colorectal cancer with relatives are at higher risk for psychological 
distress.
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Introduction
In the Netherlands more than 11.000 people are diagnosed with colorectal cancer 
each year [1]. This means that around 1 in 20 Dutch people will develop colorectal 
cancer in their lifetime. The majority of colorectal cancer patients have sporadic 
disease and only a minority of colorectal cancers has a genetic cause. One 
well-described colorectal cancer genetic syndrome is Lynch syndrome which is 
estimated to account for 3-5% of all colorectal cancer [2, 3]. Lynch syndrome is an 
autosomal dominant inherited disorder characterized by an increased risk to 
develop colorectal cancer (60-90% lifetime risk) and an increased risk of 
extra-colonic tumors, especially endometrial cancer (25-70% lifetime risk); the 
age at diagnosis for colorectal cancer is most often between 41-54 years, for 
endometrial cancer between 45-50 years [2, 3]. Lynch syndrome mutation carriers 
are advised to have regular colorectal screening, starting at the age of 25, with a 
maximum interval of 24 months between each examination [4]. Regular 
surveillance reduces morbidity and mortality by 65% over 15 years in previously 
unaffected relatives and also reduces the risk of a second colorectal cancer in 
patients [5]. Lynch syndrome is caused by mutations in one of the mismatch repair 
(MMR) genes and is characterized by tumors that show microsatellite instability 
(MSI), which is found in more than 90 percent of tumors from patients with Lynch 
syndrome [2]. In current practice, MSI analysis is used as a pre screening tool 
selecting families for further analysis of MMR gene defects [6].
Undoubtedly cancer diagnosis is a traumatic life event [7]. Genetic counseling and 
testing for hereditary cancer can also be a strong stressor [8]. It may cause 
uncertainty about future cancer which may lead to an increased level of cancer 
specific distress, activating intrusion or avoidance or both [9]. After genetic 
counseling, greater awareness of the increased risk of second cancer and of the 
genetic contribution to an increased risk of cancer for their children may lead to 
an increased level of cancer specific distress [8]. Additionally a positive genetic 
test result may reactivate or aggravate distress related to cancer diagnosis and 
treatment [10].
Studies, which address the psychological impact of genetic counseling and testing 
for hereditary colorectal cancer in healthy individuals or given time after cancer 
diagnosis, generally indicate that genetic information does not result in adverse 
psychological outcomes in the long term [11-14]. However, due to a change in 
various protocols, the time between colorectal cancer diagnosis and genetic 
counseling and testing for Lynch syndrome is decreasing. This is partly due to MSI
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testing by pathologists, for instance in tissue of patients diagnosed before age 50 
or from patients with a second CRC before age 70 [15]. A striking psychological 
difference with former practice is that these patients are confronted with a 
possibly hereditary predisposition for Lynch syndrome coincident with treatment 
for CRC. Little is known about the psychosocial impact of genetic testing in 
patients with a recent diagnosis of colorectal cancer.
The aim of the current study is to investigate whether high levels of overall 
psychological distress are present during MSI-testing and whether these levels 
are correlated with time since colorectal cancer diagnosis. For that purpose we 
use both the Impact of Event Scale (IES), the Symptom Checklist-90 and the Profile 
Of Mood States (POMS); the IES because more recently diagnosed patients might 
be more vulnerable to reactivation or aggravation of cancer specific distress and 
the SCL-90 and the POMS to measure general psychological distress during the 
past week. Concerns of heredity mediated distress and cancer specific distress 
may affect both the overall level of distress. However, this cannot be distinguished 
in our sample.
Material and methods
Study design and procedure
A cross-sectional study was performed to determine psychological distress in 
patients previously treated for colorectal cancer just after initiation of MSI testing. 
All patients visited the Department of Clinical Genetics of the Radboud University 
Medical Centre Nijmegen in the Netherlands. Before MSI-testing was started, 
comprehensive genetic counseling took place to ensure that the patient 
understands the implications of the MSI-test. MSI-testing was performed after 
informed consent of the patient. Inclusion criteria of the study were 1) patients 
with colorectal cancer 2) fulfilling one of the Bethesda criteria for MSI-testing [4] 
and 3) having a CRC to be tested for MSI. Patients were excluded in case of 1) 
previous MSI-testing or 2) current treatment for psychiatric disorders. In every 
patient medical history for psychiatric disorders and former and current psychiatric 
treatment is taken. From Augustus 2007 to September 2009, 191 eligible patients 
were approached by their genetic counselor (n=14) to participate the study. Of 
these potential eligible patientsló patients considered participating too stressful, 
three patients were in a terminal phase and two patients had already received the
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MSI-test result. Four patients were in current psychiatric treatment and therefore 
excluded from study participation. Of 77 from the remaining 81 patients personal 
reasons for non-participation were retrieved being "not interested" (64%), "too 
busy" (25%) and "just forgotten" (11%). Finally, written informed consent was 
obtained from 89 participants in accordance to the rules of the Committee on 
Research Involving Human Subjects, Region Arnhem-Nijmegen in the Netherlands. 
Psychological and social data were collected by validated questionnaires 
immediately after initiation of MSI-testing, still before MSI-test disclosure. 
Information regarding family cancer history was retrieved from medical records.
Measures
Demographic and colorectal cancer information
Data were obtained on age, gender, marital and parental status, education, 
religion, cancer status and on having a first degree relative with cancer.
Psychological distress
Cancer specific distress
The Impact of Event Scale (IES) [16, 17] was geared towards colorectal cancer as 
distressing event (scoring 0,1,3,5). A total score of 9-25 reflects moderate 
adaptation difficulties, a score above 26 indicates serious adaptation difficulties 
[18]. The IES is widely used as a measure of cancer specific distress within the 
context of genetic counselling and testing for hereditary cancer [19, 20].
Psychopathology
The Symptom Checklist-90 (SCL-90) is a 90-item indicator for psychopathology. 
A SCL-90 score above 160 is indicative for serious psychological complaints, a 
score above 200 is indicative for a psychiatric disorder [21].
M ood states
The Profile of Mood States-Brief (POMS-SF)[22] measures depression (range 0-32), 
anger (range 0-28), fatigue (range 0-24), tension (range 0-24) and vigour (range 0-20).
Social support
The Inventory for Social Support (ISS) [23] comprises 3 scales: potential emotional 
trust (range 5-20), actual trust (range 3-12) and visits (range 2-8).
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Family communication
Family communication was assessed with an adaptation of the Openness to Discuss 
Hereditary Cancer in the Family Scale (ODHCF) [24, 25]. Openness was assessed with 
the item "I discuss hereditary colorectal cancer with my partner, children, parents, 
brothers, sisters, uncles and aunts, nephews and nieces, respectively, i.e. never (1), 
rarely (2), sometimes (3) and often (4). Family communication difficulties and in need 
of help were assessed similarly (range 7-24).
Statistical analysis
The SPSS 16.0 statistical package was used to analyze the data. Correlations 
between cancer specific distress (IES), psychopathology (SCL-90) and mood states 
(POMS) were assessed by the Spearman' Rank Correlation. Time between colorectal 
cancer (CRC) diagnosis and the initiation of MSI-testing was defined as "Interval 
MSI-CRC" and measured in months. Interval MSI-CRC was divided in 3 categories: 
shortly after CRC diagnosis (< 12 months after diagnosis), recuperating from 
cancer treatment (12-36 months after diagnosis) and diagnosed with cancer longer 
ago (> 36 months after diagnosis). Interrelations between the interval CRC-MSI, 
various other personal variables (i.e. gender, marital and parental status, religion, 
cancer and cancer treatment related, having a first degree relative with cancer, 
social support, family communication) and cancer specific distress were analyzed. 
The IES was dichotomized, where 26 was used as cut-off value for clinically 
high levels of psychological distress [16]. Multivariate logistic regression 
analysis was performed for all variables that were analyzed in univariate analysis 
and were statistically significant correlated with the IES > 26, with stepwise 
removal of non-significant variables. Odds ratios (OR's) were calculated to describe 
associations between personal characteristics and the IES > 26 and presented 
with their 95% confidence intervals (95% Cl). P-values < 0.05 were considered 
statistically significant (two-tailed).
Results
From Augustus 2007 till September 2009,193 patients with a history of colorectal 
cancer were approached by their genetic counselor after genetic counseling and 
initiation of MSI analysis. Eighty-nine patients were included (response rate 46%). 
No significant differences were found regarding sociodemographic and colorectal 
cancer related characteristics between participants and non-participants.
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Sociodemographic and colorectal cancer related characteristics
Most participants were female (64%), married or cohabiting (83%), had children (88%) 
and considered themselves religious (72%). The median age at CRC diagnosis was 49 
years with the youngest patient diagnosed at age 24 years. The median age at 
initiating MSI-testing was 55 years (range 32-85 years). The median time of the CRC-MSI 
interval was 24 months (range 0-332 months). So the range in time since cancer 
diagnosis was large, with 23% of the patients diagnosed less than 12 months and 
42% of the patients diagnosed with cancer more than 36 months ago. Colorectal 
cancer related characteristics of the study sample are provided in Table 1.
Table 1 Colorectal cancer (CRC) related characteristics of the study sample
Patients with a history of CRC 
(n=89)
n %
Lynch syndrome alert
CRC < 50 years 52 58
2x Lynch syndrome related tumor' < 70 years 37 42
First degree relative with cancer 65 73
Cancer treatment
Surgery without adjuvant therapy 36 40
Surgery with chemotherapy (CT) 44 49
Surgery with radiotherapy (RT) 21 24
Surgery with both CT and RT 12 13
Time between CRC and MSI-analysis
< 12 months 21 23
12-36 months 31 35
> 36 months 37 42
* endometrial cancer and carcinomas of stomach, small bowl, biliary tract, brains, 
sebaceous gland, upper urinary tract and ovaries.
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Social characteristics
Social support and family communication characteristics are provided in Table 2. 
Mean social support scores were comparable to those of a norm group in the 
Dutch population [23]. The mean family communication openness score was 
moderate; mean family communication difficulties and in need of help scores 
were low. Of the males, 22% reported difficulties regarding family communication 
about hereditary colorectal cancer versus 55% of the females. Regarding the item 
"in need of help", 25% of the males versus 46% of the females felt the need for 
help in discussing hereditary cancer with the family.
Levels of psychological distress
The mean level of psychological distress (IES) was 16.90 (SD 21.7). More than one 
third of the study sample reported clinically elevated levels of distress (IES > 26), 
of whom 39%fem ales and 25% males. Significantly more patients who considered 
themselves religious reported an IES level above 26 compared to non-religious 
patients (41% versus 16%, P=0.04). Patients who reported difficulties regarding 
family communication were more likely to report an IES level above 26 (47%) than 
patients with good family communication (24%) (P=0.02). Of the patients 
diagnosed with colorectal cancer less than 12 months ago fewer reported high 
psychological distress (24%), than patients diagnosed between 12-36 months ago 
(39%) and those diagnosed more than 3 years ago (35%).
Relations with the total level of psychological distress (IES-total)
In table 3 Spearman rank correlations between patient's personal sociodemo­
graphic / psychosocial characteristics and the total level of psychological distress 
are shown. The total level of psychological distress was significantly correlated 
with gender (P=0.04), being religious (P=0.01), social support visits (P=0.02),family 
communication difficulties (P< 0.001) and family communication in need of help 
(P=0.009). No relation was found of time between CRC diagnosis and MSI-testing 
with levels of psychological distress.
Relations with high levels of psychological distress (IES >26)
Being religious and family communication difficulties were significantly correlated 
with high levels of psychological distress, OR 0.28 (95% Cl 0.09-0.91;P=0.03) and 
OR 0.34 (95% Cl 0.14-0.85; P=0.02), respectively. Multivariate logistic regression 
analysis showed that the presence of high psychological distress was independently 
related to family communication difficulties, OR 0.37 (95% Cl 0.14-0.95;P=0.04).
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Psychopathology and mood states
Psychopathology and mood states scores of the study sample are shown in 
Table 2. The mean psychopathology scores of our participants were low [21], while 
three patients reported high levels of psychopathology (mean 229, range 209-255). 
Mean POMS subscales scores were higher compared to patients with 
gynaecological cancer of whom the majority experienced stage I disease [26] but 
lower than patients with cancer awaiting bone marrow transplantation [27]. No 
statistically significant correlations were found between "Interval MSI-CRC" and 
the SCL-90 or between "Interval MSI-CRC" and the POMS subscales". The SCL-90 
and the POMS correlated significantly with the IES and to avoid duplication of 
results we decided not to report all retrieved data.
Table 2 Psychological and social characteristics of the study sample
Patients with a history of CRC 
(n=89)
Mean SD
Mood states ‘
Depression 2.6 4.8
Anger 2.7 4.5
Fatigue 5.4 5.7
Tension 3.2 4.4
Vigor 10.7 4.7
Psychopathologyb 122.8 30.6
Social supportc
Potential trust 17.1 3.3
Actual trust 7.2 1.9
Visits 6.2 1.2
Fam ily com m unication d
Openness 14.4 4.1
Difficulties 8.3 4.9
In need o f help 7.0 5.0
a, POMS Brief;b, SCL-90; ISS;d, ODHCF.
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Table 3 Correlations with the level of colorectal cancer specific distress 
(IES-total)
Patient's characteristics Colorectal
cancer
distress
Rsa
Sociodemographic
Gender 0.218*
Married or cohabiting - 0.029
Having children 0.014
Being religious 0.272**
Colorectal cancer related
Age at diagnosis - 0.081
Cancer treatm ent - 0.007
First degree relative with cancer - 0.110
Genetic risk assessment
Months between CRC and MSI - 0.005
Interval CRC-MSI in 3 tim e categoriesb - 0.029
Psychological characteristics
Depression 0.447**
Anger 0.348**
Fatique 0.287**
Tension 0.462**
Vigor - 0.279**
Psychopathology 0.532**
Social Support
Potential trust - 0.178
Actual trust 0.119
Visits - 0.243*
Family Communication
Openness - 0.081
Difficulties 0.397**
In need of help 0.275**
a, Rs, Spearman Rank correlation; * ,P <  0.05; **, P <0.01;
b, < 12 months, 12-36 months and >36 months since CRC diagnosis.
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Discussion
The findings suggest that the level of psychological distress is not related to time 
between colorectal cancer diagnosis and MSI testing. In fact, patients diagnosed 
with colorectal cancer less than 1 year ago reported less psychological distress 
than patients diagnosed with cancer longer ago. Contemplation and consideration 
of the cancer is more likely to occur once active treatmentfor cancer in the hospital 
is over. Experiencing intrusive thoughts may be a signal that people are working 
through the implications of the cancer [28]. In line with this, a previous study 
showed that 15% of patients with breast cancer became distressed not until after 
end of treatment, in the reentry phase [29].
Our study results indicate that in general genetic testing during the treatment 
phase of CRC may not be harmful for patients with CRC. However, approximately 
one third of the patients reported clinically high levels of psychological distress. 
The prevalence rate of high cancer distress is higher than the 3-24% reported in 
the literature [8,13,19, 30-32]. This might be explained by selection bias whereby 
individuals who chose to participate in the study were more distressed compared 
to those who did not.
We analysed which patients were at highest risk for distress and found three risk 
factors: gender, religion and reduced social support including impaired family 
communication. In our study female patients reported higher levels of 
psychological distress than male patients. This fits with many other studies in 
which gender is found to be related to psychological distress upon genetic testing
[33] and with a review which demonstrated that female patients with colorectal 
cancer are most vulnerable for hereditary cancer genetic testing related distress
[34]. Unexpectedly, religious patients were found to report the highest levels of 
psychological distress. Previous studies showed that patients use spiritual and 
religious resources to understand and cope with morbidity and mortality [35] and 
that this helps people cope with genetic uncertainty [36]. We note that there are 
positive and negative patterns of religious coping [35] and in this study we did not 
measure distinct religious coping patterns. It might be that in our study sample 
negative religious coping patterns dominated. In a study with participants tested 
for BRCA1 mutations no significant associations between religiosity and 
psychological distress were observed [37]. We conclude to this point that religious 
coping in the context of genetic testing is an area in which more studies are 
needed. Finally, low social support and difficulties with family communication 
were related to higher levels of psychological distress. This is consistent with a
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study among colorectal cancer survivors undergoing genetic testing for Lynch 
syndrome in which higher levels of cancer related distress was related to less 
social support [38]. Genetic testing and hereditary cancer are family matters. 
Family system characteristics may influence the way the individual and the family 
as a whole copes with hereditary cancer [39]. Our data showed that difficulties 
and being in need of help regarding family communication about hereditary 
cancer were related to psychological distress. Participants more frequently 
reported cancer related distress when they perceived family communication 
about hereditary cancer as inhibited [40]. The quality of communication is of 
paramount importance where open family communication may be an important 
buffer against hereditary cancer distress [40]. Patients who report difficulties 
regarding communicating hereditary cancer with the family seems vulnerable to 
high levels of psychological distress. Questioning family communication can 
identify these patients. Former experiences with cancer may also play an role in 
genetic testing responses [41]. Experiences with cancer in the family may result in 
an increased psychological vulnerability during genetic testing for hereditary 
cancer [25]. However, we found no relation between either cancer treatment or 
having a first degree relative with cancer and the level of psychological distress. 
The latter finding is in contrast with a study which showed that having a first 
degree relative with colorectal disease predicted a higher level of distress about 
colorectal cancer [42]. Previous studies found being unmarried [43] and having 
children [33] as predictors of psychological distress related to genetic testing for 
hereditary cancer. In our study sample however, no correlations were found 
between marital or parental status and the level of psychological distress.
To our knowledge, this is the first study that measures psychological distress in 
relation to time between colorectal cancer diagnosis and genetic testing for 
hereditary cancer. Moreover, this is the first study measuring psychological 
distress at the time of testing for being at high risk for Lynch syndrome by 
MSI-analysis. A point of attention is that response rate was low and our study 
sample may reflect selection-bias. Although demographic and cancer related 
characteristics of the participants and the non-participants did not differ 
significantly, psychological characteristics of the non-responders were not 
obtained. Other limitations of the study is the relatively small sample size and the 
cross-sectional design. To determine the causal effect of MSI-testing on levels of 
psychological distress a prospective randomized study design is preferred.
Our results suggest that high levels of psychological distress are not related to the 
duration of the time period between MSI-testing since CRC diagnosis. We carefully
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conclude that patients who are either female, religious, having low social support 
or those reporting difficulties in communicating hereditary colorectal cancer with 
relatives are at higher risk for psychological distress.
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Genetic testing offered directly after 
the diagnosis of colorectal cancer: 
a pilot study on the reactions of patients
Abstract
Introduction When colorectal cancer is diagnosed before the age of 50 years, 
then consideration should be given to a hereditary cause. Indications of heredity 
can be found in tumour tissue with the aid of microsatellite instability (MSI) 
testing. A positive MSI test means an increased risk of hereditary colorectal cancer, 
the so-called Lynch syndrome. Until recently, the usual approach was to postpone 
genetic testing for colorectal cancer until the family history had been studied 
extensively and information had been made available by a clinical geneticist 
about the possible consequences. However, it is now possible for MSI testing to 
be performed on the initiative of the pathologist when the newly diagnosed 
patient with colorectal cancer is younger than 50 years. This speeds up the 
procedure considerably. The psychological effects of discussing genetic testing 
and referring patients during treatment for colorectal cancer are currently 
unknown. This paper describes an exploratory study on the experience of eight 
colorectal cancer patients with the new Lynch syndrome detection strategy. 
Material and M ethods The patients were interviewed at home using a semi­
structured questionnaire based on the multicausal model of problem analysis and 
adapted with items for colorectal cancer and genetic testing.
Results Three coordinating themes were found: (1) 'a changed life after the 
diagnosis of colorectal cancer', (2) 'warning for the future' and (3) 'communication 
with family'. It was a considerable challenge for these patients to cope with the 
physical and psychosocial consequences of colorectal cancer. The majority 
regarded possible carriership of a hereditary disposition for the Lynch syndrome 
as useful medico-preventive knowledge for their children. The timing of the 
confrontation with genetic testing was considered to save time in receiving 
follow-up advice for their children. However, these patients were apprehensive 
about having to discuss a hereditary disposition for cancer with their family. 
Conclusion In this early phase, coping with the diagnosis of colorectal cancer and 
the consequences of treatment mainly determined the reactions of these patients 
and their physical well-being. This small group of patients were of the opinion 
that the advantages of genetic testing will weigh-up against the disadvantages.
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Introduction
It is important to distinguish sporadic colorectal cancer from hereditary forms of 
colorectal cancer. In the case of a proven hereditary disposition for colorectal 
cancer, it is possible to perform tailored medico-preventive and genetic testing of 
family members [1]. Until recently, the usual approach was to postpone genetic 
testing for colorectal cancer until the family history had been studied extensively 
and information about possible consequences of certain findings had been made 
available by a clinical geneticist. At the beginning of 2008, a new national guideline 
was published in the Netherlands on hereditary colorectal cancer [2]. An important 
new element is that in all new patients of younger than 50 years who are diagnosed 
with colorectal cancer, the pathologist searches for evidence of a hereditary 
cause. This takes place on the basis of molecular characteristics of the tumour, 
so-called micro-satellite instability (MSI) testing. With the additional of the Lynch 
detection-MIPA strategy (MIPA = MSI testing on the indication of a pathologist), 
patients with an indication for genetic testing can be detected more efficiently 
[3]. This MSI testing cannot diagnose heredity in patients who have recently 
undergone surgery for colorectal cancer, but it can detect an increased risk of the 
Lynch syndrome, the most common hereditary cause of colorectal cancer. If the 
MSI test is positive, the treating physician can decide to refer the patient to a 
clinical geneticist for genetic counselling. This might be followed by DNA analysis 
to detect or exclude the presence of the Lynch syndrome. Genetic testing will 
show that 1 out of 10 of the colorectal cancer patients selected using the MIPA 
strategy has an actual hereditary cause [4]. The changes in the guideline do not 
apply to patients who have been treated for colorectal cancer in the past. They 
will be referred for genetic testing on the basis of any findings suspicious of 
colorectal cancer and/or uterine cancer in the family anamnesis [5-8]. Therefore, 
referral for DNA analysis is occurring more and more frequently directly after the 
diagnosis of colorectal cancer. Thus, these new patients are being confronted in 
quick succession with: 1) the diagnosis of colorectal cancer, 2) a possible hereditary 
disposition for colorectal cancer and 3) the obligation to discuss a possible 
hereditary disposition for colorectal cancer with their children and family.
Within this population, about 20% will have an MSI-positive tumour. According to 
the new guideline, about 220 patients per year in the Netherlands will be offered 
genetic testing in the period directly after surgical removal of the tumour. This 
pilot study explored the reactions of the patients to this procedure.
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Material and methods
In a group of 55 patients who took part in a cost-effectiveness study on the MIPA 
strategy [3], nine had an MSI-positive tumour. All nine patients were approached. 
After giving informed consent, eight of the participants were interviewed at home 
(interview duration 1-1.5 hours). For this purpose, we designed a semi structured 
questionnaire based on the multicausal model of problem analysis and adapted it 
for colorectal cancer and heredity [9]. The first questions the patients answered 
addressed cognition, emotions and behaviour in relation to their colorectal cancer 
and its treatment. Subsequently, the same questions were asked in relation to an 
increased risk of having a hereditary disposition for the Lynch syndrome and the 
offer of referral for genetic testing directly after receiving the diagnosis of 
colorectal cancer. The interviews were typed out and evaluated using systematic 
thematic analysis [10]. Medical and demographic data were retrieved from the 
medical files.
Table 1 Cancer-related characteristics of the 8 interviewees
Patient
(No.)
Cancer localisation Age at diagnosis  
(yrs)
1 Jejunum 39
Endometrium 42
2 Coecum 36
3 Duodenum 47
4 Ascending colon 50
5 Ileum 49
Descending colon 58
6 Bladder 49
Ascending colon 58
7 Sigmoid 40
Endometrium 54
Renal pyelum 60
8 Transverse colon 44
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The study was approved by the Committee for Human Research Arnhem-Nijmegen, 
the Netherlands.
Table 1 shows the cancer-related characteristics of these patients. Mean age at the 
diagnosis of colorectal cancer was 45 years (range 36-58 years). Mean age at the 
diagnosis of a Lynch-associated tumour was 51 years (range 42-60 years). Three 
out of the eight patients had a stoma.
Results
Impact of colorectal cancer
Table 2 shows all the themes identified in relation to colorectal cancer. The 
patients remarked that since the start of their symptoms, it had sometimes taken 
a whole year to make the diagnosis of colorectal cancer. Chronic fatigue was 
having a heavy impact. In addition, changes in defecation patterns and the 
presence of a stoma were also affecting daily functioning. "Whenever I go 
anywhere, the first thing I do is to make sure I know where the toilet is and 
sometimes my stoma makes such disgusting noises that I wish the floor would 
open up and swallow me". The patients said that because of these problems, they 
had to be careful not to become socially isolated. Deep thoughts about what had 
happened to them physically and anxiety about lymph node métastasés were 
taking up a large part of their day: "They told me that I have been lucky, but why 
am I still so scared?" Confrontation with the finiteness of life was not only causing 
deep anxiety, but had also meant that these patients were living their lives with 
more attention and consciousness. As a result of the changes in their attitudes 
towards life, there had also been changes in the relationships within the family, 
the broader family circle and with friends; contact had intensified or broken down: 
"Many people often talk a great deal, but they don't really say anything. It was 
only then that I realised people don't listen and they just want to talk about 
themselves". Three patients were receiving professional psychosocial help to cope 
with the diagnosis of cancer. The diagnosis of colorectal cancer had also had 
considerable impact on the patients' work situation and consequently, on their 
financial position.
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Table 2 Themes identified in relation to colorectal cancer
Themes No. of times mentioned
Medical Healthier diet
Doctor-patient communication
5
4
Chronic fatigue
Problems with defaecation or stoma
4
3
Psychosocial Worried about lymph node métastasés 
Changed attitude towards life 
Loss of job/finances 
Professional psychosocial help
6
6
3
3
More enjoyment of partner and children 2
Changes in social contacts 
Impact of simultaneous life-events
2
1
Impact of genetic testing for the Lynch syndrome
Table 3 shows all the themes identified in relation to the Lynch syndrome. Two 
patients stated that even before their own diagnosis, they had often thought that 
it could not be a coincidence that there were so many people with cancer in the 
family. Thus, the message about the possible existence of heredity did not come 
as a surprise to them. In half of the patients, genetic testing had extra cognitive 
and emotional meaning, because it provided an explanation of why they had 
developed cancer at such a young age. Persistent guilt issues about what they had 
done wrong (e.g. unhealthy diet) could be exchanged for a "guilt-free" hereditary 
disposition of their colorectal cancer. The early offer of genetic testing was 
received positively. A characteristic citation from the whole patient group was: "I 
think that it would have been more difficult emotionally if I had not been 
confronted with genetic testing until a couple of years after my diagnosis. Then 
that would be another new kick in the face and I would probably have to start 
coping with the cancer all over again. Now we can have everything sorted out in 
one go and if it's true, then it is better that we know". There were positive thoughts 
about genetic testing regarding the medico-preventive value for the children. In 
this respect, the patients mentioned that early discussions about genetic testing 
meant that important time was being saved. The possible hereditary nature of the 
colorectal cancer served as a warning for the patient, the children and the rest of 
the family: "If it really is the case, then it would be best for them to go for
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check-ups". Looking at the future, the hope predominated that genetic testing 
would mean that the same thing would not happen to the children. The part that 
the patients dreaded most was to have to talk to the rest of the family if DNA 
analysis showed that their cancer was definitely hereditary. "Obviously, it is not a 
nice subject, but health comes first, so I really am going to tell them!". Some of the 
patients said that they would find it extremely useful if the Clinical Genetics 
Centre would organise family-information meetings for this inwardly complex 
and concurrently often emotionally-loaded material.
Table 3 Themes identified in relation to a possible hereditary disposition for 
the Lynch Syndrome
Themes No. of times 
mentioned
Medical Medico-preventive value for the children / family 
Time-saving / warning
6
5
Own riskof2nd primary tumour 3
Hereditary component expected 2
"If only they had found out sooner" 1
Psychosocial Hope for the future
Explanation forthe cancer (in the family)
5
4
Dreading communication with the family 4
Need for organised information meeting forthe family 1
Discussion
The patients indicated that the emotional burden was considerable and that this 
was mainly due to the diagnosis of cancer and the consequences of the treatment. 
They described the chronic fatigue, the loss of their working environment and the 
lack of control over defecation. These three items, covered by the theme "changed 
life after the diagnosis of colorectal cancer" were restricting their social lives. This 
confirms previous research into patients with colorectal cancer, particularly those 
with a stoma, whose role and physical functioning deteriorated in the first three 
months after surgery [11-16]. Poorer role, emotional and social functioning often
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persist in the first year after surgery, especially in patients diagnosed with 
colorectal cancer before the age of 60 years [12].
In relation to the reactions to the MSI-positive nature of the tumour, the two 
coordinating themes were "warning for the future" and "communication with 
family". In this small group of patients, the offer of genetic testing for the Lynch 
syndrome was seen as a hopeful source of preventive information for their 
children, but they were dreading having to talk to their family about it. The 
majority of patients said that they considered early confrontation with a possible 
hereditary disposition for colorectal cancer to be an important time saving in the 
acquisition of follow-up advice for their children. This predominantly positive 
reaction from patients to the offer of genetic testing directly after the diagnosis of 
colorectal cancer confirms an earlier report on a Scottish study on 111 patients of 
younger than 55 years who had recently been diagnosed with colorectal cancer 
[17]. An important difference from the MIPA study was that the Scottish patients 
had received a basic form of genetic counselling before undergoing genetic 
testing. In addition, after giving informed consent, blood samples had been taken 
for germ line DNA analysis. In the MIPA study, the patients had received the MSI 
test result from their surgeon and it was decided afterwards whether or not there 
would be referral to a clinical geneticist. The patients in our study stated that it 
would have been more difficult if there had been an interval of several years 
between the diagnosis of cancer and confrontation with genetic testing. Other 
studies also reported that a positive genetic test result can lead to reactivation of 
stress related to cancer diagnosed in the past [18]. In the period directly following 
the diagnosis of colorectal cancer, it is unlikely that the patients will be able to 
estimate the long-term psychosocial burden of genetic testing. Patients with 
cancer sometimes underestimate their reaction to genetic testing, because they 
are convinced that the worst, having cancer, has already happened to them [18]. 
In view  of the fact that these patients had been suffering from complaints for 
many months or even years before they were diagnosed with colorectal cancer, it 
is understandable that they hope that genetic testing will spare their children 
from the same fate. These patients expect that as a result of genetic testing, their 
children will undergo regular abdominal examinations and that if they have any 
complaints between check-ups, they will quickly be referred to a medical 
specialist.
Many patients were dreading having to discuss the possible hereditary disposition 
for the Lynch syndrome with their family, despite the preventive value of the 
information. The literature on family communication in relation to genetic testing
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showed that information about a hereditary disorder with good preventive 
opportunities, such as a hereditary disposition for intestinal polyps and colorectal 
cancer, does not always reach all the family members concerned [19, 20]. This 
means that lives can be saved by carefully supporting patients and supervising 
them in spreading the message within their family [21-23]. To supervise patients in 
the choice and consequences of genetic testing for the Lynch syndrome, 
specialised psychosocial care is available at every Clinical Genetics Centre in the 
Netherlands [24, 25].
Need for further research
Our study was limited to a very small number of patients, so it is too early to draw 
conclusions about the psychological impact of conducting MSI testing on tumours 
from recently diagnosed patients with colorectal cancer. Nevertheless it was 
striking to observe that the patients' reactions to the offer of genetic testing 
directly after surgery were largely positive. To draw firm conclusions about the 
psychosocial burden of confrontation with genetic testing directly after the 
diagnosis of colorectal cancer, it is necessary to perform prospective research into 
a larger group of patients. Such research has been started, subsidised by the 
Netherlands Digestive Diseases Foundation (Grant SW05-07).
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Psychological distress following 
microsatellite instability testing for 
Lynch syndrome by pathologists in 
new colorectal cancer patients
Abstract
Introduction According to the Dutch Guideline Hereditary Colorectal Cancer 
2008, pathologists test for high risk of Lynch syndrome by MSI-testing immediately 
after tumour resection in patients recently diagnosed with colorectal cancer (CRC) 
below 50 years or with a second CRC below 70 years (MIPA). The aim of the present 
MIPAPS-study is to investigate general distress and cancer specific distress during 
six months following MSI-testing.
Material and m ethods From March 2007 until September 2009, 400 newly 
diagnosed patients with CRC from 30 Dutch hospitals whose CRC had been tested 
for MSI were approached by surgeons to participate in the study. Levels of general 
distress (SCL-90) and cancer specific distress (IES) were assessed immediately after 
MSI-test disclosure (T1) and 6 months later (T2).
Results Response of MSI-positive and MSI-negative patients was 23/77 (30%) and 
58/323 (18%), respectively. Levels of general distress and cancer specific distress 
were moderate. In the MSI-positive group, percentages of patients with high 
general distress decreased after 6 months from 27% to 18%, while they remained 
stable in the MIPA-negative group, from 14% to 18%. High cancer specific distress 
decreased in the MSI-positive group and remained stable in the MSI-negative 
group, from 39% to 27% and from 38% to 36%, respectively. Women were more 
prone to high levels of distress, as were patients who had low social support or a 
high perceived cancer risk.
Conclusion For the majority of CRC patients, MSI-testing shortly after CRC 
diagnsosis is followed by levels of psychological distress that are similar to other 
CRC patients.
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Introduction
Each year, more than one million patients are diagnosed with colorectal cancer 
(CRC) worldwide and Lynch syndrome accounts for approximately 3%  of this 
incidence [1]. Identifying Lynch syndrome is highly relevant because surveillance 
reduces morbidity and mortality in family members carrying a mutation in one of 
the mismatch repair genes [2]. Patients at risk for Lynch syndrome can effectively 
be detected with a microsatellite instability (MSI) test, a molecular genetic test on 
tumour DNA of a CRC [3-6]. In Lynch syndrome almost all CRCs show high MSI. 
Conversely, in patients diagnosed with CRC at relatively young age finding high 
MSI is strongly associated with genetic susceptibility [7] and can therefore be 
used as an indicator for Lynch syndrome. Traditionally, patients have an MSI-test 
after referral to a clinical genetic department because of multiple CRCs in the 
family. However by family history, only a minority of the patients with Lynch 
syndrome is identified [8-11]. A new cost-effective and efficient guideline was 
shown to enhance the recognition of patients at risk for Lynch syndrome [5, 12, 
13]. With this MSI-testing-indicated-by-a-Pathologist (MIPA)-test [5, 12, 13], 
pathologists initiate MSI testing in a selection of recently diagnosed patients with 
one of the following criteria, called MIPA-criteria: 1) CRC diagnosed before age 50; 
2) second CRC before age 70 [5, 14, 15]. Pathologists report the MSI-test result to 
the surgeon. When the MSI-test is positive, the surgeon is advised to consider 
referral of the patient for genetic counselling and eventually germline 
DNA-analysis. One year before the introduction of the MIPA-procedure only 30% 
of the patients at risk for Lynch syndrome was recognized as such by the traditional 
procedure based on family history [16]. This is in line with other studies showing 
that family history is insufficient for recognizing patients at risk for Lynch syndrome 
[8-11]. After introduction of the MIPA-procedure in teams including surgeons and 
pathologists the recognition of patients at risk for Lynch syndrome increased 
substantially [13].
The MIPA-procedure implies that CRC patients are simultaneously confronted 
with 1) a diagnosis of and treatment for cancer; 2) a possibly hereditary 
predisposition for Lynch syndrome and 3) the need to inform children and relatives 
about their possible cancer risks. CRC itself is already responsible for considerable 
physical and psychosocial morbidity [17]. We asked to what extent MSI-testing 
will add to this distress. Newly diagnosed CRC patients who were offered genetic 
testing for hereditary CRC considered such testing at that point in time highly
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acceptable [18]. However, the actual psychosocial consequences of discussing a 
high genetic risk for Lynch syndrome on CRC patients during their treatment 
phase are scarcely known. The aim of the present study is to investigate distress 
and cancer specific distress of the patients. Also social support and cancer risk 
perception were studied as possible predictors of patients' distress [19-22]. 
Furthermore caregiver experiences of the partners were investigated during six 
months following MSI-testing in relatively young and recently diagnosed patients 
with CRC.
Material and methods
Patients and design
A prospective multi-centre study was performed in recently diagnosed patients 
with CRC to assess psychological and cancer specific distress and experiences of 
the partners following MSI-testing [5]. Inclusion criteria were 1) a diagnosis of CRC 
below age 50 years, or 2) a second CRC below age 70 years. Psychological 
assessment by questionnaires took place immediately after the MSI-test disclosure 
(T1) and 6 months later (T2). Patients who were diagnosed with cancer more than 
6 months ago were excluded. We used a follow-up of 6 months because for 
patients whose diagnosis warrants adjuvant therapy the treatment trajectory can 
be up to 12 months or more [23]. Since adjuvant therapy might also affect levels of 
psychological distress this variable was included in our analyses.
Procedure
From September 2006 until March 2007, 30 Dutch hospitals were invited to 
participate in the MIPAPS (= Psychosocial impact MIPA strategy) study. The 
hospital selection was based on those hospitals which had previously participated 
in the MIPA implementation study [13] and was supplemented with hospitals in 
neighbouring regions. From March 2007 until September 2009, 400 newly 
diagnosed patients with CRC who had an MSI-test were identified and eligible for 
this study. The patient's surgeon was requested to invite the MIPA patient and his 
or her partner to participate in the MIPAPS study. Time limit for inclusion by the 
treating physician was set on 6 months after CRC diagnosis. As soon as written 
informed consent was received questionnaires were sent to both patients and 
their partners. The study was approved by the local Ethical Committee (CMO nr. 
2006/042).
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Assessments
Distress
The Symptom Check List-90 (SCL-90) is a 90-item questionnaire for psycho­
pathology with a 5-point Likert scale (scoring 1-5). A total SCL-90 score above 160 
is indicative for high psychological distress, a score above 200 is indicative for a 
psychiatric disorder [24, 25]. The Profile of Mood States-Short Form [26] was used 
to assess affective states. Items are rated on a 5-point scale (0-4), resulting in 
scores for depression 0-32, anger 0-28, fatigue 0-24, tension 0-24 and vigour 0-20. 
This questionnaire was previously validated for cancer patients [27].
Cancer specific distress
The Impact of Event Scale (IES) [28, 29] was used to assess CRC specific distress. 
All 15 items were rated on a 4-point Likert scale (scoring 0,1,3,5) with total IES 
scores ranging from 0 to 75. A total IES score of 9-25 is indicative of moderate 
adaptation difficulties and a score > 26 is considered indicative of clinical 
adaptation difficulties and reflects a need for psychological or psychiatric support 
[30],
Colorectal cancer risk perception
Lifetime risk of CRC was measured with the Cancer Risk Perception List [20-22], 
measured with a single question "My chance of getting colorectal cancer again 
is..." where patients marked their risk perception on a Visual Analogue Scale (VAS 
0-100%). Absolute risk ranges were classified as follows: 0-20 (low); 20-40 
(moderate); 40-60 (fairly high); 60-80 (high); 80-100 (very high).
Social support
Social support was assessed on a 4-point Likert Scale with the Dutch self-report 
questionnaire Inventory for Social Support (ISS). The inventory comprises 3 scales: 
1) Potential emotional trust: range 5-20, moderate 13-15; 2) Actual emotional trust: 
range 3-12, moderate 5-7 and 3) Visits: range 2-8, moderate 5-6 [31], with a higher 
score indicating higher social support.
Caregiver experiences o f the partner
The partner of the patient filled in two questionnaires. Caregiver reaction was 
measured by the CRA-D, using the 7-item subscale self-esteem. The perceived 
impact is rated on a 5-point Likert scale, a higher score representing lower
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self-esteem [32, 33]. Perceived distress caused by informal care was measured 
using the validated 9-item Dutch self-report questionnaire EDIZ [34]. Total scores 
may be interpreted in three categories 9 to 20 (low load), 21 to 32 (overload) and 
33 to 45 (serious overload) [35].
Statistical analysis
Demographic and clinical characteristics of the MSI-positive and the MSI-negative 
group were analysed using the independent T-test for continuous and the 
Pearson's exact x2 test and McNemar test for categorical variables. General linear 
models for repeated measurements were used to test for differences in 
psychological distress and caregiver experiences over time. Correlations between 
distress and demographical variables, social support and cancer risk perception 
were assessed by the Spearman' Rank Correlation, represented by Spearman rho 
(p). The SPSS 16.0 statistical package was used to analyze the data and the 
probability level for statistical significance testing was set at 0.05 (two-tailed).
Results
Patient characteristics
Response rates of the patients with an MSI-high CRC (MSI-positive) and a 
microsatellite stable-CRC or MSI-low CRC (MSI-negative) were 23/77 (30%) and 
58/323 (18%), respectively. No significant differences between participants and 
non-responders were found considering age at diagnosis or gender. The 
participating CRC patients (n=81) were aged 48 ± 10 years. Baseline data were 
received 5 ± 3 months after CRC diagnosis and 50% of the participants were male. 
Baseline characteristics (T1) of the two groups are provided in table 1. Both groups 
had similar demographic characteristics. Tumour characteristics were significantly 
different. As expected in the MSI-positive group more patients were found with a 
right-sided tumour and a low TNM tumour stage. Moreover, these MSI-positive 
patients received less often adjuvant therapy. Of the MSI-positive and MSI-negative 
patients, 13 (56%) and 37 (63%) partners participated respectively (28 female, 22 
male).
Distress
At baseline no significant differences in psychological distress (SCL-90) between 
the MSI-positive and the MSI-negative group were found. Mean scores of
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Table 1 Baseline characteristics of the patients
MSI-positive
groupA
M SI-negative
group
Patient characteristics n = 23
00LOIIc P
Age at cancer diagnosis 48 ± 10 48 ± 12 nsa
Male 12 (52%) 29 (50%) nsb
Married or cohabiting 23 (100%) 50 (86%) nsb
Having Children 21 (91%) 49 (89%) nsb
Educational level > high school 14(61%) 30 (52%) nsb
Religious 17 (74%) 34 (59%) nsb
CRC diagnosed below 50 year 15 (65%) 38 (66%) nsb
Second CRC diagnosed below 70 year 7 (32%) 20 (35%) nsb
Tumour characteristics
Right sided tumour location 11 (50%) 15 (26%) 0.06b#
TNM stage 1 or II 16 (73%) 26 (45%) 0.04b*
Adjuvant therapy 12 (55%) 40 (78%) 0.04b*
A MSI-positive means that the MSI-test in the tumour is positive and is performed at the initiative of 
a pathologist, either because the CRC was diagnosed below 50 years or because it was the second 
CRC below 70 years;3, Independent Samples T-test;b, Pearson Chi-Square test;*, p <0.1;*, p <0.05; ns, 
not statistically significant.
psychological distress of the study sample were moderate at both T1 (131 ± 38) 
and T2 (131 ± 46), as compared to patients with for example breast cancer (151 ± 
45) or haematological cancer (145 ±33), and similar to patients with a variety of 
other solid tumours (130 ± 25) [36]. In the course of the study differences in 
psychological distress between the two groups were found (figure 1A). Concerning 
the level of psychological distress a significant interaction effect between MSI-test 
result and time of assessment was observed, indicating a decrease of psychological 
distress in the MSI-positive group and an increase in the MSI-negative patient 
group between T1 and T2 (p=0.03). Although statistically significant, the observed 
change in psychological distress may be not clinically relevant because mean 
distress levels did not reach the cut-off score of 160 (indicative for high distress). 
At T1, almost double the amount of high psychological distress was reported in 
the MSI-positive group (27%) compared to the MSI-negative group (14%), but this
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Figure 1 A Course of mean levels of psychological distress in 22 MSI-
positiveA and 51 MSI-negative patients with CRC. B Course of mean 
levels of caregiver experiences in 13 partners of MSI-positiveA 
patients and 37 partners of MSI-negative patients with CRC, a lower 
CRA-D score indicates higher caregiver's esteem, a higher EDIZ 
score indicates higher perceived distress by informal care.
190
MSI-positive group 
MSI-negative group
170 \-
SCL-90: p<0.03 (interaction-effect)
Tl T2
MSI-positive group 
Caregiver's esteem (CRA-D)
MSI-negative group 
Caregiver's esteem (CRA-D)
-a- MSI-positive group 
Experienced pressure by 
informal care (EDIZ)
MSI-negative group 
Experienced pressure by 
informal care (EDIZ)
CRAD: p=0.01 (time-effect), EDIZ: p=0.04 (time-effect)
A MSI-positive means that the MSI-test in the tumour is positive and is performed at the initiative 
of a pathologist, either because the CRC was diagnosed below 50 years or because it was the 
second CRC below 70 years.
difference was not statistically significant. In the MSI-positive group, percentages 
of patients with high distress decreased after 6 months from 27% (T1) to 18% at T2 
(p=0.5), while remaining stable in the MSI-negative group, from 14% (T1) to 18% 
(T2) (p=0.6). So, at T2 high psychological distress was reported by 18% of both the 
MSI-positive and the MSI-negative group still. In figure 2, it is shown that per 
patient in general psychological distress remained stable over time, both in the 
MSI-positive and MSI-negative group. Psychological distress was significantly 
correlated with female gender (p=0.269, p=0.02), low social support (potential 
trust p= -0.298, p=0.01, visits p= -0.263, p=0.03) and high CRC lifetime risk 
perception (p= 0.318, p=0.006). No significant relation was found between levels 
of distress with TNM stage or adjuvant therapy.
Figure 2 Psychological distress per MIPAPS patient at T1 and T2. A score
above the cut off of 160 (dotted line) indicates high psychological 
distress
MSI test result
MSI-positive MSI-negative
350 -
50 -
1 2 1 2
Time
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In table 2 mean levels of mood states (POMS) of both the MSI-positive and the 
MSI-negative group at T1 and T2 are provided. All mean affective states were 
within the same range of other patients diagnosed with cancer [27]. No significant 
differences were found between the MSI-positive and the MSI-negative group.
Cancer specific distress
At baseline, cancer specific distress levels were within the same range in the 
MSI-positive and the MSI-negative group. Mean scores of cancer specific distress 
in the study sample were moderate at both T1 (21 ± 15) and 12 (21 ± 17). Over time 
no significant differences of cancer specific distress levels were found in both 
groups. At T1, 38% of the total group reported high cancer specific distress 
(IES>26), 39% and 38% in the MSI-positive and the MSI-negative group, respectively. 
At T2, cancer specific distress was slightly decreased in the MSI-positive group 
and had remained stable in the MSI-negative group, from 39% to 27% (p=0.3) and 
from 38% to 36% (p=1.0) respectively. Cancer specific distress scores were 
significantly correlated with female gender (p=0.328, p=0.005). No significant 
relation was found between these levels and TNM stage or adjuvant therapy.
Social support and cancer risk perception
Mean social support levels were moderate compared to a norm group of healthy 
adults in both the MSI-positive and the MSI-negative group at T1 and T2 [31]. 
Additionally, no significant differences in social support levels between groups 
were found (table 2). In table 2 is shown that at T1 patients of both groups reported 
a fairly high-risk perception for being diagnosed with CRC in the near future. Risk 
perception at T2 significantly increased from 43% to 50% (p=0.03) in the total 
group: in the MSI-negative group from 43% to 48% (p=0.2), in the MIPA-positive 
group from 44% to 53% (p=0.07).
Partners experiences
There were significant time effects on both CRA-D and EDIZ levels (p=0.01 and p=0.04, 
respectively) indicating that the negative impact of care giving decreased in both 
groups (figure IB). In the group of partners, caregivers self esteem (CRA-D) was within 
the same range of partners of patients with other types of cancer [37] (table 2). 
Caregivers distress by informal care (EDIZ) was reported by 49% and 38% of all 
partners atTI and T2, respectively. No significant differences in selfesteem and distress 
were found between the MSI-positive and the MSI-negative group. No significant 
correlation was found between partner's gender and caregiver experiences.
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Discussion
To our knowledge this is the first multicentre study concerning psychological 
distress, following genetic pre-screening for Lynch syndrome by MSI-testing in 
recently diagnosed patients with CRC. Our data suggest that disclosure of the 
MSI-test result does not result in high levels of distress, for the majority of these 
patients. Distress and cancer specific distress levels were moderate in both the 
MSI-positive and the MSI-negative group. It is important to note that a minority of 
our patients with CRC did report high levels of psychological distress and cancer 
specific distress after MSI-testing. These levels decreased over time in the 
MSI-positive group and remained stable in the MSI-negative group. Six months 
after MSI-test disclosure, almost a year after CRC diagnosis, about 20% of all 
CRC-patients was still highly distressed and about 40% still experienced high cancer 
specific distress. These levels of psychological distress were independent of MSI-test 
result, but related to patient's characteristics such as female gender, social support 
and cancer risk perception. In our study the overall prevalence of high psychological 
distress was lower than in a previous study in which 32% of newly diagnosed 
patients reported high distress [25]. From literature it is known that two-thirds of 
patients with cancer will adapt to their diagnosis without any psychological 
intervention [25].This initial psychological adaptation to a cancer diagnosis is highly 
influenced by pre-existing psychosocial factors [38]. These results highlight the 
necessity for identifying those patients with high levels of distress.
The results of our study in recently diagnosed young CRC patients are in line with 
studies among patients recently diagnosed with breast cancer who were actively 
approached for genetic counselling and testing. In this group of patients, overall 
no short-term or long term additional psychological distress was found [39, 40]. 
One of the previously given explanations is that the possibly hereditary nature of 
cancer is not nearly as distressing as the diagnosis of cancer itself [41]. A genetic 
diagnosis may lead to understanding the origin of CRC and reduce feelings of 
guilt and psychological distress. Another explanation might be that in general the 
MSI-positive CRC patients have a good overall prognoses and such patients were 
less often treated with adjuvant therapy in our study. Therefore, the potentially 
negative effect of being at high risk of Lynch syndrome may have been psycho­
logically compensated. Worse prognosis and more often treatment with adjuvant 
therapy might also explain why levels of distress and cancer specific distress of 
the MIPA-negative CRC patients remained stable over time. However, we could 
not detect any effect of adjuvant therapy on psychological distress.
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The partners of both groups of CRC patients showed moderate to high levels of 
caregiver esteem. These levels are comparable to those described in literature of 
partners of patients with CRC [33] or with other types of cancers [37]. The partners 
of both groups perceived decreasing levels of distress over time. This is in 
concordance with previous literature describing that the treatment phase is 
experienced as the most stressful phase in which emotional and informational 
support is needed most [42].
The MIPA-procedure greatly enhances the efficiency of genetic counselling 
because patients with an MSI-high CRC are at high risk for being a mismatch repair 
(MMR) gene mutation carrier. Ten out of the 22 MSI-high CRC patients (45%) were 
subsequently found to be carrier of a mutation in one of the MMR genes (n=6 
MLH1, n=2 MSH6 and n=2 PMS2). In 6 of these patients (27%) MSI was explained by 
non-hereditary hypermethylation of the MLH1 promoter. The DNA-test result at 
T2 was not significantly correlated with psychological distress or cancer specific 
distress.
One limitation of our study is the low response rate for inclusion. This may have 
biased our results especially if selection by the surgeon has occurred in such a 
way that patients with a bad prognosis or with emotional problems were less 
likely to be recruited into the study. This would have resulted in an underestima­
tion of psychological distress. At present we cannot assess whether such a bias is 
present in our study cohort. However, we note that levels of psychological distress 
in our sample were lower than those previously described in the literature. Another 
reason for low response rate may be the complex logistic inclusion procedure of 
the present study [13], which could result in communication of the test result to 
the patient after the inclusion period of 6 months. After surgery it could take 
several months before a written MSI-test report was sent to the surgeon and 
another couple of weeks before communication with the patient. Many patients 
did not fulfill the time period inclusion criteria.
We conclude that despite some methodological concerns, our study data indicate 
that MSI-testing does not increase psychological distress in the majority of 
patients with CRC.
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Educational-support groups for female 
BRCA-mutation carriers
Karin Landsbergen 
Judith Prins 
Yvonne Kamm 
Han Brunner 
Nicoline Hoogerbrugge
Fam Cancer. 2010 J un;9(2):213-20.
Female ß/?CA-mutation carriers with 
a preference for prophylactic mastectomy 
are more likely to participate an educational- 
support group and to proceed with the 
preferred intervention within two years
Abstract
Introduction Women with a ß/?G4-mutation face a complex choice between 
breast cancer surveillance and prophylactic mastectomy. We determined risk 
management preferences shortly after genetic test disclosure and mastectomy 
status after a median observation period of 2 years. The effect of an educational- 
support group on the realization of risk management preference was explored. 
Material and Methods We included 163 newly disclosed ß/?G4-mutation carriers 
with no history of cancer, whose breast cancer risk management preferences were 
recorded. All carriers were offered the opportunity to participate an educational- 
support group. Mastectomy status was checked after a median observation period 
of 2 years.
Results Of the total sample 27% had an initial preference for mastectomy and 
48% attended an educational-support group. After a median observation period 
of 2 years, 30% of the total sample had undergone prophylactic mastectomy. Of 
the women with a preference for surveillance 90% of educational-support group 
attendees and 88% of the other mutation carriers were still under surveillance. 
The number of women with a preference for mastectomy who actually had a 
mastectomy performed, was significantly higher in the group that attended an 
educational-support group as compared to those who did not, 89% and 63% 
respectively (OR 4.8, P = 0.04). Strong predictors for prophylactic mastectomy 
within 2 years were younger age and prior preference for mastectomy (R 2 = 0.57). 
Conclusion Nearly all ß/?G4-mutation carriers proceed with their initial choice for 
surveillance or prophylactic mastectomy. The study provides presumptive 
evidence that educational-support group participants decide to undergo 
prophylactic mastectomy earlier than non-attendees.
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Introduction
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian 
cancer [1-6]. A meta-analysis of ten studies estimated the lifetime risk of breast 
cancer in BRCA1 mutation-carriers to be 47-66% and 40-57% in BRCA2 mutation 
carriers. The ovarian cancer risk was estimated at 35-46% in BRCA1 mutation 
carriers and 13-23% in BRCA2 mutation carriers [7]. Women with mutations in 
either of these genes are thus at great increased risk of breast cancer and are 
usually offered breast cancer surveillance which includes at least annual clinical 
breast examination, annual mammography and annual contrast-enhanced breast 
magnetic resonance imaging (MRI) [8-10]. These women may also opt for 
prophylactic bilateral mastectomy, with or without breast reconstruction [11-13]. 
There is large international variation in rates of uptake of prophylactic bilateral 
mastectomy in ß/?G4-mutation carriers, ranging from 3 to 51% [14-19].
A challenging issue for many health care professionals is how to optimally guide 
and support these women in making the psychologically most suited choice as 
both intensive breast cancer surveillance and prophylactic mastectomy are 
medically possible in most Western countries. All nine Family Cancer Clinics in The 
Netherlands offer individual psychosocial support for women from hereditary 
breast-ovarian cancer families [20]. For more than 10 years psychosocial workers 
of the Radboud University Medical Centre Nijmegen have additionally organized 
educational-support groups for proven female ß/?G4-mutation carriers. The 
decision regarding breast cancer risk management involves the processing of 
complex and evolving information and choices [21]. Generally, the decision is not 
a medically urgent one and women can take time to process all the information 
and to talk about it with others [22]. Therefore, the goal of such an educational- 
support group is assisting women in making an informed choice respecting and 
taking into account their private lives and circumstances. For clarity, the starting 
point is that one preference is not better or worse than the other.
Many factors influence women's breast cancer risk reducing management 
preference over the course of time, including age and levels of breast cancer 
anxiety [21, 23-26]. Overall, younger age and higher levels of breast cancer anxiety 
are strong predictors of prophylactic mastectomy. Little is known about the effect 
of an educational-support group on breast cancer risk management decisions. In 
the whole process of women's decision making, an educational-support group for 
women with an BRCA1 or BRCA2 mutation is one of many events which might 
influence a woman's decision. After having organized these groups for a few
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years, the clinical impression emerged that after participation an educational- 
support group many women opted for prophylactic mastectomy. Women may 
evolve in their choice due to new or complementary information. However, the 
question arose whether an educational-support group for female ß/?G4-mutation 
carriers might have an undesirable side-effect, that is unintended persuasion 
towards prophylactic mastectomy. This meant that we wanted to investigate this 
specific psychosocial intervention for female ß/?G4-mutation carriers. The clinical 
relevance is that this adds to our knowledge on how to guide and support these 
women in daily clinical practice and to be able to ameliorate specific and pointed 
psychosocial care for the still increasing group.
Therefore, the aims of this study were to determine to what extent the initial 
preference for breast cancer surveillance or prophylactic mastectomy was 
proceeded at a median of 2 years after first breast cancer surveillance visit and to 
explore the effect of an educational-support group on the realization of risk 
management preference.
Patients
The study sample consisted of 163 women without a personal history of breast or 
ovarian cancer, with a deleterious ß/?G4-mutation. These women were seen at the 
Human Genetics Department of the Radboud University Medical Centre Nijmegen 
from September 1999 to September 2005. According to the genetic counseling 
protocol, all women were contacted by a psychosocial worker within 2 weeks 
after genetic test disclosure with the offer of individual psychosocial support. All 
healthy carriers were also offered the opportunity to participate in an education- 
al-support group.
Participants of an educational-support group
Eligible participants were women with a newly disclosed ß/?G4-mutation without 
a personal history of breast cancer and without a current psychiatric disorder. 
Women participating in the group were expected to attend at least 6 of the 8 
sessions. The medical information sessions were accessible to the women, their 
spouses, family members and close friends. Sessions on psychosocial issues were 
accessible to women only
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Structure of an educational-support group
The complete programme included 8 sessions of two and a half hour each, with 
an interval time of 4-6 weeks. The sessions had alternately a psychosocial (5 
sessions) and a medical information (3 sessions) focus. A group was organized 
and guided non-directively by two psychosocial workers, specialized in hereditary 
cancer. It had a closed character for the purpose of optimal group binding. This 
meant that no newly informed ß/?G4-mutation carrier could join the group after 
the first session. To create optimal interaction effects the number of participants 
was between 8 and 12.
Contents of an educational-support group
Psychosocial themes
The first psychosocial session was always focused on making acquaintance, 
sharing family stories related to being a BRCA carrier, personal beliefs and 
experiences concerning cancer. The second session centered on coping with 
anxiety and tension due to cancer risk and on past and anticipated grief. Themes 
in thethird session werefam ily communication, reproductive decisions and issues 
related to work and insurance. The last two sessions concentrated on making 
breast cancer risk management choices. One session aimed to outline the physical 
and psychosocial consequences of each possible choice. Four women with a 
ß/?G4-mutation who had received their genetic test result several years ago were 
invited as "experts by experience". To give a complete picture, two women who 
had chosen surveillance and two who had opted for prophylactic mastectomy 
were invited. Women shared their narratives regarding the impact of intensive 
breast cancer surveillance or about their process towards, during and after 
prophylactic mastectomy. Positive as well as negative experiences were discussed 
openly. In this session body image and sexuality were also intensively discussed. 
In all sessions participants were invited to put forward and discuss psychosocial 
topics.
Medical themes
Three sessions were coordinated by medical specialists involved in the Family 
Cancer Clinic of the Radboud University Nijmegen Medical Centre in the 
Netherlands. In the first medical session an internist provided information on 
breast cancer risk factors and imaging of breast cancer. In the second session a 
gynecologist explained both the advantages and disadvantages of ovarian 
screening, prophylactic salpingo-oophorectomy and attendant menopause. A
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videotape of a laparoscopic preventive risk reducing salpingo-oophorectomy was 
shown. In the last medical session both a surgeon and a plastic surgeon presented 
a complete picture on prophylactic mastectomy and various breast reconstruction 
procedures. Care was taken to allow enough room for questions and interaction 
with the medical specialists.
Methods
We prospectively assessed breast cancer risk management preferences of 163 
female ß/?G4-mutation carriers at first breast cancer surveillance visit. This first 
surveillance visit was planned shortly, usually between 1 and 2 months after BRCA 
genetic test disclosure and always took place before first attendance of an educa- 
tional-support group. The standard question at first surveillance visit was whether 
the women had a preference for either intensive breast cancer surveillance or 
prophylactic mastectomy. When a woman did not have a preference for preventive 
surgery or were indecisive, the procedure of intensive breast cancer surveillance 
was followed and recorded as such. So it was either prophylactic mastectomy or 
not (yet). All newly disclosed mutation carriers were offered the possibility of 
group participation and each group started in the first year after genetic test 
disclosure latest. As soon as more than 10 female mutation carriers had indicated 
wanting to participate, a group was organized. In practice the next group started 
between 2 and 8 months after DNA-test disclosure, so usually less than 6 months 
after first breast cancer risk preference assessment.
Breast cancer risk management status was assessed by checking medical files 
after a median observation period of 2 years. Over 90% of the women went in 
surgical follow-up in the Radboud University Nijmegen Medical Centre. In the 
Radboud University Nijmegen Medical Centre, most women opt for prophylactic 
mastectomy followed by breast reconstruction by means of tissue expanders. The 
average waiting list for a preventive mastectomy including breast reconstruction 
with tissue expanders is 1-2 months. Only in case of preventive breast surgery 
followed by DIEP flap reconstruction the waiting list could be 1 year.
We asked for breast cancer risk management preference which we note is a 
thought and thus a cognitive expression. After 2 years we checked mastectomy 
status which in contrast is a behavioral expression. Women's choice regarding 
reducing their cancer risk mainly concerns their breasts, according to current 
protocols proven ß/?G4-mutation carriers are advised to have their ovaries
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removed from age 38-40 years onward. Patients with breast cancer detected 
during surveillance were excluded from final analysis, since this would substantially 
impact on their previous decision. Sociodemographic, medical, family cancer and 
genetic test related characteristics were retrieved from medical records.
Data analysis
The SPSS 16.0 statistical package was used to analyze the data. Frequencies were 
used to describe the study sample. Group comparisons were tested for statistical 
significance. Spearman rank correlations were calculated for continuous variables 
and Pearson's x2 analyses for categorical variables. Age was divided into four 
categories based on quartiles. A Pearson's x2 test was adopted to examine the 
association between educational-support group attendance, breast cancer risk 
management preference at first surveillance visit, and breast cancer risk 
management status after a median observation period of 2 years. Odds ratios (OR) 
were calculated to describe associations between the determinants and actual 
breast cancer risk management status at a median of 2 years after genetic test 
disclosure and presented with their 95% confidence intervals (95% Cl). P-values 
<0.05 were considered statistically significant. A multivariate logistic regression 
analysis using Backward Wald was applied with prophylactic mastectomy as 
independent, dichotomized variable (0 = still under surveillance and 1 = obtained 
surgery). Odds ratios (OR) were calculated to describe associations between the 
determinants and the rate of patients who underwent prophylactic mastectomy 
and presented with their 95% confidence intervals (95% Cl). The percentage of 
variation that the independent variable could explain was calculated using 
Nagelkerke R2.
Ethics
The study was performed according to the rules of the Committee on Research 
Involving Human Subjects, Region Arnhem-Nijmegen in the Netherlands.
Results
From September 1999 to September 2005 six educational-support groups were 
organized. A group started within 1 year after women's genetic test disclosure. 
The team of psychosocial workers and the medical specialists running the groups 
remained the same over the study period. All participants were present at least at
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6 out of 8 sessions. Of all 163 female ß/?G4-mutation carriers, 79 (48%) women 
participated in an educational-support group and 84 (52%) did not. Of all proven 
female ß/?G4-mutation carriers we excluded 30 women with a history of breast 
cancer and 5 women with a history of ovarian cancer during the study period. 
Breast cancer was detected in 12 patients during breast cancer surveillance Of 
these 12 patients 7 women did participate a BRCA group and 5 women did not. 
These women were excluded from analysis, so for final analysis, 151 female BRCA- 
mutation carriers remained.
BRCA group participants versus non-participants
No significant differences between group participants and non-participants were 
found regarding demographic (age, children), medical (postmenopausal), family 
cancer history (mother and/or sister with breast cancer), BRCA genetic test related 
(BRCA1 or BRCA2, maternal or paternal inheritance) variables or having received 
individual psychosocial support. Psychosocial support records were retrievable 
from 2003 onward. From both the 79 group participants and from the 84 
non-group participants 31 records were available. From the group participants 19 
women and from the non-group participants 18 women received individual 
support, i.e. 61 and 58% respectively. In both groups individual psychosocial 
support mainly focused on the emotional preparation of upcoming preventive 
operations and on the provision of emotional care after preventive surgery. Only 
breast cancer risk reducing management preference at first surveillance visit was 
significantly different. Educational-support group participators were less likely to 
opt for breast cancer surveillance being 52/79 (66%) versus 67/84 (80%) for non­
participators. Consequently, more participants preferred mastectomy 27/79 (34%) 
than did non-participants 16/84 (19%; P = 0.05).
Breast cancer risk management preference at first visit
The data in Table 1 show breast cancer risk reducing management preference of 
163 female ß/?C/\-mutation carriers at first breast cancer surveillance visit. Of these 
ß/?C/\-mutation carriers, 119 (73%) women had a preference for intensive breast 
cancer surveillance and 44 (27%) for prophylactic mastectomy. Mother's age at 
breast cancer was significantly lower for women with a preference for prophylactic 
mastectomy compared to women with a prior preference for surveillance being 
41 years (range 28-67), versus 50 years (range 27-71), respectively (P = 0.03). 
More women with an expressed intention to undergo a prophylactic mastectomy 
in the future participated in an educational-support group, compared to women
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with an intention to undergo surveillance, that is 61% versus 44% respectively 
(P = 0.05).
Table 1 Breast cancer risk reducing management preference of 163 female 
BRCA1/2 mutation carriers as expressed during first breast cancer
su rve illance  v is it sh o rtly  a fte r g en e tic  test discilosure
Breast cancer 
surveillance
Prophylactic
mastectomy
N % a or 
[range]
N % a or 
[range]
P-value
N =  163 119 73% 44 27%
Age (year)
<30 27 23% 9 21% 0.6b
30-40 34 29% 14 32%
40-50 35 29% 16 36%
>50 23 19% 5 11%
Daughters 59 50% 20 48% 0.6b
Sons 49 41% 17 40% 0.7b
Postmenopausal 21 18% 8 18% 0.9b
Mother with BC 39 33% 20 45% 0.1b
Mother's age at BC in years (median) 50 [27-71] 41 [28-67] 0.03c'*
Sister with BC 28 24% 9 20% 0.6b
Youngest sister's age at BC in years (median) 39 [26-61] 37 [29-46] 0.7C
Youngest relative's age at BC in years 
(median)
39 [18-80] 39 [24-59] 0.7C
BRCA1 77 65% 31 71%
_QLOo
BRCA2 42 35% 13 19%
Inheritance
Maternal 79 71% 31 78% 0.4b
Paternal 33 29% 9 22%
Educational-support group attendance 52 44% 27 61% 0.05b'*
BC Breast cancer
aBecause of missing values %  do not always add up to 100% 
bPearson chi-square test 
cSpearman's rank correlation
* considered statistically significant
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Breast cancer risk management status 2 years after first breast cancer 
surveillance visit
The data in Table 2 show the actual breast cancer risk reducing management 
decisions of 151 ß/?G4-mutation carriers after a median of 2 years after first breast 
cancer surveillance visit. From these 151 mutation carriers, 70% were still under 
surveillance and 30% underwent prophylactic mastectomy. Age was significantly 
different in the group of women who were still under surveillance and in those 
who underwent prophylactic mastectomy. Women aged between 30 and 50 more 
often underwent prophylactic mastectomy than did those younger than 30, or 
older than 50 (P = 0.02). Mother's age at breast cancer was significantly lower for 
women who underwent prophylactic mastectomy than for women who were still 
under breast cancer surveillance (P = 0.03). Also educational-support group 
attendance was significantly related to obtaining prophylactic mastectomy within 
2 years after first breast cancer surveillance visit (P = 0.05).
Multivariate logistic regression analysis showed that age between 30 and 50 and 
prior preference for mastectomy were two strong predictors for actually 
performing mastectomy (OR respectively 9.6, P = 0.03 and OR 42.3, P < 0.001. The 
estimate of explained variance of the multivariate model was 57% (Nagelkerke R 
2 = 0.568).
Influence of a BRCA psycho-education group on breast cancer risk 
management decisions
In Table 3 a comparison is given concerning actual breast cancer management 
decisions 2 years after the initial breast cancer surveillance to breast cancer risk 
management preference as expressed at the initial breast cancer surveillance 
visit, separately for women who had attended an educational-support group and 
those who had not.
Prior preference surveillance
The data indicate that attending an educational-support group does not change 
prior preference of breast cancer surveillance or prophylactic mastectomy. Of the 
48 women with a preference for surveillance, 90% were still under surveillance 
after a median observation period of 2 years. Similarly, of the 60 women with a 
preference for surveillance who did not attend an educational-support group, 
88% were still under surveillance.
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Table 2 Breast cancer risk reducing management performance of 151 female 
BRCA1/2 mutation carriers after a median observation period of 2 
years after first breast cancer surveillance visit after genetic test dis­
closure
Breast cancer 
surveillance
N % a or 
[range]
Prophylactic
mastectomy
N  % a or 
[range]
P-value
N =  151 105 70% 46 30%
Age in years
<30 30 29% 5 11% 0.02b*
30-40 26 25% 18 39%
40-50 28 26% 18 39%
>50 21 20% 5 11%
Daughters 52 50% 21 46% 0.6b
Sons 41 39% 18 39% 0.7b
Postmenopausal 19 18% 8 17% 0.9b
Mother with BC 35 34% 17 37% 0.1b
Mother's age at BC in years (median) 47 [27-71] 41 [31-67] 0.03c'*
Sister with BC 23 24% 11 24% 0.6b
Youngest sister's age at BC in years (median) 39 [26-61] 37 [29-46] 0.7C
Youngest relative's age at BC in years 
(median)
39 [18-80] 35 [24-59] 0.7C
BRCA1 66 63% 30 65%
_QLOo
BRCA2 36 34% 13 28%
Inheritance
Maternal 68 65% 33 77% 0.4b
Paternal 29 20% 10 23%
Educational-support group attendance 46 44% 29 63% 0.05b'*
For this analysis, all 12 women detected with breast cancer were excluded 
SC Breast cancer
aBecause of missing values %  do not always add up to 100% 
bPearson chi-square test 
cSpearman's rank correlation
* considered statistically significant
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Table 3 Influence of a educational-support group on breast cancer risk 
management stability
Intention at first visit: breast surveillance
Actual statusProphylactic 
mastectomy
N (%)
Actual status 
Surveillance
N (%)
Group yes 5 (10%) 43 (90%) OR (95% Cl) 
0.9 (0.26-3.0)
P-value
0.8
Group no 7 (12%) 53 (88%)
Intention at first visit: prophylactic mastectomy
Actual status 
Prophylactic mastectomy
N (%)
Actual status 
Surveillance
N (%)
Group yes 24 (89%) 3 (11%) OR (95% Cl) 
4.8 (1.0-23.1)
P-value
0.04*
Group no 10 (63%) 6 (38%)
* considered statistically significant
Prior preference mastectomy
Of the 27 women with an intention to undergo prophylactic mastectomy and 
participating in an educational-support group, 89% actually had undergone a 
prophylactic mastectomy 2 years after first breast cancer surveillance visit after 
genetic test disclosure. These women were significantly more inclined to have a 
prophylactic mastectomy performed than women with the same preference who 
did not attend an educational-support group (89% vs. 63%, OR 4.8, P = 0.04). Of 16 
women with a prior preference for prophylactic mastectomy, who did not join an 
educational-support group 38% were still under breast cancer surveillance 2 years 
after first surveillance visit.
Discussion
Nearly all ß/?G4-mutation carriers follow their first preference for breast cancer 
surveillance or prophylactic mastectomy. This is in line with a study which indicates 
that most women have already formed stable risk-management preferences
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before DNA test disclosure [26]. Educational-support group participants seem to 
decide to undergo prophylactic mastectomy shorter after making preference 
decision then non-participants. A recent study showed that women who choose 
prophylactic mastectomy often do so within months of receiving BRCA positive 
results [27]. An explanation for the advanced decision to undergo prophylactic 
mastectomy by group attendees compared to non-attendees might be that the 
occurrence of group members getting cancer during surveillance had effect on 
the other educational-support group members.This could have triggered feelings 
of anticipated regret, i.e. the amount of regret women think they would have if 
they were diagnosed with breast cancer after rejecting the option of prophylactic 
mastectomy [26]. In contrast, aberrant findings on imaging with mammography 
or MRI during breast cancer surveillance do not induce a preference for mastectomy 
[28]. In the group of women with an initial preference for mastectomy, who did 
not attend an educational-support group, 38% was still under surveillance. These 
women had no other notable features compared to the women with a prior 
preference for mastectomy who did join a group, except that none of these 
women had a sister with a history of breast cancer. We initially asked for women's 
preference about breast cancer risk management but finally determined breast 
cancer risk behaviour by checking medical files. Thus although data suggest that 
not-attending a group changes preference from prophylactic mastectomy in 
breast cancer surveillance, we cannot say with certainty that women's preferences 
have changed.
We realize that an important limitation of this study is the selection and allocation 
bias since women with different baseline attitudes towards breast cancer risk 
management self-selected themselves to attend (or not) the educational-support 
group. This is a difficulty when trying to draw conclusions regarding exclusive effects 
of the group. Whether the intent to attend a group and the intent to prefer mastectomy 
are associated with for example the same (active) coping style, might be an interesting 
topic for further research. There might also be an effect of individual psychosocial 
support on cancer risk management decisions. However, received individual support 
was comparable for group participants and non-group participants, plausibly 
resulting in a comparable effect on cancer risk management decisions.
Considering this it can be concluded that most female ß/?G4-mutation carriers 
are steadfast in their breast cancer risk management preference, as expressed 
during first breast cancer surveillance visit shortly after genetic test disclosure. 
Our data also provides presumptive evidence that an educational-support group 
strengthens the initial expressed intention to undergo prophylactic mastectomy.
ch
ap
te
r 
6 
BR
CA
 
ed
uc
at
io
na
l-
su
pp
or
t 
gr
ou
ps
 
an
d 
br
ea
st
 c
an
ce
r 
ris
k 
m
an
ag
em
en
t
Implications for daily care
It is commonly recommended that women with a ß/?G4-mutation have access to 
support groups throughout the decision process [22]. We emphasize that a well- 
structured educational-support group may provide support without intentionally 
inducing any specific breast cancer risk management strategy. The current body 
of knowledge does still not answer the question whether by participating an 
educational-support group women are better able to cope with their BRCA carrier 
ship in daily life and if these women are satisfied by this additionally offered care. 
Therefore we have recently started a prospective study to investigate the effects 
of these educational-support groups on psychosocial well-being and family 
communication.
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Educational-support groups for 
ß/?CA-mutation carriers satisfy need 
for information but do not affect 
emotional distress
Abstract
Introduction Due to high cancer risks, women carrying a BRCA1/2 mutation face 
a complex choice between breast and ovarian cancer surveillance and prophylactic 
surgery. The aim of this study is to evaluate educational-support groups, which 
are offered to facilitate mutual support between ß/?G4-mutation carriers and to 
provide adequate information.
Material and methods Female ß/?C/\-mutation carriers were approached by a 
social worker after genetic test disclosure and offered participation in education- 
al-support groups. Data regarding emotional well-being, breast cancer risk 
knowledge and perception, cancer risk management behaviour and family 
communication were collected both before (T1) and after group participation 
(T2).
Results Of the 34 participants mean levels of negative mood states at T1 were 
significantly higher compared to those of a norm group (depression p<0.001, 
anger p<0.001, fatigue p=0.04, tension p=0.03) and remained high at T2. 
Self-perceived breast cancer risk and frequency of cancer thoughts were high 
both at T1 and T2. Breast cancer risk knowledge was accurate both at T1 and T2; 
women either followed current surveillance advices or obtained prophylactic 
surgery. Communication with the family of origin was significantly reduced at T2 
compared to T1 (p=0.02). At T2 all women indicated that group participation 
highly met their needs of ß/?G4-related information to support their decision­
making processes regarding cancer surveillance or prophylactic surgery. 
Conclusion After following an educational support group female ß/?G4-mutation 
carriers were able to make cancer risk management decisions but still reported 
high levels of emotional distress while family communication appeared 
diminished.
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Introduction
Women carrying a BRCA1/2 mutation face considerable health risks with a 
cumulative lifetime risk for breast cancer of 39-85% and for ovarian cancer of 
11-63% at age 70 years [1, 2]. From the age of 25 years these women are usually 
advised intensive breast cancer surveillance which entail annual mammography 
and annual contrast-enhanced breast magnetic resonance imaging (MRI) and 
monthly self-breast examination (SBE) [3, 4]. Regular breast cancer surveillance 
aims at early detection of breast cancer but does not guarantee the detection of a 
tumor before metastasis has occurred. Those women may also opt for prophylactic 
bilateral mastectomy (PBM) [5-7] which is highly effective with respect to cancer 
risk reduction [8-11]. From the age of 35 years, ß/?C/\-mutation carriers are also 
offered regular ovarian cancer surveillance [4]. Screening by means of the current 
modalities fails to detect ovarian cancer at an early stage and provokes a high 
number of false positive findings [12]. Because prophylactic bilateral salpingo-oo- 
phorectomy (PBSO) from age 35-40 years is the most effective risk reducing 
strategy PBSO should be the cornerstone in the discussion with BRCA1/2 mutation 
carriers regarding risk management [13]. PBSO significantly reduces ovarian cancer 
risk [8, 9] while a small residual risk of developing extra ovarian, peritoneal cancer 
remains [14]. Moreover, it is estimated that removing the ovaries and fallopian 
tubes halves the risk of developing breast cancer [15,16].
After genetic test disclosure ß/?G4-mutation carriers face the processing of 
complex and evolving information and choices between cancer surveillance and 
PBM with or without breast reconstruction [17-20]. Additional stressors include 
communication of the dissemination of the genetic risk to relatives together with 
fears and worry concerning the health of offspring. Also concerns regarding 
insurance issues, potential confusion or misinterpretation concerning the complex 
genetic knowledge and ongoing fears of one's own risk for cancer may play an 
important role after genetic test disclosure [21-23]. A challenging issue for 
professionals is how to guide and support these women in making the 
psychologically most suited choice regarding cancer risk management. Few 
services exist for women carrying a ß/?G4-mutation [24]. Supportive expressive 
groups have been found very helpful in cancer populations for facilitating 
psychological adjustment to a life threatening illness [25, 26]. Features of such 
groups are the facilitation of mutual support, the creation of a sense of 
normalization through shared experience, the encouragement of emotional
ch
ap
te
r 
7 
BR
CA
 
ed
uc
at
io
na
l-
su
pp
or
t 
gr
ou
ps
, 
in
fo
rm
at
io
na
l 
ne
ed
s,
 e
m
ot
io
na
l 
di
st
re
ss
 
an
d 
fa
m
ily
 
co
m
m
un
ic
at
io
n
expressiveness, the promotion of family and social support, the enhancement of 
an expanded coping repertoire, vicarious learning through others and acceptance 
of being at high cancer risk [27, 28]. Women carrying a ß/?G4-mutation appear 
interested in psychosocial group support [29]. A previous study showed that a 
supportive-expressive group intervention was highly acceptable to female BRCA- 
mutation carriers. It appeared to be a good forum for them to explore key-issues 
such as the notification of test results to family, guilt regarding transmission of a 
mutation and decision-making regarding risk-reducing options [30]. It was also 
demonstrated that speaking to a peer was a highly valuated intervention for 
women considering PBM because this dialogue enabled them to answer questions 
of which they felt professionals could not know first-hand [31].
Since 1997, social workers of the hereditary cancer clinic of the Radboud University 
Nijmegen Medical Centre in the Netherlands have been organizing educational- 
support groups for recently proven female ß/?G4-mutation carriers. Main goals of 
these educational-support groups are providing professional ß/?G4-related 
information and facilitating mutual support. Next to information sessions provided 
by medical specialists and supportive sessions guided by medical social workers, 
the educational-support group programme includes a session with women 
carrying a ß/?G4-mutation who are 'experts by experience'. The aim of the present 
study is to evaluate educational support g roups for female ß/?G4-mutation carriers 
in clinical practice. This study addresses questions concerning informational 
needs and effects of the groups on emotional well-being, breast cancer risk 
perception, cancer risk management behaviour and family communication.
Material and methods
Study design
The educational-support groups were offered to patients in clinical practice and 
evaluated in an uncontrolled study.
Study sample and procedure
The study cohort consisted of women who had previously undergone genetic 
counselling and mutation testing at the Department of Human Genetics of the 
Radboud University Nijmegen Medical Centre in the Netherlands. Between March 
2005 and September 2008, women carrying a ß/?G4-mutation were contacted
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within 2 weeks after genetic test disclosure and offered the opportunity to 
participate an educational-support group. Individuals were excluded from group 
participation if they met the following criteria: 1) a personal history of breast- or 
ovarian cancer, 2) a history of a major psychiatric disorder (e.g. psychosis), as 
classified in the Diagnostic and Statistical Manual of Mental Disorders, the 
DSM-IV-TR [32] and 3) unwillingness to attend at least 6 of the 8 group sessions. 
Each new educational-support group started when 12 women were on the waiting 
list. In practice a new group started within a year after BRCA genetic test disclosure. 
In order to enable women with a day-job to participate, the meetings were held in 
the evening.
Structure o f  an educationa l-support group
The programme included eight sessions of two and a half hour, every 4-6 weeks. 
The focus of the sessions alternated between psychosocial support (5 sessions) 
and medical information (3 sessions). Sessions on psychosocial issues were only 
accessible to female ß/?C/\-mutation carriers. The medical information sessions 
were also accessible to their spouses, family members and close friends. A group 
was guided non-directively by two medical social workers specialized in hereditary 
cancer. It had a closed character for the purpose of optimal group bonding. To 
create optimal interaction effects the maximal number of participants was 12.
Contents o f  an educationa l-support group  
Psychosocial issues
The first psychosocial session was focused on sharing medical and/or family 
histories related to being a BRCA carrier, personal beliefs and experiences 
concerning cancer. The second session focussed on coping with anxiety and 
tension due to cancer risk and on past and anticipated grief. Themes in the third 
session were family communication, reproductive decisions and issues related to 
work and insurance. The last two sessions focussed on making breast cancer risk 
management choices. One session aimed to outline the physical and psychosocial 
consequences of each possible choice. Four women with a ß/?G4-mutation who 
had received their genetic test result several years ago were invited as "experts by 
experience"; two women who had chosen surveillance and two who had opted 
for prophylactic mastectomy were invited. Women shared their narratives 
regarding the process and impact of intensive breast cancer surveillance or 
prophylactic mastectomy. In this session body image and sexuality were also 
intensively discussed. In the last meeting women shared their personal choices
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regarding breast cancer risk management with each other and the support group 
was evaluated orally. Questions and interaction between group members were 
encouraged.
Medical information
Three sessions were coordinated by medical specialists involved in hereditary 
cancer. In the first medical session an internist provided information on breast 
cancer risk factors and imaging of breast cancer. In the second session, a 
gynaecologist explained both the advantages and disadvantages of ovarian 
screening, PBSO and attendant menopause. A videotape of a laparoscopic 
preventive risk reducing BSO was shown. In the last medical session both a 
surgeon and a plastic surgeon presented a complete picture on BPM and various 
breast reconstruction procedures. Questions and interaction with the medical 
specialists were encouraged.
Measures
Baseline data were collected one week before the start of the educational-support 
groups (T1). Follow-up data were completed within two weeks after the last group 
meeting (T2). Measurements contained both data from medical records and 
self-report questionnaires.
Em otional well-being
Emotional well-being was operationalized in terms of mood, social anxiety, self- 
confidence and body confidence. Mood was measured with the Profile of Mood 
States (POMS) Brief [33]. It consists of an inventory for measuring five types of 
moods: depression, anger, fatigue, vigour and tension. The POMS is a reliable and 
valid questionnaire for measuring emotional well-being. The subscales have been 
previously assessed for reliability and validity, demonstrating Cronbach's alphas 
ranging from 0.66-0.95 with a mean of 0.80 [34]. Impact of BRCA carriership on 
self-confidence was assessed with a single item "Can you indicate how BRCA 
carriership influences your self-confidence ?, i.e. 'positive' or negative'. Impact on 
body confidence was assessed with a similar question.
Breast cancer risk knowledge and perception
Breast cancer risk knowledge was defined in terms of knowledge of absolute 
lifetime breast cancer risk and knowledge of relative lifetime breast cancer risk. 
Knowledge of absolute lifetime breast cancer risk was measured as follows: "My
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risk of developing breast cancer is Patients marked their lifetime risk perception 
on a Visual Analogue Scale (VAS 0-100%). Knowledge of relative lifetime breast 
cancer risk was measured on a 7-point Likert scale as follows: "Compared to the 
average Dutch woman, my risk of getting breast cancer is 'very much lower' (1) 
through 'equal to' (4), to 'very much higher' (7)".
Breast cancer risk perception was assessed by the items self-perceived breast 
cancer risk and frequency of cancer thoughts. Perceived (subjective) breast cancer 
risk was assessed on a 7-point Likert scale using the item "Independent of my 
actual risk, I feel my risk of developing breast cancer is 'not likely'(l) to 'very 
likely'(7)". These three items regarding breast cancer risk knowledge and 
perception were used in similar studies on the impact of genetic testing for 
hereditary cancer with an adequate reliability, i.e. Cronbach's alpha of 0.73 
(post-genetic counselling) [35-38]. Frequency of cancer thoughts was measured 
as follows: "How often do you think about your chances of getting cancer?", i.e. 
'daily', 'weekly', 'monthly', 'few times a year', 'never'. At both T1 and T2, an 
open-ended question addressed the impact of BRCA carriership on daily life: "The 
most important consequence my BRCA carriership has on daily life is...".
Cancer risk management behaviour
Cancer risk management behaviour was defined in terms of breast cancer 
surveillance, ovarian cancer surveillance, PBM, PBSO and BSE. Intention towards 
breast cancer risk management was measured as follows: "W hat is your current 
intention to preventive measures regarding your breasts?", i.e. intensive breast 
cancer surveillance or prophylactic surgery. Intention regarding ovarian cancer 
risk management was assessed by a similar question. BSE was measured with the 
item "How often do you check your breasts for cancer?", i.e. 'daily', 'weekly', 
'monthly', 'few times a year', 'never'.
Fam ily and other BRCA-related communication
Familial communication concerning hereditary cancer was assessed by the 
Openness to Discuss Hereditary Cancer in the Family Scale, which is based on the 
Openness to Discuss Cancer in the Family Scale [39] and adapted and used in 
other studies on the impact of genetic testing for hereditary cancer [37,40].
To gain more insight in the aspect of women's ß/?G4-related family communication, 
a self-developed questionnaire addressed additional BRCA communication related 
issues. ß/?G4-related communication in general was measured with the item: "How
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often do you discuss BRCA carriership?", i.e. 'daily', 'weekly', 'monthly', 'few times a 
year', 'never'. Communication with the General Practitioner was assessed by a 
similar question. The need to discuss BRCA carriership was assessed with two 
items: "Would you like to discuss BRCA more often than is sometimes possible?", 
i.e. 'yes' or 'no' and "Would you like to discuss BRCA less often than is sometimes 
necessary?", i.e. 'yes' or 'no'.
Patient evaluation o f educational-support groups
Whether the medical information regarding BRCA was perceived as sufficient was 
assessed with the item "Do you consider the ß/?G4-related medical information 
which you received sufficient?, i.e. 'yes' or 'no'. An open-ended question addressed 
the source of ß/?G4-related information: "W ho or what provides you with 
ß/?G4-related information?" An additional open-ended question addressed the 
matters on which the participant had wanted more information. At T2, two 
open-ended questions regarding the consequences of having participated in an 
educational-support group were inserted.
Data analysis
Frequencies were used to describe the study sample. Correlations between 
variables were assessed by the Spearman' Rank Correlation for continuous 
variables and forthe ordinal variables which were obtained on a 5 or 7-Point Likert 
sea le. The Point Biserial Correlation was used to assess correlations for dichotomous 
variables. To analyze changes in the self-report measures between T1 and T2, the 
Paired Samples T-test was used for continuous variables. The McNemar test was 
used for categorical variables which were all dichotomized before analysis. To 
determine if there were major differences between the four groups regarding 
depression scores at T1, the Kruskal-Wal I is test was applied. To compare our POMS 
and ODHCF data with data from literature, the Welch's two sample t-test was used. 
This test is intended for use with two samples having possibly unequal variances. 
Levels of POMS negative mood states were considered high when mean levels 
were statistically significant higher than POMS levels of a sample from the female 
Dutch general population [33]. Breast cancer risk was considered accurate when it 
was between the genetic counselled risk of 60-80% Life Time Risk (LFT). Relative 
breast cancer risk was considered accurate when stated as 'very high'. 
Self-perceived breast cancer risk was considered high when stated as "my risk of 
developing breast cancer is 'very likely'. Frequency of cancer thoughts was 
considered high when stated as 'daily' or 'weekly'. BSE frequency was considered
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accurate when stated as 'monthly', i.e. accurate according to the Dutch guideline 
on hereditary breast and ovarian cancer [41]. Participants' answers to the open 
questions regarding the reported benefits of the educational-support group were 
categorized in themes conducting deductive qualitative content analysis [42]. The 
probability level for statistical significance testing was set at 0.05 (two-tailed). The 
SPSS 16.0 statistical package was used to analyze the data.
Ethics
Written informed consent was obtained from all participants in accordance to the 
rules of the Committee on Research Involving Human Subjects, Region Arnhem- 
Nijmegen in the Netherlands.
Results
Study sample
Between March 2005 and September 2008, a pathogenic ß/?G4-mutation was 
detected in 194 women not previously affected with cancer. Those women were 
approached by a medical social worker to participate in an educational-support 
group. Fifty-three women did not return phone-calls inviting them to participate. 
Of the 141 women with whom contact was obtained, 98 women (70%) declined 
from group participation to avoid ß/?G4-related issues or due to practical reasons 
(exact percentages not available). Of the remaining 43 potential group participants, 
two women (1%) were excluded due to a current psychiatric disorder. Over a 
period of four years a total of 41 female ß/?G4-mutation carriers, i.e. 29% of all 
contacted women, participated in one of the four groups, of whom 34 women 
(83%) participated in the current study. Waiting list time for the next group ranged 
from 1-12 months, the median waiting time was 4 months. The four groups, of 
which the first started September 2005 and the last in September 2008, consisted 
of ten, ten, twelve and nine female ß/?C/\-mutation carriers of whom respectively 
seven, nine, ten and eight participated in the study. At T2, 27 women (79%) had 
completed both thefirst and the last questionnaire. Demographic and ß/?G4-related 
characteristics of the study sample are provided in Table 1.
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Table 1 Baseline demographic and ß/?G4-related characteristics of female 
ß/?C/\-mutation carriers (N=34)
Before participation
%
Married 97
With children 79
Daughters N 
Mean age (SD)
21
13.6 (11.1)
Sons N 
Mean age (SD)
22
12.6(11.7)
Educational level > high school 41
Employed 88
Dutch native 100
BRCA1 68
Mean (SD)
Age BRCA detection in family 38.5 (10.5)
Age BRCA detection participant 39.6 (10.0)
Correlations between breast cancer perception, emotional status, cancer 
risk management behavior and family communication
Self-perceived breast cancer risk and absolute breast cancer risk appeared highly 
correlated. All negative emotions (depression, anger, fatigue, tension, low self- 
confidence) appeared highly correlated and had no correlation with vigor or with 
influence of BRCA on body confidence. Risk management of the breast was 
significantly correlated with SBE and risk management of the ovaries, while no 
correlation was found between risk management of the ovaries and SBE. Negative 
emotions were significantly correlated with perceived risk perception and risk 
management of the breasts. Absolute breast cancer risk was significantly 
correlated with communication in the nuclear family. Relative breast cancer risk 
was negatively correlated with vigor, but not correlated with negative emotions. 
Cancer thoughts were negatively correlated with lower self-confidence and 
positively correlated with discussing BRCA in general.
Emotional well-being
POMS negative emotions were high at T1 compared to those of a group of females 
in the Dutch general population [33] and remained high atT2.The mean scorefor
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depression appeared 2.4 times higher (p<0.001), for anger 1.9 times higher 
(p<0.001), for fatigue 1.5 times higher (p=0.04) and for tension 1.4 times higher 
(p=0.03) than the corresponding general population scores [33]. The POMS 
positive vigour score was similar to the vigour score of the norm group [33]. Higher 
levels of POMS negative emotions compared to a norm group of healthy adults 
were 63% for depression, 70% for anger, 67% for fatigue and 59% for tension. It 
should be noted that of all these women, 41% had high scores on all subscales at 
T1. A positive influence of BRCA on self-confidence was reported by 72% of the 
women at T1; this percentage falls to 50% at T2 (p=0.2). A negative influence of 
BRCA on body confidence was reported by 86% and by 82% of the women at T1 
and T2, respectively (Table 2).
Table 2 ß/?G4-related emotional well-being of 27 female ß/?G4-mutation
carriers before and after participating an educational support group
Before After P-value
PO M Sa Mean (SD) Mean (SD)
Depression 6.9 (6.7) 6.4 (4.8) 0.6b
Anger 6.0 (5.4) 7.0 (5.5) 0.2b
Fatigue 7.6 (6.3) 7.0 (5.2)
-QLOo
Vigor 10.7(4.9) 10.9 (5.6) 0.8b
Tension 7.4 (5.6) 7.0 (4.1) 0.7b
% %
Self-perceived breast cancer risk high 60 63 1.0C
BRCA influence on self-confidence 72 50 0.2C
BRCA influence on body-confidence 14 18 1.0C
a, Profile of Mood States;b, Paired-samples T-test;c, McNemar test; P <0.05 is considered statistically 
significant.
Breast cancer risk knowledge and perception
Participants report an accurate absolute breast cancer risk, i.e. 77% Life Time Risk 
(LFT) at T1 and 72% LFT at T2 (p=0.3). Both at T1 and at T2, 93% of the women 
report an accurate relative breast cancer risk, very high compared to 'the average 
Dutch woman'. Self-perceived breast cancer risk is high in, respectively 60% and
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63% of the participants at T1 and 12. Frequency of cancer thoughts is very high 
(i.e. daily/weekly) in 81% of the women at T1 and in 93% at 12 (p=0.4). Regarding 
the open-ended questions at 12, two frequently reported influences of BRCA on 
daily life were "cancer risk thoughts" and "future worries".
Cancer risk management behaviour
The intention towards PBM was present in 37% of the women at T1, in 44% of the 
women at 12 (p=0.7). An intention towards undergoing PBSO was present in 
respectively 71% and 81% of the women at T1 and 12. (p=0.6), including women 
who were not 35 years yet, but stated they would certainly have preventive 
surgery of their ovaries in the future. Accurate monthly breast self-examination 
was performed by respectively 67% and 78% of the women at T1 and 12 (p=0.4). 
Family and other ß/?G4-related communication
Following an educational-support group communicating with the nuclear family 
did not change (p=0.4), while BRCA carriership was significantly less often 
discussed with parents and sibs (p=0.02). Family communication openness scores 
for both nuclear family and family of origin of study participants were significantly 
lower (p=0.006 and p=0.02 respectively), than those of a group of women (n=175) 
from proven BRCA1/2 families during genetic counselling [37]. Both at T1 and T2, 
85% of the women discuss BRCA carriership daily or weekly with relevant others 
and almost half of the women discuss BRCA carriership with the General 
Practitioner. At T1, 30% wants to discuss BRCA more often and 15% less often than 
is sometimes possible. At T2, these percentages have reversed with an overall 
tendency towards less need to discuss BRCA carriership in general at T2 (Table 3).
Reported benefits of participating an educational-support group
At T1, 85% of the women and at T2 all women report to have received sufficient 
ß/?G4-related medical information to make well-informed decisions regarding 
cancer risk management. At T1, 81% and at T2 up to 100% (p=0.06) of this 
information is provided by genetic counsellors, medical social workers, medical 
specialists and by peer-information received at the educational-support group. 
At T1, 21% of the women (n=7) had wanted more medical information regarding 
PBM, at T2 this percentage have fallen down to zero. With open questions, the 
most reported effects of group participation were information and mutual 
support (Table 4).
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Table 3 Family and other ß/?G4-related communication status of 27 female 
ß/?G4-mutation carriers before and after participating an educational- 
support group
Before After P-value
Family communicationa Mean (SD) Mean (SD)
Nuclear family 24.1 (5.2) 22.4 (6.2) 0.2b
Family of origin 25.8 (7.4) 22.2 (7.3) 0.02b*
% %
With others regularlyc 85 85 1.0d
With general practitioner regularlyc 44 48 1.0d
Wants to discuss BRCA more often 30 19 0.5d
Wants to discuss BRCA less often 15 33 0.2d
a, Measured with the Openness to Discuss Hereditary Cancer in the Family Scale;b, Paired samples 
T-test;c, regularly: daily/weekly;d McNemar test; P <0.05 is considered statistically significant.
Table 4 Reported benefits of participating an educational support group 
(N=27 female BRCA1/2 mutation carriers)
Before % After % P-value
BRCÆ-related information
Sufficient 85 100 0.1a
From genetic counselor (before) 
supplemented by group (after)
81 100 0.0 6a
Most important effect BRCA on daily life: 
cancer risk worries
56 52 1.0a
Most important effect BRCA group: support 
/information
- 56/44
a, McNemar test, P <0.05 is considered statistically significant.
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Discussion
Women carrying a ß/?G4-mutation who attended an educational-support reported 
less family communication after the group meetings, while high emotional 
distress, and adequate breast cancer risk knowledge, perception and management 
behaviour were unchanged. Following an educational-support group, women 
discussed BRCA significantly less often with their parents and sibs. Women may 
experience a lack of support when communication on this subject is limited [37]. 
However, diminished family communication with parents and sibs is not necessarily 
problematic because there is no explicit clinical need to discuss BRCA carriership 
with these relatives repeatedly. We observed that discussions on BRCA with sisters 
who were proven non-carriers or with brothers decreased over time. Women 
reported an attenuated need to discuss ß/?G4-related issues in general. These 
women require tailored information regarding BRCA carriership and the option to 
discuss management strategies in detail with relevant others such as professionals 
from the hereditary cancer clinic and experienced experts. Women indicated that 
participating in the educational-support group met their needs for information 
and support and enabled them to make more well-informed decisions regarding 
their "ß/?C4-future". These findings suggest that the group was very helpful to 
women's decision-making regarding risk-reducing options and are in line with a 
previously reported study [30]. Female ß/?G4-mutation carriers in our study 
reported high levels of negative emotions both before and following an 
educational-support group.
It is not possible to generalize this findings to the large population of female 
ß/?C/\-mutation carriers, since of all contacted female ß/?G4-mutation carriers, only 
29% accepted the offer to participate in the educational-support groups, so 
selection bias may have occurred. These women may have decided to participate 
in the educational-support groups, because they experienced high levels of 
distress. These female participants may for instance had a monitoring coping 
style, i.e. are more inclined to seek information and support, react with greater 
psychological distress both before and after genetic counselling and are less 
satisfied with the information received during genetic counselling [43]. This is 
supported by clinical experience by which participating women can roughly be 
divided in two groups: 1) those who openly expressed their cancer distress and 
were actively looking for ways to deal with ß/?G4-related cancer risks and 2) those 
who considered PBM and were especially looking for information regarding 
preventive breast surgery and breast reconstruction. Next, it is also possible that
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the group in some way catalysed the expression of emotions by having the women 
reflect on personal ß/?C4-related issues [30]. As time between BRCA genetic test 
disclosure and start of the group ranged considerably, psychosocial variables may 
have been influenced by many events during this waiting period. Support needed 
just after disclosure will be different from support needed many months after 
disclosure. However, in this small study sample it is impossible to take this waiting 
time interval into account in the analyses. Overall, the results of this study should 
be considered carefully, since further research on this topic is needed with a larger 
study sample and using a randomised controlled study design.
From these data we cautiously conclude that in this cohort risk knowledge is 
accurate after BRCA genetic counselling, while self-perceived breast cancer risk 
and negative mood states levels are high. Following an educational-support 
group women were able to make cancer risk management decisions, high levels 
of negative moods remained and communication on ß/?G4-related issues with the 
family of origin was diminished.
We cautiously conclude that ß/?G4-related information may well be offered in an 
educational-support group setting as still 19% of ß/?G4-related information could 
be added. However, because high emotional distress did not improve and family 
communication diminished after participating in a group we consider separating 
the offer of ß/?G4-related information from a full program of emotional support. 
As an alternative to these group sessions we believe that a more effective strategy 
may be to offer individual psychosocial support to those with high levels of 
emotional distress. Individual psychosocial support will then focus on ß/?G4-related 
negative moods and family communication.
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General discussion
The aim of the first part of this thesis was to address psychological distress after 
pre-screening for Lynch syndrome by MSI-testing during active treatment for CRC. 
Until recently, the usual approach was to postpone MSI-testing for Lynch syndrome 
until the family history had been studied extensively and information about all possible 
consequences had been made available by a clinical geneticist during genetic 
counseling. According to the Dutch Guideline Hereditary Colorectal Cancer [1] 
pathologists instead of clinical geneticists initiate MSI-testing in newly diagnosed 
patients who fulfill one of the following criteria, called MIPA-criteria: 1) CRC diagnosed 
before age 50 or 2) second CRC before age 70. MSI-testing which is indicated by a 
pathologist is called MIPA-testing and generally takes place immediately after tumour 
resection. The pathologists reports the MIPA-test resultto the surgeon who can discuss 
referral to a clinical geneticist with his or her patient. A striking psychological difference 
between traditionally cancer genetics practice and MIPA-testing is that MIPA-patients 
are confronted with a possibly hereditary predisposition for Lynch syndrome shortly 
after their cancer diagnosis and often during active treatment for CRC. At that time 
these patients may be extra emotionally vulnerable to genetic testing related distress. 
Although the potential medical preventive benefit of MIPA-testing has been proven [2] 
minimizing potential psychological harm is of utmost importance.
The aim of the second part of this thesis was to evaluate educational-support groups 
for female ß/?G4-mutation carriers. The challenge for these women is to make 
well-informed decisions about available cancer risk reduction strategies while 
processing uncertain outcomes [3]. In addition to facing difficult medical management 
decisions these women are confronted with complex psychosocial issues [4]. Requests 
by applicants for predictive genetic testing to get in contact with others facing a 
similar situation resulted in setting up support-groups for female ß/?G4-mutation 
carriers. Working with educational-support groups is a methodical way of giving care 
to people who are at risk for a certain disease before their problems escalate. In the 
Radboud University Nijmegen Medical Centre in the Netherlands, social workers have 
been organizing educational-support groups for female ß/?GA-mutation carriers from 
1997 onwards. Female mutation carriers regularly indicated, both in surveys and 
orally, to be strengthened in making ß/?G4-related choices through group participation 
This clinical observation is important, but needs more evidence. Based on all findings 
implications for clinical practice will be discussed and directions for future research 
will be reflected on.
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Parti Summary of the main findings
The key findings of the studies described in the first part of this thesis are:
1) Most patients with CRC experience diminished physical, social and role 
functioning during the first 3 months after primary treatment. Reduced emotional 
and social functioning continues up to 1 year after treatment for CRC, especially in 
patients diagnosed before age 60 or with a stoma. In male patients strain due to 
sexual impairment is found; female patients report higher spiritual well-being 
than men. After genetic counseling and testing for Lynch syndrome a minority of 
patients with CRC reports clinically relevant anxiety and depression levels. Most 
vulnerable to genetic testing related distress are female patients and male patients 
diagnosed with CRC before age 50 (literature review, chapter 2).
2) Shortened time interval between CRC diagnosis and MSI-testing is not 
associated with higher levels of psychological distress. Prone to high distress are 
women and patients who are religious, with low social support or those reporting 
difficulties in communicating hereditary colorectal cancer with relatives 
(traditionally MSI-testing study, chapter 3).
3) Newly diagnosed patients with CRC whose tumours are tested for the presence 
of MSI consider timely medico-preventive knowledge for their children as most 
valuable but are apprehensive about having to discuss hereditary CRC with 
relatives. Physical and psychological well-being are particularly impacted by the 
diagnosis and treatment for CRC (MIPAPS-pilot study, chapter 4).
4) MIPA-testing is not followed by high levels of psychological distress in general. 
High general distress is reported by 18% and high cancer specific distress by 40% 
of the total MIPA-group. No significant distress differences are found between the 
MIPA-positive (high risk Lynch syndrome) and the MIPA-negative group (low risk 
Lynch syndrome). Six months after MIPA-test disclosure, both distress and cancer 
specific distress decrease in the MIPA-positive group while remaining stable in 
the MIPA-negative group. Perceived distress by care giving is reported by half of 
all partners but is also independent of MIPA-test result (MIPAPS study, chapter 5).
In this chapter the above key messages and their implications will be discussed. 
First, psychological distress following MIPA-testing will be addressed. Next, the 
psychological impact of CRC will be discussed. Finally, vulnerability to high 
psychological distress will be reflected on.
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Psychological distress following MIPA-testing
In the introduction of this thesis it was hypothesized that MSI-testing in recently 
diagnosed patients with CRC (MIPA-testing) was followed by high psychological 
distress. The extent of psychological distress after MIPA-testing was defined by the 
extent of general distress as measured by the Symptom-Checklist-90 (SCL-90) and 
the extent of CRC specific distress measured by the Impact of Event Scale (IES-CRC). 
Mean distress levels were comparable to those reported in other studies on testing 
for hereditary cancer [5-7]. In both the MIPA-positive and the MIPA-negative group 
high levels of general distress and cancer specific distress were reported, but these 
levels were not significantly different between the groups. Perceived distress by the 
partners of these patients were not different between the MIPA-positive and the 
MIPA-negative group either. In our study on traditionally MSI-testing we found that 
shortened time interval between CRC diagnosis and MSI-testing was not associated 
with higher levels of psychological distress (chapter 3). Moreover, all patients in our 
MIPAPS pilot study (chapter 4) indicated that the CRC diagnosis and its subsequent 
treatment dominated their feelings of distress, not the knowledge of being at 
increased risk for Lynch syndrome. All our findings point in the same direction, 
namely that in general MSI-testing in recently diagnosed patients with CRC is not 
followed by clinically elevated levels of psychological distress.
An explanation for not finding high levels of psychological distress following 
MIPA-testing is given by the patients of our MIPAPS-pilot study (chapter 4). In this 
sample all patients considered MIPA-testing as highly valuable just because of 
this early timing. First, because of the thus obtained timely medical-preventive 
value for their children. As has been previously reported, 'obtaining certainty' 
about their own risk as well as that of their children, is an important motive for 
and psychological benefit of undergoing genetic testing [8-10]. Second, because 
these patients anticipated that psychological distress due to their recent CRC 
would be greatly reactivated when genetic testing was discussed years after. Now 
they could cope with their CRC and a possible hereditary predisposition for Lynch 
syndrome all at once which enabled them to finish this chapter to a large extent. 
These findings are in line with studies among recently diagnosed breast cancer 
patients for whom no additional burden was imposed by actively approaching 
them for genetic counseling and testing [11, 12]. In fact, the majority of these 
recently diagnosed breast cancer patients stated that the offer for genetic 
counseling and testing should take place at primary treatment or even earlier, 
immediately after breast cancer diagnosis [11,12].
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It may be that patients cannot immediately overlook the ultimate consequences 
of MIPA-testing. To be clear, MSI-testing is not a conclusive diagnostic test. A 
MIPA-positive test result refers to a possibly high genetic cancer risk but may also 
be due to non-hereditary, somatic hypermethylation of for example the 
MLH7-promoter. Therefore, to pinpoint the exact cause of the microsatellite 
instability, further genetic testing by DNA-analysis must take place and will take 
place only after comprehensive genetic counseling. Notwithstanding this fact, 
the current findings on psychological distress are contrary to assumptions about 
the potentially negative impact of offering and performing genetic risk assessment 
immediately after cancer diagnoses [13] at a time one would expect patients to be 
more psychologically vulnerable [14-16]. Patients with breast cancer who have not 
yet reached a decision about definitive surgical cancer treatment may benefit 
from genetic risk assessment [17]. In general subtotal colectomy seems to be the 
preferred treatm entfor CRC in young patients with Lynch syndrome [18].
Distress delay
High general distress and high cancer specific distress in recently diagnosed 
patients with CRC (chapter 5) were 18% and 40%, respectively. High cancer specific 
distress was present in 24% of the patients diagnosed with CRC less than 1 year 
ago. This high distress percentage was less than in patients diagnosed with CRC 
between 12-36 months ago (39%) or diagnosed longer than 36 months ago (35%) 
(chapter 3). An explanation might be that contemplation and consideration of the 
cancer is more likely to occur once active treatment for cancer in the hospital is 
over. A previous study showed that 15% of patients with breast cancer became 
distressed not until after end of treatment, in the reentry phase [19]. In line with 
this it was found that informational and support needs are most present between 
2 till 5 years after cancer diagnosis [20]. This could indicate that distress levels may 
become higher when time goes by. In view  of this, it has been demonstrated that 
distress fluctuates over a 5-year period following BRCA genetic test disclosure due 
to the continuous integration process of carriership in daily life [21].
Psychological impact of CRC
Our review demonstrated that decreased social and emotional functioning could 
persist up to one year after primary treatment for CRC, especially in patients 
younger than 60 years and in those with a stoma. Our MIPAPS pilot study revealed 
that the CRC diagnosis and subsequent treatment dominated patients' 
psychological well-being and not MIPA-testing (chapter 4). Many other studies
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have found that a CRC diagnosis leads to significant changes in people's lives. 
Patients with CRC are at risk of experiencing poor quality of life [22, 23], fatigue 
and altered bowel habits [24-26], continual fear of recurrence [27], future concerns 
[26, 28] and struggle to adapt living with a stoma [29, 30]. Sexual identities of 
patients with CRC were disrupted as a result of their surgery or having to live with 
a temporary or permanent stoma [31, 32]. Professional identities were lost due to 
an inability to meet social expectations about professional behaviour within a 
work context [32]. Our MIPAPS study revealed that neither TNM-stage, nor 
adjuvant treatment or MSI-test result were related to general distress or to cancer 
specific distress. To conclude, multiple factors such as demographic characteris­
tics of the person, their social environment, the way they appraise the illness and 
only to some extent medical factors influence how well patients psychologically 
adjust to a new CRC diagnosis [33].
Patients most vulnerable to psychological distress
The results of our MIPAPS study (chapter 5) did not confirm our hypothesis that 
MSI-testing in recently diagnosed patients with CRC is followed by high 
psychological distress. Moreover, neither TNM-stage nor adjuvant treatment were 
associated with high levels of psychological distress. Our studies however 
indicated that instead of cancer related or genetic riskfactors patients' character­
istics are predominant in reported psychological distress. High psychological 
distress in patients previously diagnosed with CRC was related to female gender, 
religiousness and family communication difficulties (chapter 3). In recently 
diagnosed patients with CRC psychological distress was associated with female 
gender, low social support and high cancer risk perception (chapter 5). Below an 
overview is given of the main risk factors associated with high psychological 
distress in patients with CRC.
Our review showed that patients diagnosed with CRC below the age of 50 were 
most vulnerable to genetic testing related psychological distress. A study on the 
demands of illness in patients with CRC revealed that especially the youngest age 
group (26-45 years) was most susceptible to disruption by their diagnosis and 
treatment of CRC, which can be explained by the developmental tasks associated 
with this age group, i.e. marital adjustment, child rearing and career development 
[34]. MIPA-testing mostly concerns relatively young patients with CRC, often 
below the age of 50 years. Therefore, professionals caring for CRC patients who
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may be at high risk for Lynch syndrome should be aware of the fact that especially 
younger patients may experience intense illness-related problems and thus 
should apply appropriate interventions [34].
Gender
Both in our literature review (chapter 2), our traditionally MSI-testing study 
(chapter 3) and in our MIPAPS study (chapter 5), women appeared to be most 
prone to psychological distress. Studies showed that in general women in contrast 
to men are responsible for managing more roles inside and outside of the family, 
are involved in more interpersonal relationships, assume more care giving roles 
and are more responsive to the events affecting other people's lives [35] and 
hence experience more distress when illness occurs [33].
Social support
Social support in the context of genetic testing involves the nuclear family with 
partner and children and the broader family including parents, sibs and second 
degree relatives such as uncles and aunts. Both our traditionally MSI-testing study 
and the MIPAPS study show that patients with low social support are vulnerable 
to high psychological distress. This is consistent with findings from studies among 
testing for hereditary cancer in which those with a perceived lack of social support 
reported heightened levels of distress and worries [36].
Partners
It was previously found that patients with cancer are more distressed and need 
more social support when having a highly distressed partner [12, 37]. There is a 
considerable impact of the CRC diagnosis on partners' before and 3 months after 
surgery [38]. In the MIPAPS study, perceived distress by informal care giving of the 
total partner group indicated overload at a mean of 5 months after their partner's 
CRC diagnosis. In a study among partners of patients with another form of 
hereditary colorectal cancer, i.e. familial adenomatous polyposis (FAP), 
approximately one-quarter of the sample reported clinically relevant levels of 
distress [39]. Partner's often observe the patient's suffering but are unsure how to 
help [40], feel unprepared for dealing with their partner's reactions and often 
assume the role of caregiver with little support from others [41]. Partners of 
patients with CRC are strongly affected by the disease with female caregivers 
reporting more distress, more role problems and less marital satisfaction than 
male caregivers [33]. Social support may function as a buffer between stressful
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situations and psychological distress [42] .This suggests that professionals caring 
for CRC patients should include distress-assessment of the patient's partner. Our 
MIPAPS study did not reveal a relation between caregiver experiences and gender, 
probably due to small sample size.
Family
Being at increased risk for Lynch syndrome is a family affair. Social support from 
relatives may be essential not only to adapt to the cancer diagnosis but also to 
cope with being the first in the family in whom a for Lynch syndrome predisposing 
mutation could be detected. The patients of our MIPAPS-pilot study were 
apprehensive about having to discuss a hereditary disposition for cancer with 
their family [43] and in our study among previously diagnosed patients with CRC 
who were offered MSI-testing psychological distress was significantly related to 
family communication difficulties [44]. Our and other studies [45, 46] show that 
family communication problems not only inhibits adequate dissemination of 
genetic risks in the family but is also related to psychological distress of the index 
patient. It has been found that the effect of a less open family communication 
style on psychological distress may maintain for years [21]. Therefore, it seems 
worth considering that the discussion of family communication with the patient 
at high risk for hereditary CRC should not only focus on dissemination of genetic 
risks results but also on sources of social support offered by relatives.
Partii Summary of the main findings
The key findings of the studies described in the second part of this thesis are:
1) Following an educational-support group nearly all ß/?G4-mutation carriers 
proceed with their initial choice for breast cancer surveillance or prophylactic 
bilateral mastectomy (PBM). Educational-support group participants decide to 
undergo prophylactic mastectomy earlier than non-attendees (chapter 6).
2) Following an educational-support group female ß/?G4-mutation carriers are 
able to make cancer risk management decisions. These women still report high 
levels of emotional distress and their communication with parents and sibs is 
diminished (chapter 7).
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In this chapter above key findings and their implications will be addressed. First, 
breast cancer risk management decisions in the context of an educational- 
support group will be evaluated. Subsequently, the focus will be on meeting 
informational needs, emotional distress and family communication of female 
ß/?C/\-mutation carriers following an educational-support group. Below the 
educational-support groups for ß/?G4-mutation carriers will be referred to as 
ß/?G4-groups.
Breast cancer risk management decisions
For more than ten years social workers of the family cancer clinic of the Radboud 
University Nijmegen Medical Centre in the Netherlands, have organized 
ß/?G4-groups. Since a core-goal of a BRCA-group is assisting women in making 
well-informed decisions on reducing breast cancer risk, the first study on these 
groups focused on breast cancer risk management choices (chapter 6). The aims 
of this study were to determine to what extent the initial preference for breast 
cancer surveillance or prophylactic bilateral mastectomy (PBM) was proceeded at 
a median of 2 years after first breast cancer surveillance visit and to explore the 
effect of a BRCA-group on the realization of risk management preference. We 
found that female mutation carriers with a preference for PBM are more likely to 
participate in a BRCA-group. This seems reasonable since the decision to opt for 
surgery is more complex, radical and irreversible compared to opting for 
surveillance so these women can use some guidance. Moreover, we found that 
nearly all ß/?G4-mutation carriers proceed with their initial choice for breast cancer 
surveillance or PBM. Our finding is in line with other studies which showed that 
the choice to undergo PBM is largely determined by a woman's prior preference 
to PBM before or just after BRCA-test disclosure [47, 48]. Next, we found presumptive 
evidence that BRCA-group participants decide to undergo PBM earlier than 
non-attendees. It was previously found that more women with a prior preference 
to PBM opt for a PBM after a positive MRI or mammography than women without 
such prior intention [47]. All together, these data suggest that in case female 
ß/?C/\-mutation carriers with a prior preference for PBM are well-informed and 
well-prepared, the step to undergo PBM is more easily set compared to women 
who do not participate a BRCA-group. It can be concluded that by providing 
comprehensive PBM related information, these women feel empowered to reach 
well-informed breast cancer risk management decisions.
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Informational needs, emotional distress and family communication
The aim of the study described in chapter 7 was to evaluate overall ß/?G4-related 
aspects following participation in a BRCA-group. The results of this study indicate 
that following a BRCA-group, women were able to make cancer risk management 
decisions but still reported high levels of emotional distress while family 
communication appeared diminished. In this study response rate was low and an 
explanation is that group support simply does not meet the needs of every 
ß/?C/\-mutation carrier [49, 50]. Informational needs were met since still 19% of 
ß/?G4-related information could be added and women reported to be well-informed 
to reach breast cancer risk decisions. The need to be well-informed to make 
personally suitable cancer risk reducing decisions is known from more studies. A 
majority of female ß/?G4-mutation carriers who underwent prophylactic bilateral 
salpingo-oophorectomy (PBSO) wished more information regarding the impact 
of this surgery on their sex life, the availability of sex counseling and the risk of 
coronary heart disease [51]. Proper and sufficient information about the PBM 
procedure and its possible aftermaths is one of the common and importantfactors 
related to satisfaction with the (cosmetic) outcome as well as the alterations on 
the sexual relationship and will lead to enhanced adaptation [52, 53]. So it may be 
concluded that these ß/?G4-groups meet informational needs of ß/?G4-mutation 
carriers.
It warrants attention that emotional distress of the women in our sample did not 
diminish after following group participation. This finding is in line with a study in 
which attendance at a retreat for ß/?C/\-families did not significantly impact 
psychological distress, although the opportunity to meet others dealing with 
similar issues and a place to obtain both information and receive emotional 
support were highly appreciated [54]. It is therefore proposed to give more explicit 
focus on coping with emotional distress during following ß/?G4-meetings.
Finally, it was found that communicating ß/?G4-related issues with parents and sibs 
was diminished following group participation. Decreased family communication 
may be an unintended side effect of group participation and it is therefore 
proposed to give more direct attention to family communication during following 
ß/?C/\-educational meetings. Medical confidentiality prohibits clinicians from 
directly contacting relatives of his or her patient about a genetic disease in the 
family [45]. Therefore, family communication of genetic cancer risks is of major 
importance to achieve the necessary transmission of information to relatives. 
Adequate family communication is essential if relatives are to have access to 
cancer prevention and surveillance programs and might therefore be life-saving
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[56]. The study comprised an evaluation of clinical practice. As a result it is not 
sure whether diminished family communication is a group effect or simply a time 
effect. Perhaps, over time also non-attendees discuss ß/?C4-related issues with 
their relatives less. After all, it is not necessary to discuss ß/?G4-related issues with 
your relatives repeatedly. It is likely that communication relating to hereditary 
cancer confirms to the rules and patterns that govern communication generally in 
families [56]. Moreover, it is likely that the specific and detailed information 
regarding for example PBM is shared more easily with women facing the same 
choices, e.g. group participants, compared to relatives who are either not-tested 
yet, proven non-carrier or without any intention towards preventive surgery.
Implications for clinical practice
Applicability of MIPA-testing
We found that shorter time interval between cancer diagnosis and genetic 
prescreening for Lynch syndrome was not related to higher psychological distress 
(chapter 2). MIPAPS-pilot study patients indicated that the advantages of early 
genetic prescreening for Lynch syndrome according to the MIPA-method 
outweighed the disadvantages (chapter 3). The MIPAPS study showed that 
MIPA-testing is not followed by clinically elevated psychological distress in either 
the MIPA-positive or the MIPA-negative group. Also caregiver experiences of their 
partners were unrelated to the MIPA-test result, (chapter 4). Notwithstanding the 
fact that low response rate of our MIPAPS-study may have biased our results all 
data point in the same direction namely that prescreening for Lynch syndrome by 
MSI-testing in recently diagnosed patients with CRC is applicable from a 
psychological point of view.
Psychological distress
It warrants clinical attention that a subgroup of recently diagnosed patients with 
CRC reported high distress which remained stable over time. Since short-term 
distress is a strong predictor for long-term distress it is of utmost importance to 
detect this highly distressed group and to offer them early psychosocial 
intervention. Adjustment to cancer is a family affair. Professional support needs to 
be directed toward both the patient and his or her immediate social environment in 
which the impact of parental cancer on children should not be overlooked [57, 58]. 
To avoid or reduce long-term distress, psychosocial assessment and if indicated
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subsequent professional support should start early after the (hereditary) CRC 
diagnosis and should also be partner, family and socially focused. A screening 
tool for use in cancer genetics is currently being developed (Bleiker et at., Dutch 
Cancer Society, project grant NKI 2008-4016).
Information and support for patients at genetic risk for cancer
The overall conclusion regarding the ß/?G4-groups as described in this thesis is that 
they contribute to well-founded cancer risk management decisions. Because 
emotional distress did not diminish after participating in an BRCA-group, we 
consider separating the offer of ß/?G4-related information from the offer of 
psychosocial support. According to our results, ß/?G4-related informational meetings 
should focus on ways of coping with emotional distress, family communication and 
on the choice between breast cancer surveillance and PBM. As an alternative to the 
ß/?G4-support sessions, we believe that a more effective strategy may be to offer 
individual psychosocial support to women with high emotional distress. Patients at 
risk for Lynch syndrome do not face complex cancer risk management decisions. 
[50]. However, it might be worth investigating overall Lynch syndrome related needs 
and to explore whether informational meetings might meet those needs.
In society in general and also in the area of clinical genetics there is a growing 
interest in tailored websites, internet-based interventions and online guided 
self-help. Studies have shown that online guided self-help and face-to-face 
interventions can have comparable effects [59-63]. Online services have not been 
incorporated into existing genetic testing protocols. Although people are 
interested in services to support the ongoing integration of genetic information 
into daily life these are generally not available yet [64]. Given the profile of the 
majority of patients involved in genetic testing for hereditary cancer, namely 
relatively young, often having (small) children, being employed and sometimes 
with feelings of stigmatization, it is worth investigating the need for tailored 
online information and support for patients at risk for hereditary cancer.
Limitations and future directions
To our knowledge we were the first to study psychological distress following 
MSI-testing in recently diagnosed patients with CRC. This nationwide prospective 
study has given a first understanding in the psychological reactions to MIPA-testing 
of both patients and their partners. However, we did not achieve a high response 
rate and all patients were Dutch natives. Therefore, larger and international 
studies are needed to confirm our results.
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Both from our as from other studies it is becoming increasingly clear that gender 
and social support are main aspects in adaption to potentially distressing events 
such as a cancer diagnosis or genetic testing for hereditary cancer. In future 
studies it is worth investigating patients' specific strengths and needs regarding 
these aspects to offer customized care.
The ultimate medical preventive benefit of genetic testing for hereditary cancer 
depends on adequate dissemination of genetic test results and its consequences 
in the family. Future studies are needed to investigate how family communication 
barriers can be addressed adequately.
In the nearby future next generation sequencing including whole exome 
sequencing will provoke more genetic knowledge on multiple genes involved in 
complex and common diseases like cancer, heart disease, diabetes and mental 
illness. Individual risk assessments can be made based on the set of genes and 
individuals can be confronted with many genetic-based risks at the same time. 
In view  of these future developments more studies regarding the impact of 
genetic health risks are needed on both health behavior, on related psychosocial 
well-being and on ways to support the ongoing integration of genetic information 
into daily life.
160
References
1. Dutch Guideline Hereditary Colorectal Cancer. 13. 
www.oncoline.nl 1-1-2008.
2. Kievit W, de Bruin JH, Adang EM et al (2005) Cost 
effectiveness of a new strategy to identify HNPCC 14. 
patients. Gut 54:97-102
3. Roussi P, Sherman KA, Miller S et al (2010) 
Enhanced counselling for women undergoing 
BRCA1/2 testing: Impact on knowledge and 
psychological distress-results from a randomised 15. 
clinical trial. Psychol Health 25:401-15
4. van Riper M., McKinnon WC (2004) Genetic testing 
for breast and ovarian cancer susceptibility: a 
family experience. J  Midwifery Womens Health 16. 
49:210-9
5. BleikerEM,MenkoFH,Kluijtletal (2007)Colorectal 
cancer in the family: psychosocial distress and 
social issues in the years following genetic 17. 
counselling. Hered Cancer Clin Pract 5:59-66
6. Douma KF, Bleiker EM, Vasen HF et al (2010) 
Psychological distress and quality of life of 
partners of individuals with familial adenomatous 18. 
polyposis. Psychooncology
7. Meiser B, Halliday JL  (2002) What is the impact of 
genetic counselling in women at increased risk of 
developing hereditary breast cancer? A meta- 19. 
analytic review. Soc Sci Med 54:1463-70
8. Bleiker EM, Aaronson NK, Menko FH et al (1997) 
Genetic counseling for hereditary cancer: a pilot 
study on experiences of patients and family 20. 
members. Patient Educ Couns 32:107-16
9. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT et 21. 
al (2000) Presymptomatic DNA testing and 
prophylactic surgery in families with a BRCA1 or 
BRCA2 mutation. Lancet 355:2015-20
10. Tibben A, Frets PG, van de Kamp JJ  et al (1993) 22. 
Presymptomatic DNA-testing for Huntington 
disease: pretest attitudes and expectations of 
applicants and their partners in the Dutch 
program. Am J  Med Genet 48:10-6 23.
11. Schlich-Bakker KJ, Warlam-Rodenhuis CC, van EJ et al
(2006) Short term psychological distress in patients 
actively approached for genetic counselling after 24. 
diagnosis of breast cancer. Eur J  Cancer 42:2722-8
12. Schlich-Bakker KJ, Ausems MG, Schipper M et al
(2007) BRCA1/2 mutation testing in breast cancer 25. 
patients: a prospective study of the long-term 
psychological impact of approach during adjuvant 
radiotherapy. Breast Cancer Res Treat
van Zuuren FJ (1997) The standard of neutrality 
during genetic counselling: an empirical 
investigation. Patient Educ Couns 32:69-79 
Ardern-Jones A, Kenen R, Eeles R (2005) Too much, 
too soon? Patients and health professionals' views 
concerning the impact of genetic testing at the 
time of breast cancer diagnosis in women under 
the age of 40. Eur J  Cancer Care (Engl ) 14:272-81 
Millar K, Purushotham AD, McLatchie E et al (2005) 
A 1-year prospective study of individual variation 
in distress, and illness perceptions, after treatment 
for breast cancer. J  Psychosom Res 58:335-42 
Tjemsland L, Soreide JA, Malt UF (1998) 
Posttraumatic distress symptoms in operable 
breast cancer III: status one year after surgery. 
Breast Cancer Res Treat 47:141 -51 
Schwartz MD, Lerman C, Brogan B et al (2005) 
Utilization of BRCA1/BRCA2 mutation testing in 
newly diagnosed breast cancer patients. Cancer 
Epidemiol Biomarkers Prev 14:1003-7 
de Vos tot Nederveen Cappel WH, Buskens E, van 
DP et al (2003) Decision analysis in the surgical 
treatment of colorectal cancer due to a mismatch 
repair gene defect. Gut 52:1752-5 
Henselmans I, Helgeson VS, Seltman H et al (2010) 
Identification and prediction of distress trajectories 
in the first year after a breast cancer diagnosis. 
Health Psychol 29:160-8
NIVEL. Ondersteuningsbehoeften van (ex-) kanker- 
patienten en de rol van de huisarts. NIVEL; 2010. 
van Oostrom I, Meijers-Heijboer H, Lodder LN et al 
(2003) Long-term psychological impact of carrying 
a BRCA1/2 mutation and prophylactic surgery: a 
5-year follow-up study. J  Clin Oncol 21:3867-74 
Dunn J, Lynch B, Rinaldis M et al (2006) Dimensions of 
quality of life and psychosocial variables most salient 
to colorectal cancer patients. Psychooncology 
15:20-30
Engel J, Kerr J, Schlesinger-Raab A et al (2003) 
Quality of life in rectal cancer patients: a four-year 
prospective study. Ann Surg 238:203-13 
CamiIIeri-Brennan J, Steele RJ (2002) Objective 
assessment of morbidity and quality of life after 
surgery for low rectal cancer. Colorectal Dis 4:61 -6 
Desnoo L, Faithfull S (2006) A qualitative study of 
anterior resection syndrome: the experiences of 
cancer survivors who have undergone resection 
surgery. Eur J  Cancer Care (Engl ) 15:244-51
161
26. Simpson MF, Whyte F (2006) Patients' experiences 
of completing treatment for colorectal cancer in a 
Scottish District General Hospital. Eur J Cancer 
Care (Engl ) 15:172-82
27. Northouse LL, Schafer JA, Tipton J et al (1999) The 
concerns of patients and spouses after the 
diagnosis of colon cancer: a qualitative analysis. J 
Wound Ostomy Continence Nurs 26:8-17
28. Persson E, Hellstrom AL (2002) Experiences of 
Swedish men and women 6 to 12 weeks after 
ostomy surgery. J Wound Ostomy Continence 
Nurs 29:103-8
29. Brown H, Randle J (2005) Living with a stoma: a 
review of the literature. J Clin Nurs 14:74-81
30. Desnoo L, Faithfull S (2006) A qualitative study of 
anterior resection syndrome: the experiences of 
cancer survivors who have undergone resection 
surgery. Eur J Cancer Care (Engl ) 15:244-51
31. Manderson L (2005) Boundary breaches: the body, 
sex and sexuality after stoma surgery. Soc Sci Med 
61:405-15
32. Rozmovits L, Ziebland S (2004) Expressions of loss 
of adulthood in the narrartives of people with 
colorectal cancer. Qualitative Health Research
14(2); 187-203
33. Northouse LL, Mood D, Templin T et al (2000) 
Couples' patterns of adjustment to colon cancer. 
Soc Sci Med 50:271-84
34. Fernsler Jl, Klemm P, Miller MA (1999) Spiritual 
well-being and demands of illness in people with 
colorectal cancer. Cancer Nurs 22:134-40
35. Shumaker SA, Hill DR (1991) Gender differences in 
social support and physical health. Health Psychol 
10 :102-11
36. Lepore S, Revenson T (2007) Social constraints on 
disclosure and adjustment to cancer. Social and 
Personality Psychology Compass
37. Schlich-Bakker KJ, Ten Kroode HF, Warlam 
Rodenhuis CC et al (2009) Distress in couples 
approached for genetic counseling and BRCA1/2 
testing during adjuvant radiotherapy. 
Psychooncology
38. Tuinstra J, Hagedoorn M, Van SE et al (2004) 
Psychological distress in couples dealing with 
colorectal cancer: gender and role differences and 
intracouple correspondence. Br J Health Psychol 
9:465-78
39. Douma KF, Bleiker EM, Vasen HF et al (2010) 
Psychological distress and quality of life of 
partners of individuals with familial adenomatous 
polyposis. Psychooncology
40. Zahlis EH, Shands ME (1993) The impact of breast 
cancer on the partner 18 months after diagnosis. 
Semin Oncol Nurs 9:83-7
41. Northouse LL (1988) Social support in patients' 
and husbands' adjustment to breast cancer. Nurs 
Res 37:91-5
42. Kornblith AB, Herndon JE, Zuckerman Eet al (2001) 
Social support as a buffer to the psychological 
impact of stressful life events in women with 
breast cancer. Cancer 91:443-54
43. Landsbergen KM, Prins JB, Brunner HG et al (2009) 
Genetic testing offered directly after the diagnosis 
of colorectal cancer: a pilot study on the reactions 
of patients. Genet Couns 20:317-25
44. Landsbergen KM, Prins JB, Brunner HG et al (2010) 
Shortened time interval between colorectal 
cancer diagnosis and risk testing for hereditary 
colorectal cancer is not related to higher 
psychological distress. Fam Cancer
45. Claes E, Evers-Kiebooms G, Boogaerts A et al 
(2003) Communication with close and distant 
relatives in the context of genetic testing for 
hereditary breast and ovarian cancer in cancer 
patients. Am J Med Genet A 116:11-9
46. van Oostrom I, Meijers-Heijboer H, Duivenvoorden 
HJ et al (2007) Family system characteristics and 
psychological adjustment to cancer susceptibility 
genetic testing: a prospective study. Clin Genet 
71:35-42
47. Hoogerbrugge N, Kamm YJ, Bult P et al (2008) The 
impact of a false-positive MRI on the choice for 
mastectomy in BRCA-mutation carriers is limited. 
Ann Oncol 19:655-9
48. van Dijk S., Otten W, Zoeteweij MW et al (2003) 
Genetic counselling and the intention to undergo 
prophylactic mastectomy: effects of a breast 
cancer risk assessment. Br J Cancer 88:1675-81
49. Di Prospero LS, Seminsky M, Honeyford J et al 
(2001) Psychosocial issues following a positive 
result of genetic testing for BRCA1 and BRCA2 
mutations: findings from a focus group and a 
needs-assessment survey. CMAJ 164:1005-9
50. Dorval M, Maunsell E, Dugas MJ et al (2001) 
Support groups for people carrying a BRCA- 
mutation. CMAJ 165:740
51. Campfield BD, Moyer A, Matloff ET (2010) What I 
wish I'd known before surgery: BRCA carriers' 
perspectives after bilateral salipingo-oophorecto- 
my. Fam Cancer
52. Bresser PJ, Seynaeve C, Van Gool AR et al (2006) 
Satisfaction with prophylactic mastectomy and
162
breast reconstruction in genetically predisposed 64. Werner-Lin A (2008) Formal and informal support 
women. Plast Reconstr Surg 117:1675-82 needs of young women with BRCA-mutations. J
53. Bresser PJ, Van Gool AR, Seynaeve C et al (2007) Psychosoc Oncol 26:111-33 
Who is prone to high levels of distress after
prophylactic mastectomy and/or salpingo-ova- 
riectomy? Ann Oncol 18:1641-5
54. McKinnon W, Naud S, Ashikaga T et al (2007)
Results of an intervention for individuals and 
families with BRCA-mutations: a model for 
providing medical updates and psychosocial 
support following genetic testing. J  Genet Couns 
16:433-56
55. Landsbergen K, Verhaak C, Kraaimaat F et al (2005)
Genetic uptake in BRCA-mutation families is related 
to emotional and behavioral communication charac­
teristics of index patients. Fam Cancer 4:115-9
56. Gaff C Family matters: theory and practice in the 
communication of genetic information. Euopean 
Journal of Human Genetics 18[1 ]. 2010.
57. Huizinga GA, Visser A, van der Graaf WT et al 
(2005) Stress response symptoms in adolescent 
and young adult children of parents diagnosed 
with cancer. Eur J  Cancer 41:288-95
58. van Oostrom I, Meijers-Heijboer H, Duivenvoorden 
HJ et al (2006) Experience of parental cancer in 
childhood is a risk factor for psychological distress 
during genetic cancer susceptibility testing. Ann 
Oncol
59. Cuijpers P, Donker T, van SA et al (2010) Is guided 
self-help as effective as face-to-face psychotherapy 
for depression and anxiety disorders? A systematic 
review a nd meta-ana lysis of comparative outcome 
studies. Psychol Med 40:1943-57
60. DonkerT, van SA, Riper H et al (2009) Implementation 
of Internet-based preventive interventions for 
depression and anxiety: role of support? The design 
of a randomized controlled trial. Trials 10:59
61. Hoek W, Schuurmans J, Koot HM et al (2009)
Prevention of depression and anxiety in 
adolescents: a randomized controlled trial testing 
the efficacy and mechanisms of Intern et-based 
self-help problem-solving therapy. Trials 10:93
62. van SA, Cuijpers P, Smits N (2008) Effectiveness of a 
web-based self-help intervention for symptoms of 
depression, anxiety, and stress: randomized 
controlled trial. J  Med Internet Res 10:e7
63. Warmerdam L, van SA, Jongs ma J  et al (2010)
Online cognitive behavioral therapy and problem­
solving therapy for depressive symptoms:
Exploring mechanisms of change. J  Behav Ther 
Exp Psychiatry 41:64-70
ch
ap
te
r 
8 
Ge
ne
ra
l 
di
sc
us
si
on

Summary / Samenvatting 
List of publications 
Dankwoord 
Curriculum Vitae

Summary
The first part of this thesis addressed psychological distress after prescreening for 
Lynch syndrome by microsatellite instability (MSI)-testing in relatively young and 
recently diagnosed patients with colorectal cancer (CRC). Lynch syndrome is the 
most frequent form of hereditary colorectal cancer. To improve the recognition of 
Lynch syndrome among patients with CRC, the MIPA-strategy was developed 
according to which prescreening for Lynch syndrome by MSI-testing takes place 
immediately after tumor resection in a selection of patients: diagnosed with CRC 
below age 50 years or with a second CRC below age 70 years. The next step of the 
MIPA-method is discussion of the MSI-test result and referral to genetic counseling 
with a patient with an MSI-positive tumor by the treating physician. From 2008 
onwards, MIPA-testing is included in the Dutch Guideline Hereditary Colorectal 
Cancer. It implies a striking difference compared to former practice in which 
MSI-testing takes place only after comprehensive genetic counseling of the 
patient. As a result of MIPA-testing patients are almost simultaneously confronted 
with a diagnosis of and treatmentfor CRC and a possibly hereditary predisposition 
for Lynch syndrome. CRC is in itself already responsible for considerable physical 
and psychosocial morbidity. The question is to what extent MIPA-testing is 
followed by high levels of psychological distress.
The second part of this thesis focused on educational-support groups for female 
ß/?G4-mutation carriers. Due to a high breast cancer risk, female ß/?G4-mutation carriers 
face a complex choice between breast cancer surveillance and prophylactic bilateral 
removal of their breasts. The decision is usually not a medical urgent one. Women can 
take time to process all information to make a well-informed decision. An important 
goal of so-called ß/?G4-groups as organized at the hereditary cancer clinic of the 
Radboud University Nijmegen Medical Centre in the Netherlands is assisting women in 
making informed choices regarding cancer risk management. Another goal is to 
address overall psychosocial related issues related to ß/?G4-carriership.
Part 1: Psychological impact of prescreening for Lynch syndrome in new 
colorectal cancer patients
Many studies have focused on the psychological impact of presymptomatic genetic 
testing for Lynch syndrome, i.e. in unaffected individuals. Also extended work has
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been accomplished on familial cancer in general, including patients with CRC tested 
for Lynch syndrome. However, very few studies addressed the psychological impact 
of genetic testing for Lynch syndrome in recently diagnosed patients with CRC. The 
first step in this project was to perform a literature review to understand what was 
already known about psychological distress of patients in their first year following 
CRC diagnosis and about the psychological impact of symptomatic genetic testing 
for Lynch syndrome, i.e. in patients affected with CRC. This study is presented in 
Chapter 2. We reviewed reports published between January 1997 and October 2007. 
Searches took place in the electronic databases of PubMed, Psychlnfo, Embase and 
the Cochrane Library. Only a limited number of relevant studies could be identified. 
Studies on the psychological impact of genetic testing in newly diagnosed patients 
were not available. What we did find was that reduced emotional and social 
functioning continues up to 1 year after CRC treatment, especially in patients with a 
stoma or diagnosed before age 60. In addition it was shown that most vulnerable to 
Lynch syndrome genetic testing related distress are female patients in general and 
male patients diagnosed before age 50.
In case of an MSI-positive tumor, the patient is at high risk for Lynch syndrome. 
Blood DNA-analysis must follow to detect its underlying cause. Studies on the 
psychological impact of genetic testing for Lynch syndrome generally focused on 
this period of blood DNA-analysis, not on the period of MSI-testing. Given our 
questions regarding the psychological impact of MIPA-testing, it was obviously 
important to know the impact of MSI-testing in former practice, i.e. after genetic 
counseling for Lynch syndrome. In Chapter 3 the focus was on the psychological 
impact of MSI-testing in former clinical genetics practice. We assessed whether 
high levels of psychological distress are present during MSI-testing and whether 
distress levels are related to the time between CRC diagnosis and MSI-testing. In 89 
patients with a history of CRC, data were collected during MSI-testing just after 
genetic counseling. The median time between CRC diagnosis and MSI-testing was 
24 months. General psychological distress (SCL-90) was low but more than one third 
of these patients reported high cancer specific distress (IES>26). Time between CRC 
diagnosis and MSI-testing was not significantly related to general distress nor to 
cancer specific distress. High cancer specific distress was reported by 25% of the 
patients diagnosed with CRC less than 12 months ago versus 39% and 35% by those 
diagnosed between 12 and 35 months and more than 36 months ago, respectively. 
Psychological distress following MSI-testing was related to female gender, 
religiousness, low social support and family communication difficulties.
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The first step to understand the psychological impact of MIPA-testing was to explore 
the overall reactions of patients who had been confronted with this new Lynch 
syndrome detection method. In Chapter 4 a pilot study is described in which we 
investigated the experiences of 8 patients who were recently confronted with 
MIPA-testing. Patients were interviewed at home using a self-administered 
questionnaire based on the multicausal model of problem analysis adapted for 
hereditary CRC. Three themes emerged: 1) a changed life after CRC, 2) warning for the 
future and 3) family communication barriers. In this early stage after diagnosis coping 
with the treatment for CRC mainly determined the reactions. These few patients were 
of the opinion that as a result of MIPA-testing the preventive medical value especially 
for their children greatly outweighed possible family communication barriers.
The final step was to assess patients' psychological distress in a larger sample at 
both short-term and longerterm and to investigate caregiver experiences of their 
partners. Chapter 5 comprises the MIPAPS-study in which we prospectively 
determined psychological distress in recently diagnosed patients with CRC 
immediately following MSI-testing and 6 months later. From March 2007 until 
September 2009, 400 Dutch patients with a new CRC and their partners were 
approached by their treating surgeon to participate in our study. Levels of general 
distress (SCL-90) and cancer specific distress (IES) were moderate. In the 
MSI-positive patient group (high risk Lynch syndrome), high general distress 
(SCL-90>160) decreased after 6 months from 27% to 18%, while remaining stable 
in the MSI-negative group (low risk Lynch syndrome), from 14% to 18%. High 
cancer specific distress (IES>26) decreased in the MSI-positive group and remained 
stable in the MSI-negative group, from 39% to 27% and from 38% to 36%, 
respectively. Female patients were most prone to high levels of psychological 
distress as were patients with low social support or a high cancer risk perception. 
The partners of both the patients at low and at high risk for Lynch syndrome 
showed moderate to high levels of caregiver esteem (CRA-D) while in both groups 
perceived distress by caring (EDIZ) decreased over time.
Conclusions
Identification of Lynch syndrome is important because surveillance reduces CRC 
mortality in healthy relatives. Prescreening for Lynch syndrome by MIPA-testing 
implies a striking difference for patients compared to former clinical genetics 
practice. Relatively young and recently diagnosed patients with CRC are confronted 
with a possibly hereditary predisposition of their CRC during active treatment for
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their CRC. Ourfindings indicate that time between CRC-diagnosis and MSI-testing 
is not related to general distress or cancer specific distress. Moreover, MIPA-testing 
is not followed by high levels of distress in general. Perceived distress by their 
partners is not related to MIPA-test result either. However, a subgroup of these 
patients report high psychological distress. Female patients with CRC are most 
vulnerable to distress as are patients with low social support or with high cancer 
risk perception. These patients need customized psychosocial care.
Part 2: Educational-support groups for female ß/?C^-mutation carriers
The second part of this thesis addressed educational-support groups in the area 
of hereditary breast and ovarian cancer. In this thesis two studies are described 
which evaluated such groups for recently proven female ß/?G4-mutation carriers, 
the so-called ß/?G4-groups. Healthy female ß/?G4-mutation carriers face a complex 
choice between intensive breast cancer surveillance and prophylactic bilateral 
mastectomy (PBM). A BRCA-group aims at assisting women in making a 
well-informed decision. However, it was unknown whether in fact participating in 
a BRCA-group changed the initial intention of surveillance into PBM. To be clear, 
this would be considered an unintended side-effect of group participation. In 
Chapter 6 we determined breast risk management preferences of 163 recently 
proven female ß/?G4-mutation carriers shortly after genetic test disclosure and 
their mastectomy status after a median observation period of 2 years. We 
additionally explored the effect of a BRCA-group on the realization of women's 
breast cancer risk management preferences. Of the total sample, 27% had a 
preference for PBM and after two years 30% had actually undergone PBM. Female 
ß/?C/\-mutation carriers with a preference for PBM are significantly more likely to 
participate in a BRCA-group compared to women with a preference for breast 
cancer surveillance. The number of women with a preference for PBM who actually 
had a mastectomy performed was significantly higher in the group that attended 
a BRCA-group compared to those who did not, 89% and 63%, respectively. Of the 
women with a preference for breast cancer surveillance, 90% of the BRCA-group 
attendees and 88% of the other mutation carriers were still under surveillance. We 
concluded that nearly all ß/?C/\-mutation carriers proceed with their initial 
preference for surveillance or prophylactic mastectomy expressed during first 
surveillance visit after genetic test disclosure while participating in a BRCA-group 
group seems to strengthen the initial expressed intention to undergo PBM.
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Above mentioned study did not answer the question whether women were more 
capable of coping with ß/?G4-mutation carriership in daily life after participating 
in a BRCA-group. In Chapter 7 we assessed informational needs, emotional 
distress and family communication of female ß/?G4-mutation carriers just before 
(T1) and after following ß/?C4-groups (T2). All 34 women indicated that group 
participation highly met their need for ß/?G4-relation information to support their 
decision-making process regarding breast cancer risk management. Mean levels 
of depression, anger, fatigue and tension were high and remained high at T2. Also 
cancer risk perception and frequency of cancer thoughts were high at both T1 and 
T2. Family communication with parents, brothers and sisters was significantly 
reduced at T2 compared to T1. This study showed that after following a BRCA-group 
these women were very capable of making cancer risk management decisions. 
However, these women still reported high levels of emotional distress and 
communicated with theirfam ily less after group participation.
Conclusions
Female ß/?G4-mutation carriers may opt between intensive breast cancer surveillance 
and prophylactic removal of their breasts with or without breast reconstruction. 
So-called ß/?G4-groups aim at assisting these women in making well informed and 
the most suitable BRCA-related choices. Female ß/?G4-mutation carriers with an 
intention towards prophylactic surgery are most likely to participate in a ß/?G4-group. 
Participating in a ß/?G4-group does not change the choice for breast cancer 
surveillance or prophylactic surgery but reinforces women to take action on 
prophylactic surgery. A ß/?G4-group contributes to well-informed decision-making 
but emotional distress does not improve and ß/?G4-related family communication 
with parents and sibs is diminished following a ß/?G4-group. A topic for future research 
and a challenge for clinical practice is to continuously improve our understanding of 
what is required to adequately meet the specific needs of these women.
In view  of the studies described in this thesis it is concluded that the majority of 
people who are confronted with (a predisposition to) hereditary cancer gets 
through it without major psychological problems. However, a subgroup reports 
serious and more or less stable psychological complaints including adaptation 
problems, depressive symptoms and continuous fear of cancer. In contrast to 
what one may expect these complaints are not related to the medical or genetic 
context but to more stable characteristics such as age and gender, to social 
characteristics such as social support and family communication and to cancer risk 
perception. It is desirable to trace these people and to offer customized support.
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Samenvatting
Het eerste deel van dit proefschrift richt zich op psychische klachten na het 
pre-screenen voor Lynch syndroom door het testen van microsatelliet instabiliteit 
(MSI) in tumoren van relatief jonge en recent gediagnosticeerde patiënten met 
dikke darmkanker. Lynch syndroom is de meest voorkomende vorm van erfelijke 
darmkanker. Om de herkenning van Lynch syndroom in patiënten met dikke 
darmkanker te vergroten is een aanvullende strategie ontwikkeld. Volgens deze 
zogenaamde MIPA-strategie vraagt de patholoog een MSI-test aan voor alle 
patiënten met dikke darmkanker onder de 50 jaar of met een tweede tumor 
horend bij Lynch syndroom onder de 70 jaar. MIPA staat voor MSI-test op indicatie 
van een patholoog. Patiënten met een MSI-positieve tumor hebben een verhoogd 
risico op Lynch syndroom. Zij kunnen vervolgens door hun behandelend arts 
verwezen worden voor erfelijkheidsadvisering in een klinisch genetisch centrum. 
Vanaf 2008 is MIPA-testen opgenomen in de Nederlandse Richtlijn Erfelijke 
Darmkanker. Deze methode betekent een voor patiënten belangrijk verschil in 
vergelijking met de tot dan toe gangbare klinisch genetische praktijk waarin een 
MSI-test pas wordt ingezet na uitgebreide genetische counseling van de patiënt. 
Door MIPA-testen worden patiënten bijna gelijktijdig geconfronteerd met een 
diagnose van en behandeling voor dikke darmkanker én met een mogelijk erfelijke 
aanleg voor Lynch syndroom. Dikke darmkanker alleen kan al ernstige lichamelijke 
en psychosociale morbiditeit tot gevolg hebben en de vraag is in hoeverre 
MIPA-testen zal leiden tot ernstige psychische klachten.
In het tweede deel van dit proefschrift staan informatie-support groepen voor 
vrouwen met een ß/?G4-mutatie centraal. Door hun hoge borstkankerrisico staan 
vrouwelijke BRCA- mutatie draagsters voor een complexe keuze tussen intensieve 
borstcontroles en preventieve borstverwijdering. Over het algemeen hebben 
deze vrouwen de tijd om alle informatie hieromtrent te verwerken en een 
weloverwogen besluit te nemen. Een belangrijk doel van de ß/?G4-groepen van 
de Polikliniek Familiaire Tumoren van het UMC St Radboud in Nijmegen is om 
deze vrouwen te ondersteunen bij het maken van weloverwogen keuzes. Een 
ander doel van deze groepsbijeenkomsten is het bevorderen van de integratie 
van ß/?G4-dragerschap in het dagelijkse leven.
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Deel 1: Psychologische invloed van pre screenen voor Lynch Syndroom 
in nieuwe patiënten met dikke darmkanker
Er is inmiddels veel onderzoek gedaan naar de psychologische gevolgen van 
erfelijkheidsonderzoek naar Lynch syndroom bij zowel patiënten met dikke 
darmkanker als bij hun vaak nog gezonde familieleden. Echter weinig studies 
betroffen de psychologische invloed van erfelijkheidsonderzoek naar Lynch 
syndroom in recent gediagnosticeerde patiënten met dikke darmkanker.
De eerste stap in dit project was het uitvoeren van een literatuuronderzoek. Het 
doel was om te achterhalen wat er al bekend was over psychische klachten bij 
patiënten gedurende het eerste jaar na een diagnose dikke darmkanker en van de 
psychologische impact van genetisch testen in patiënten met dikke darmkanker. 
Dit literatuuronderzoek wordt beschreven in Hoofdstuk 2. We zochten in de 
elektronische databases van PubMed, Psychlnfo, Embase en de Cochrane Library 
naar studies die gepubliceerd waren tussen Januari 1997 en Oktober 2007. Slechts 
een beperkt aantal relevante studies kon worden geïdentificeerd. We vonden 
geen onderzoeken naar de psychologische impact van genetisch testen in recent 
gediagnosticeerde patiënten met dikke darmkanker. Uit de gevonden studies 
bleek dat beperkt emotioneel en sociaal functioneren kon blijven bestaan tot een 
jaar na de dikke darmkanker diagnose, met name bij patiënten met een stoma en 
bij patiënten onder de 60 jaar. Verder bleek dat vrouwen in het algemeen en 
mannen met een diagnose onder de 50 jaar het meest kwetsbaar zijn voor 
psychische klachten gerelateerd aan de periode rondom erfelijkheidsonderzoek 
naar Lynch syndroom.
In het geval van een microsatelliet instabiele (= MSI-positieve) tumor heeft de 
patiënt een verhoogd risico op Lynch syndroom. DNA-analyse in bloed kan 
vervolgens uitwijzen wat de precieze oorzaak is van de MSI in het tumorweefsel. 
Onderzoeken naar de psychologische impact van genetisch testen voor Lynch 
syndroom richtte zich meestal op de periode rondom DNA-analyse en niet op de 
periode daarvoor, die van de MSI-test. In Hoofdstuk 3 beschrijven wij de mate 
van psychologische klachten na MSI-testen van 89 patiënten met een geschiedenis 
van darmkanker in de gangbare klinisch genetische praktijk dus na uitgebreide 
genetische counseling. We onderzochten daarbij de invloed van timing van de 
MSI-test door te bekijken of de mate van psychische klachten gerelateerd was aan 
de tijd tussen dikke darmkanker diagnose en het inzetten van de MSI-test. De
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mediane tijd tussen de dikke darmkanker diagnose en het inzetten van de MSI-test 
bedroeg 24 maanden. Het algemene psychische klachten niveau was laag maar 
meer dan een derde van deze patiënten rapporteerde ernstige verwerkingsklach- 
ten. Er werd geen relatie gevonden betreffende de tijd tussen de diagnose van 
dikke darmkanker en MSI-test en de mate van algemene psychische klachten 
noch met verwerkingsklachten. Ernstige verwerkingsklachten werden 
gerapporteerd door 25% van de patiënten die minder dan een jaar geleden 
werden gediagnosticeerd met dikke darmkanker. Dit percentage was aanzienlijk 
lager dan de gerapporteerde percentages van 39% en 35% van respectievelijk 
patiënten met een diagnose tussen de 12 en 35 maanden end ievan langerdan36  
maanden geleden. Vrouwen, gelovige patiënten en patiënten met problemen ten 
aanzien van erfelijke darmkanker relateerde familiecommunicatie waren het 
meest kwetsbaar voor psychische klachten.
Om een eerste indruk en inzicht te krijgen in mogelijke psychologische reacties 
op MIPA-testen verrichtten wij een kwalitatieve studie in recent gediagnosticeer­
de patiënten met een aan Lynch gerelateerde kanker. In Hoofdstuk 4 beschrijven 
we deze pilotstudie waarin we de ervaringen onderzochten van 8 MIPA-positieve 
patiënten, dus met een verhoogd risico op Lynch syndroom. Deze patiënten 
werden thuis geïnterviewd met behulp van een vragenlijst gebaseerd op het 
multicausale model van probleemanalyse en aangepast voor erfelijke darmkanker. 
Uit de data werden drie overkoepelende thema's zichtbaar: 1) een veranderd 
leven na dikke darmkanker, 2) waarschuwing voor de toekomst en 3) familiecom­
municatie problemen. In dit vroege stadium na de diagnose waren de diagnose 
van kankeren de bijbehorende behandeling dominant aanwezig inde beschrijving 
van hun ervaringen met MIPA-testen. Deze patiënten waren allen van mening dat 
door de vroege opsporing van Lynch syndroom de preventieve medische waarde 
voor met name hun kinderen toenam en daardoor opwoog tegen eventuele 
familiecommunicatie problemen over erfelijke kanker.
De laatste stap was om de mate van psychische klachten op zowel korte als 
langere termijn te bepalen in een grote groep patiënten en om tevens de 
ervaringen van de partners te onderzoeken. Hoofdstuk 5 omvat de MIPAPS-studie 
waarin we prospectief psychische klachten onderzochten in recent gediagnosti­
ceerde patiënten met dikke darmkanker onmiddellijk na MSI-testen (T l) en 6 
maanden later (T2). Van Maart 2007 tot September 2009, werden 400 Nederlandse 
patiënten met een recente dikke darmkanker en hun partners benaderd door hun
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behandelend arts (chirurg of MDL-arts) voor deelname aan onze studie. Het 
gemiddelde algemene psychische klachten niveau (SCL-90) en dat van de verwer­
kingsklachten (IES) waren matig. Door 27% van de MSI-positieve patiënten (hoog 
risico Lynch syndroom), werden ernstige psychische klachten (SCL>160) 
gerapporteerd op T l; na 6 maanden (T2) was dit afgenomen naar 18%. In de 
MSI-negatieve groep (laag risico Lynch syndroom) bleef dit percentage stabiel, 
van 14% op Tl naar 18% op T2. Het percentage van patiënten met ernstige ver­
werkingsklachten nam in de MSI-positieve groep af van 39% naar 27% en bleef 
stabiel in de MSI-negatieve groep van 38% naar 36%. Vrouwelijke patiënten 
bleken het meest kwetsbaar voor ernstige psychische klachten, evenals patiënten 
met weinig sociale steun en patiënten met een hoge kanker risicoperceptie. De 
partners van zowel de patiënten met een hoog en laag risico op Lynch syndroom 
rapporteerden een matig tot hoog gevoel van eigenwaarde door het verlenen 
van zorg terwijl de ervaren druk door het geven van zorg in beide groepen 
partners na 6 maanden was afgenomen.
Conclusies
Identificatie van Lynch syndroom is belangrijk omdat daarna dankzij intensieve 
surveillance van familieleden met een erfelijke aanleg voor Lynch syndroom de 
mortaliteit vermindert. Pre screenen voor Lynch syndroom door MIPA-testen 
impliceert een voor patiënten belangrijk verschil met de klinisch genetische 
praktijk tot dan toe. Relatief jonge en recent gediagnosticeerde patiënten worden 
nu geconfronteerd met een mogelijk erfelijke aanleg van hun dikke darmkanker 
tijdens de behandeling van hun kanker. De tijd tussen dikke darmkanker diagnose 
en MSI-test blijkt niet gerelateerd aan algemene psychische klachten noch aan 
verwerkingsklachten. De meeste patiënten rapporteren geen ernstige psychische 
klachten na MIPA-testen. Bovendien zijn de psychische klachten van de patiënt 
noch die van de partners gerelateerd aan de uitslag van de MIPA-test. Echter een 
subgroep van deze patiënten ervaart ernstige psychische klachten. Het blijkt dat 
met name vrouwelijke patiënten, patiënten met weinig sociale steun en patiënten 
met een hoge kanker risicoperceptie psychische klachten ervaren. Deze patiënten 
hebben zorg nodig die aansluit bij hun specifieke behoeften.
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Deel 2: Informatie-support groepen voor vrouwen met een ß/?C^-mutatie
Het tweede deel van dit proefschrift betreft informatie-support groepen voor 
vrouwen met een ß/?G4-mutatie. Gezonde vrouwelijke ß/?G4-mutatie draagsters 
staan voor een complexe keuze tussen intensieve borstcontroles en preventieve 
verwijdering van de borsten. Een BRCA-groep heeft tot doel om deze vrouwen te 
ondersteunen bij het nemen van een bij hen passende en weloverwogen 
beslissing waarbij de ene keuze niet beter is dan de andere. De aanleiding voor 
het eerste onderzoek naar deze groepen was de indruk die in de klinische praktijk 
was ontstaan dat vrouwen na deelname aan een BRCA-groep vaker en sneller 
overgingen tot preventieve borstverwijdering. Een ongewenst neveneffect van 
de groep zou zijn dat vrouwen zich voelden overgehaald tot preventieve borst­
verwijdering door de uitgebreide aandacht hiervoor gedurende de bijeenkomsten. 
In Hoofdstuk 6 bepaalden we de voorkeur van de vrouwen ten aanzien van 
borstkanker risicoreducerende maatregelen tijdens het eerste consult bij de 
internist, vlak na de BRCA testuitslag. Vervolgens keken we na twee jaar hoeveel 
vrouwen preventief hun borsten hadden laten verwijderen en wie van deze 
vrouwen hadden deelgenomen aan een BRCA-groep. Uit de data bleek dat van de 
totale onderzoeksgroep 27% een voorkeur had voor preventieve borstverwijde­
ring. Na twee jaar had 30% van de totale groep daadwerkelijk de stap van 
preventieve chirurgie gezet. Significant meer vrouwen met een voorkeur voor 
preventieve borstverwijdering kwamen naar een BRCA-groep, vergeleken met 
vrouwen met een voorkeur voor borstcontroles. Vrouwen met een voorkeur voor 
preventieve chirurgie die aan een BRCA-groep hadden deelgenomen hadden 
significant vaker hun borsten laten verwijderen dan vrouwen die net als zij in 
eerste instantie hun borsten wilden laten verwijderen, maar niet aan een 
BRCA-groep hadden deelgenomen, 89% versus 63%. Na twee jaar was van de 
vrouwen met een voorkeur voor borstcontroles de meerderheid nog onder 
controle, 90% van de BRCA-groep deelneemsters en 88% van de andere 
ß/?C/\-mutatie draagsters. We kunnen concluderen dat bijna alle vrouwen met een 
ß/?C/\-mutatie standvastig zijn in het volgen van hun eerste voorkeur ten aanzien 
van borstkanker-reducerende maatregelen. Een andere belangrijke conclusie is 
dat groepsdeelname de keuze van deze vrouwen niet verandert, maar het naleven 
van hun oorspronkelijke voorkeur lijkt te versnellen. Vrouwen met een voorkeur 
voor preventieve chirurgie zetten die stap namelijk eerder wanneer zij deelnemen 
aan een groep.
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Bovenstaande studie gaf nog geen antwoord op de vraag of deze vrouwen na een 
BRCA-groep beter in staat waren om met de gevolgen van het ß/?C/\-mutatie 
dragerschap om te gaan in hun dagelijks leven. In Hoofdstuk 7 onderzochten we 
daarom de mate van emotionele klachten en familiecommunicatie vlak voor 
aanvang van (T l) en meteen na groepsdeelname (T2). Alle 34 vrouwen gaven aan 
dat groepsdeelname in hoge mate tegemoet kwam aan hun behoefte aan 
informatie ter ondersteuning van hun keuze voor borstkankerreducerende 
maatregelen. Het gemiddelde niveau van zowel depressie, boosheid, vermoeidheid 
als spanning was hoog en dat bleef zo op T2. Ook kanker risicoperceptie en de 
frequentie van gedachten aan kanker waren hoog op zowel Tl als T2. De familie­
communicatie met ouders, broers en zussen was significant afgenomen op T2 
vergeleken met T l. Dit onderzoek toont aan dat na groepsdeelname vrouwen 
goed in staat zijn te beslissen over de bij hen passende kankerreducerende 
maatregelen. Echter, deze vrouwen rapporteren nog veel emotionele klachten en 
praten na groepsdeelname significant minder over ß/?G4-gerelateerde zaken met 
hun ouders, broers en zussen dan daarvoor.
Conclusies
Vrouwelijke ß/?G4-mutatie draagsters staan voor de complexe keuze tussen 
intensieve borstcontroles en preventieve borstverwijdering met of zonder borst- 
reconstructie. Het doel van een BRCA-groep is het ondersteunen van deze 
vrouwen bij het maken van weloverwogen keuzes. Vrouwen met een voorkeur 
voor preventieve borstverwijdering blijken vaker aan een groep deel te nemen 
dan vrouwen met een voorkeur voor borstcontroles. Groepsdeelname verandert 
de voorkeur niet maar versnelt de keuze voor het laten verwijderen van de 
borsten. Onze beide onderzoeken tonen aan dat een BRCA-groep bijdraagt tot 
het versterken van keuzes ten aanzien van borstkankerreducerende maatregelen. 
Er treedt echter geen verbetering op in de mate van emotionele klachten en 
ß/?G4-gerelateerde familiecommunicatie met ouders, broers en zussen blijkt af te 
nemen na groepsdeelname. Een onderwerp voor verder onderzoek en een 
uitdaging voor de klinische praktijk is om steeds beter te begrijpen wat nodig is 
om adequaat aan de specifieke behoeftes van deze vrouwen tegemoet te 
komen.
Uit de in dit proefschrift beschreven studies wordt geconcludeerd dat de 
meerderheid van de mensen die geconfronteerd wordt met (een aanleg voor) 
erfelijke kanker hiermee zonder ernstige psychische klachten om kan gaan. De
178
basale psychosociale zorg die geboden wordt in de huidige oncogenetische 
praktijk lijkt voor hen voldoende. Echter een subgroep rapporteert ernstige en 
min of meer stabiele psychische klachten waaronder verwerkingsproblemen, 
depressieve gevoelens en een continue angst voor kanker. In tegenstelling tot 
wat men zou kunnen verwachten, zijn deze klachten niet gerelateerd aan de 
medische of genetische context maar aan demografische kenmerken zoals leeftijd 
en geslacht, aan sociale kenmerken zoals sociale steun en familiecommunicatie 
en aan kanker risicoperceptie. Het is wenselijk om deze kwetsbare mensen tijdig 
op te sporen en de zorg te bieden die nodig is.
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Ik bedank alle "Vrije Lopers" voor hun gezelligheid. De gesprekken maar ook juist 
de stiltes tijdens het hardlopen door de bossen van Berg en Dal en het Geldersch 
Landschap zorgden voor de broodnodige ontspanning. Met name wil ik Peter 
Rikken noemen. Als trainer maar zeker ook als masseur schiep hij de voor mij 
benodigde ruimte waardoor ik mijn weg energiek kon vervolgen. Heel hartelijk 
dank daarvoor!
Op deze plek bedank ik ook graag Hetty, Roelien en Marina die tijdens het werken 
aan mijn onvermijdelijke lichamelijk verval ook mijn emotionele ups en downs 
liefdevol hebben verzorgd.
Het is al vaker geschreven en genoemd, maar een proefschrift komt niet tot stand 
zonder een fantastisch sociaal netwerk. Vrienden en familie die ondanks dat ze 
"even op een lager pitje staan", je onvoorwaardelijk blijven steunen. Al mijn 
vrienden en vriendinnen, die ik hier niet allemaal bij name kan noemen: heel 
hartelijk bedankt voor jullie geduld als ik weer eens niet gezellig kon zijn omdat ik 
aan mijn artikelen moest werken.
Carel, Jolande, Pieter, Mien, Rinie, Marja, Sophie, Henk, Mieke en Sjoerd, jullie bedank 
ik allen vanuit de grond van mijn hart voor de inspirerende gesprekken en 
verhelderende inzichten tijdens onze maandagavondbijeenkomsten en daarbuiten. 
Ik hoop dat we met zijn allen het juiste pad mogen blijven bewandelen.
Monique en Andre, bij jullie kon ik en kan ik altijd terecht voor een goed maar 
gelukkig ook voor een slecht gesprek. We hebben heel veel mooie maar ook 
verdrietige momenten gedeeld met zijn vieren. Ik ben er trots op dat jullie mijn 
vrienden zijn en hoop nog heel lang met jullie wijn en wat er nog meer in huis is 
(als het maar geen water is, haha) te mogen drinken.
Monique en Yvonne, mijn "Sleedoorn-vriendinnen". Dat jullie het al ruim 25 jaar 
met mij volhouden, verdient alle lof. Yvonne, ondanks (of misschien juist wel 
daarom) dat wij op veel punten nogal verschillend zijn, vind ik het heerlijk om in 
jouw  omgeving te vertoeven. Dat jij nu mijn collega bent en we ook dat kunnen 
delen maakt voor mij onze vriendschap heel speciaal. Monique, de laatste jaren 
zijn we steeds dichter naar elkaar toe gegroeid. Ik heb diep respectvoor de keuzes 
die je in je leven hebt gemaakt en nog steeds maakt. Ik ben ervan overtuigd dat jij 
op de voor jou juiste weg zit. Ga zo door meissie!
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Mijn schoonfamilie bedank ik voor hun begrip voor als ik op zondag thuis bleef 
om te werken terwijl Ton en Floor in het Brabantse waren. Janus, An, Bertus, 
Chanette, Angela, Hans, Jeny en Ramon (en alle schatten van kinderen): Ik hoop in 
de toekomst weer een stuk vaker van jullie gezelligheid te mogen genieten!
Lieve ouders, zonder de basis die jullie me gaven was dit proefschrift er niet 
geweest. Jullie hebben er altijd voor gezorgd dat ik kon leren en studeren en pa, 
jij hebt mij geleerd nieuwsgierig te zijn. Als ik als kind vroeg hoe iets zat, pakte jij 
steevast de (toen nog gewoon papieren) encyclopedie erbij zodat ik stukje bij 
beetje steeds meer van de wereld om me heen te weten kwam. Zo'n opvoeding is 
goud waard! Ben, Astrid&Tineke en Paul, hoewel het meeste van de tijd op de 
achtergrond, weet ik dat jullie stiekem trots zijn op jullie kleine zusje. Bedankt!
Lieve Ton, allerliefste Floor, ik ga alle tijd die ik gedurende de laatste jaren niet 
met jullie heb doorgebracht of te vol en te veel in mijn hoofd was om een leuk 
persoon te kunnen zijn dubbel en dwars goed maken. Ton, kun je rekenen? 
Reken er maar op dan! Bedankt dat je me letterlijk en figuurlijk de ruimte hebt 
gegeven om dit proefschrift te kunnen voltooien. En Floor, ik ga jou de hele wereld 
laten zien. Ik hoop dat we met zijn 3-en nog heel veel mooie momenten mogen 
meemaken.
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Curriculum Vitae
Karin Landsbergen (1965) studeerde in 1989 af aan de faculteit Biologie van de 
Katholieke Universiteit Nijmegen. Haar hoofdvak betrof een onderzoek naar de 
invloed van zure regen op de decompositie van de witte waterlelie en de gele 
plomp. Daarnaast voltooide ze op de faculteit Psychologie een keuzevak 
betreffende de biopsychologische werking van hersenen. Ze behaalde een 
aantekening op het gebied van wetenschapsjournalistiek en tevens het nationale 
diploma Public Relations en Voorlichting (NGPR-A). Van 1989 tot 1994 werkte ze 
als publieksvoorlichter bij de Informatie Beheer Groep.
In 1994 startte ze de opleiding Maatschappelijk Werk en Dienstverlening aan de 
Hogeschool Arnhem Nijmegen waar ze in 1998 cum laude afstudeerde. Ze werkte 
als woonbegeleidster in een sociaal pension van het RIBW in Arnhem en 
begeleidde bij het Psychiatrisch Spectrum Gelderland Oost jongvolwassenen 
met een aanleg voor schizofrenie. Daarna begeleidde ze patiënten met een 
dwarslaesie en patiënten met multiple sclerose op de afdeling revalidatie van de 
St. Maartenskliniek in Nijmegen. Vervolgens werkte ze bij de Grift, een instituut 
voor verslavingszorg in Nijmegen, met een focus op harddrugsverslaafden en 
verslaafde straatprostituees.
Vanaf 2001 werkt ze als maatschappelijk werkster op de Polikliniek Familiaire 
Tumoren van de afdeling Klinische Genetica van het UMC St Radboud te Nijmegen. 
Hier begeleidt ze patiënten en families met een erfelijke vorm van kanker. Vanaf 
2006 werkte ze daarnaast aan de wetenschappelijke onderzoeken zoals beschreven 
in dit proefschrift. Ze is lid van GLOBE, het Georganiseerd Landelijk Overleg van 
Begeleiders bij Erfelijkheidsproblematiek en secretaris van de werkgroep 
Familiaire Tumoren van de Nederlandse Vereniging voor Psychosociale Oncologie 
(NVPO). Verder is ze lid van de Raad van Advies van de Patiëntenvereniging 
HNPCC-Lynch. Tevens is ze lid van de Nederlandse Vereniging van Maatschappelijk 
Werkers (NVMW) en redactieraadlid van Maatwerk, het vakblad voor maatschap­
pelijk werk.
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